



EFI 2026

EDINBURGH

39TH EUROPEAN IMMUNOGENETICS & HISTOCOMPATIBILITY CONFERENCE

*From Genes to Grafts:
Where Innovation Meets Medicine*

Final Programme



BSHI
British Society for
Histocompatibility
and Immunogenetics



21-24 April 2026
Edinburgh, Scotland
Edinburgh International Conference Centre

CONTENT

Click on section for hyperlink 

WELCOME ADDRESS	3
PARTNERS	4
CONFERENCE INFORMATION	5
REGISTRATION	7
INSTRUCTIONS FOR ORAL PRESENTATION	9
INSTRUCTIONS FOR POSTER PRESENTERS	11
ORGANISERS AND COMMITTEES	12
SPEAKERS	13
PROGRAMME OVERVIEW	14
FINAL PROGRAMME	18
LIST OF POSTERS	30
SATELLITE SYMPOSIA	61
SOCIAL NETWORKING EVENTS	64



WELCOME ADDRESS

Dear colleagues, dear friends,

It is a great honour and privilege to welcome you to Edinburgh for the 39th European Federation for Immunogenetics Conference, held jointly this year with the British Society for Histocompatibility and Immunogenetics (BSHI). As you know our last attempt to gather people to Scotland in 2020 did not go so well, so we are excited that we can now give delegates an opportunity to see some of the sights (and sounds!) of this part of the UK. Our theme for the meeting will be From Genes to Grafts: Where Innovation meets Medicine, reflecting the broad science and clinical interaction which comes under the EFI umbrella.

We would firstly like to thank all the speakers who have agreed to participate in the Scientific and Teaching sessions at the conference. We hope we have created, in collaboration with the EFI Scientific and Education Committees, a varied and interesting selection of talks which will expand our knowledge of the science of immunogenetics and histocompatibility and its role in current treatments and future therapies. Also, thanks to the EFI and BSHI members who have submitted abstracts to present their data in the oral abstract sessions or poster sessions. This is such a key part of the conference, bringing delegates together to discuss their latest work, triggering new collaborations and projects.

We would also like to thank everyone who has been involved in the organisation of the meeting. The help of the Guarant team, as EFI's PCO, is invaluable and the continuity provided by their involvement in the conference over the last few years really helps things to run smoothly. The EFI Office team have helped enormously in ensuring nothing has been overlooked in the preparations for the meeting.

The local team at the Edinburgh International Conference Centre (EICC) have also been exceedingly helpful from the moment they were first contacted regarding a possible booking for 2026. They, and we, hope you find the venue comfortable and navigable as the conference proceeds.

The last and most important thank you must go to the Sponsors and Exhibitors at the conference. It is only when involved in the organisation of such a meeting that you really do appreciate the financial commitment of our trade partners to EFI and BSHI. Thanks also to them for contributing to the Conference with a selection of important and informative symposia. Please support our trade partners by attending these symposia and by visiting their stands during the breaks.

We hope everyone enjoys the joint 39th EFI / 36th BSHI Conference and their time in Scotland and goes home invigorated with new scientific enthusiasm and with memories of a warm welcome and a great time!


David Turner and Ann-Margaret Little

On behalf of the Local Organising Committee

PARTNERS

We would like to thank the following partners for their support

Platinum Partners



Silver Partner



Bronze Partners



Partner of Welcome Drink



Partner of Networking Event



Bursary Supporter




CONFERENCE INFORMATION

CONFERENCE VENUE


Edinburgh International Conference Centre

<https://www.eicc.co.uk/>


Level 3




Level -1




Level 1



Level -2




Level 0



EXHIBITION PLAN

List of Exhibitors

- | | |
|--|---|
| 1 Cytotar | 16 GenDx |
| 2 CareDx AB | 17 Thermo Fisher Scientific |
| 3 Werfen | 18 Biotype GmbH |
| 4 DKMS Life Science Lab GmbH | 19 Viska AI AB |
| 5 inno-train Diagnostik GmbH | 20 Axon Labortechnik GmbH |
| 6 Devyser | 21 ROSE Genomics Corp. Ltd Beijing |
| 7 BAG Diagnostics GmbH | 22 Protrans medizinische diagnostische Produkte GmbH |
| 8 JETA Molecular | 23 Promega UK |
| 9 STEMCELL Technologies | 24 Clinisys |
| 10 PIRCHE AG | 25 V.H. Bio Limited |
| 11 EFI | 26 SCC Soft Computer |
| 12 Insight Molecular Diagnostics (IMDx) | 27 Takara Bio Europe |
| 13 NHS Blood & Transplant | |
| 14 Histogenetics | |
| 15 Hansa Biopharma | |



EFI BOOTH

You are more than welcome to visit the EFI booth in stand number 11 in the exhibition area and pay your membership fee on:

Wednesday 22 April 2026	08:30-16:30
Thursday 23 April 2026	08:30-16.30

FREE WI-FI

SSID: EFI 2026
Password: Edinburgh2026

EFI 2026 MOBILE APPLICATION

With the mobile application, you will have access to the detailed program and all the important information related to the conference.

Download the mobile app in the App Store / Google Play.



EFI SOCIAL MEDIA

Follow EFI on Social Media

- <https://www.facebook.com/EFI2026>
- <https://www.linkedin.com/company/efi-conference-2026/>

As for EFI conference 2026 use #EFI2026.

REGISTRATION

SELF-CHECK-IN

On-site registration and issue of badges will take place at self-check-in stations. You will receive a QR code before the conference via email. You can print the QR code or use your mobile device to obtain your badge.

On-site Registration Fee

Member	805 EUR
Non-member	915 EUR
Technician/ Students / Retired	525 EUR
One-day fee (22-23 April)	585 EUR
One-day fee (24 April)	440 EUR
Distributor	545 EUR
Accompanying Person	180 EUR

Registration fee includes 20 % VAT.

The Registration Fee Includes:

- Access to the conference and all its sessions (not included for Accompanying Persons)
- Welcome Cocktail
- Opening ceremony
- Coffee and lunch breaks
- Wine and cheese poster session

The distributor fee allows for access to the exhibition only. Access to the sessions need a full conference ticket.

The One-day Registration Fee Includes:

- Access to the conference and all sessions taking place on the selected day
- Coffee and lunch breaks

The Accompanying person's Registration Fee includes:

- Access to the building and exhibition
- Welcome Cocktail
- Wine and cheese poster session
- Accompanying persons do not have access to scientific sessions

REGISTRATION DESK

Opening Hours

Tuesday 21 April 2026	07:45–19:45
Wednesday 22 April 2026	07:30–17:30
Thursday 23 April 2026	07:45–17:30
Friday 24 April 2026	08:30–13:30

NAME BADGE

All delegates will receive a name badge upon registration. Everyone is kindly requested to wear his/her badge when attending the conference.

DELEGATE

PARTNER / EXHIBITOR

ONE-DAY REGISTRATION 22

ACCOMPANYING PERSON

ONE-DAY REGISTRATION 23

GUEST

ONE-DAY REGISTRATION 24

SPEAKER

ORGANIZER

DISTRIBUTOR

CERTIFICATE OF ATTENDANCE

The certificate of attendance will be available after the conference.



INSTRUCTIONS FOR ORAL PRESENTATION

PREPARING YOUR PRESENTATION

Please prepare your presentation in 16:9 format (screen is in format ratio 16:9). We recommend to save your PowerPoint presentation using PPTX format.

PowerPoint instructions

All session halls are equipped with standard PowerPoint presentation facilities.

Your presentation must be submitted to the “Session Room” at least 1 hour before the beginning of your session. A technician is available in every session room to provide assistance when needed. Due to the online presentation system, all speakers are kindly requested to use the provided PC onsite. **Please be present in the session room 15 minutes before the start of your session and follow the instructions from the Chairs and/or technician.**

General Information

Please use **Microsoft PowerPoint** (.pptx), or **Adobe Acrobat Reader** (.pdf) to guarantee they will open successfully on an on-site PC.

We recommend you save your **PowerPoint** presentation using **PPTX**.

You can also use our [Powerpoint template](#).

Please note that we cannot guarantee the quality of Macintosh-based presentations, please check in advance (2 hours before your session starts) their Windows compatibility.

Please prepare your presentation in 16:9 format (screens are in 16:9 aspect).

PRESENTATION LENGTH, if not scheduled otherwise:

Plenary Sessions	30 minutes incl. Q&A (please allow 5 minutes)
Teaching Sessions	30 minutes incl. Q&A (please allow 5 minutes)
Abstract Sessions	10 minutes incl. Q&A (please allow 2 minutes)

Pictures/Videos

JPG images are the preferred file format for inserted images. GIF, TIF, or BMP formats will be accepted as well.

Images inserted into PowerPoint are embedded into the presentations. Images that are created at a dpi setting higher than 200 dpi are not necessary and will only increase the file size of your presentation. Try to avoid overloading your presentation with unnecessary images.

If you have any videos in your presentation, please test them with the on-site PC several hours before your presentation. Generally, the MP4, MOV and AVI formats should work with no difficulties. Video inserted into MS PowerPoint 2013 and higher versions are embedded into the presentations.

How to save your presentation

Please save your presentation on one of the following discs or mediums: an external portable hard drive or USB flash disc.

Save all files associated with your presentation (PowerPoint file, movie/video files, etc.) to one folder/location.

If you are giving more than one presentation during the event, please save each one in a separate folder and clearly label it with the presentation code to avoid any on-site confusion or technical issues.

Always make a backup copy of your presentation and save it on a different portable disc or medium than the original presentation.

SPEAKERS' READY ROOM

All session halls are equipped with standard PowerPoint presentation facilities. All presentations will be networked to the appropriate room "Speakers' Ready Room" (**Lomond Foyer** located on the ground floor of the venue – Level 0).

All speakers are kindly requested to submit their presentations to the Speakers' Ready Room **at least one hour prior to the session** in which they are presenting. For early morning sessions, please submit your presentation the day before.

We kindly ask you to hand in your presentation to the technical staff in the Speakers' Ready Room on-site via an external drive. While doing so, we encourage speakers to verify their presentation. This will ensure no formatting errors.

IT support will be available in all the conference rooms during live sessions. All speakers are kindly requested to use provided PC onsite. Please be present in the session room 15 minutes before the start of your session and follow the instructions from the Chairs and/or technician. During your presentation, a remote control will be available for controlling your presentation. Please adhere to your allocated time, as you will not be permitted to exceed it. At the end of the Conference, all presentations will be deleted from the presentation system and computers on-site.

Opening Hours of the Speakers' Ready Room

Tuesday 21 April 2026	15:30–20:00
Wednesday 22 April 2026	07:40–17:30
Thursday 23 April 2026	07:40–18:30
Friday 24 April 2026	08:00–14:00

OTHER INFORMATION

During your lecture, you may use a remote control to operate your presentation.

Use of personal notebooks for presentations is not permitted unless it has been specifically arranged in advance.

All presentations will be deleted from all the PC used during the event.

We kindly ask all the speakers to keep the time of their presentations.

INSTRUCTIONS FOR POSTER PRESENTERS

All posters will be presented in a “paper” format (printed posters).

Posters **must be in a portrait-oriented – A0 format is recommended (width x height) (841 × 1189 mm / 33.1 × 46.8 in)** which will be displayed on the poster boards in the **Poster Area**.

Posters will be displayed throughout the whole conference.

- The visual display area is: **900 x 1700 mm**
- Fixing material (hook and loop fastener/Velcro stickers and pins) will be available in the Posters Area. Congress staff will be available to assist you during the time of poster mounting.
- The poster boards will be numbered by the organizers and grouped by topic.
- The poster board is covered with blue polyweave fabric.



The number of your poster can be found in the [List of posters](#). The presentation number assigned to your poster should not be placed on your poster.

POSTER CREATION

The header of the Conference can be downloaded here ([JPG format](#), [PDF format](#)), and the instructions on layout, font style, and margins are in the attached [preview](#). The preview is informative only. The text, illustrations, etc. should be big enough to be read from a distance of 1.5 meters, and the message of the poster should be clear and understandable.

Please print your poster and bring it with you to the Conference.

No poster printing service is provided by the organizers.
Please **DO NOT** prepare a landscape poster.

A SPECIAL SESSION

Poster Viewing Is Scheduled on Wednesday 22 April from 17:30–19:00

Please be at your poster during the poster session to discuss your work with visiting scientists. A selection of posters will be assessed for the Best Poster Awards. The awards will be announced during the Closing Ceremony on Friday, 24 April at 13:00.

Poster mounting time

Tuesday 21 April 2026	16:00–19:30
Wednesday 22 April 2026	07:40–10:00

Poster removal time

Thursday 23 April 2026	15:30–18:00
-------------------------------	-------------

We kindly ask the presenters to remove their posters right after the session preferably before 18:00 otherwise they will be removed and discarded.

OTHER INFORMATION

Poster presenters are requested to be available by their posters during the entire poster session to present their work and answer questions from conference participants.

ORGANISERS AND COMMITTEES

Local Organizing Committee

D. Turner, *United Kingdom*

A-M. Little, *United Kingdom*

Scientific Committee

L. Vago, *Italy, Chair*

J. Trowsdale, *United Kingdom*

P. Crivello, *Germany*

R. Carapito, *France*

A. Sanchez-Mazas, *Switzerland*

E. Spierings, *the Netherlands*

G. Karahan, *the Netherlands*

N. de Groot, *the Netherlands*

S. Schaub, *Switzerland*

J. Lucas, *United Kingdom*

EFI Executive Committee

M. Andreani, *Italy, President*

D. Roelen, *the Netherlands, Secretary*

K. Poulton, *United Kingdom, Deputy-Secretary*

J. Villard, *Switzerland, Treasurer*

N. Vince, *France, Deputy-Treasurer*

Councillors

S. Heidt, *the Netherlands*

F. Heinemann, *Germany*

S. Tafulo, *Portugal*

K. Tarassi, *Greece*

P. Koefoed-Nielson, *Denmark*

L. Wieten, *the Netherlands*



SPEAKERS

Plenary Session 1 – Haematopoietic Stem Cell Transplantation

Bronwen Shaw, USA
Rob Wynn, UK
Katharina Fleischhauer, Germany

Plenary Session 2 – Cell Therapies And Regenerative Medicine

Roger Barker, UK
Wolfram-Hubertus Zimmermann, Germany
Sandra Petrus-Reurer, UK

Plenary Session 3 – Joint with ESOT: Increasing Access to Transplantation

Gabriel Oniscu, Sweden
Eckhard Wolf, Germany
Shareen Forbes, UK

Plenary Session 4 – HLA and Disease

Lars Fugger, UK
Paul Bowness, UK
Prof Nicholas McGranahan, UK

Plenary Session 5 – Antigen Presentation, Neoantigens and MiHAs

Marieke Griffioen, Netherlands
Carla Baan, Netherlands
Michal Bassani-Sternberg, Switzerland

Teaching Session 1 – Non-HLA antibodies in SOT

Deborah Pritchard, UK
Raphael Carapito, France
Clare Collins, UK

Teaching Session 2 – HLA and Cancer: From HLA antigen presentation modeling to personalized tumor vaccines

Nicola Ternette, UK
Morten Nielsen, Denmark

Teaching Session 3 – Non-HLA and non-classical HLA genes in the MHC

Lotte Wieten, Netherlands
Katarzyna Bogunia-Kubik, Poland
Michael Eikmans, Netherlands

Teaching Session 4 – New methods for post transplant monitoring in SOT

Manuel Muro, Spain
Jakob Nilsson, Switzerland
Stefan Schaub, Switzerland

PROGRAMME OVERVIEW

Monday 20 April 2026	
09:00-17:30	Tinto + Moorfoot
	EFI Inspectors' Workshop
	Carrick 1 + 3
	ESHI Diploma Examination

Tuesday 21 April 2026	
08:30-16:30	Carrick 2
	Executive Committee Meeting
09:30-14:00	Harris 2
	EPT Committee Meeting
08:30-17:00	Ochil 1 + 2
	Accreditation Committee Meeting
08:30-17:00	Carrick 1
	Standards Committee Meeting
13:30-17:00	Carrick 3
	Education Committee Meeting
11:00-14:00	Harris 1
	IT & Bioinformatics Committee Meeting
14:00-16:00	Ochil 3
	Scientific Committee Meeting
16:00-17:30	Harris 1 + 2
	EFI Population Genetics Working Group
17:30-19:45	Pentland Suite
	Opening Ceremony And Awards
17:30-17:45	Welcome addresses <i>Chairs: Marco Andreani, David Turner, Ann-Margaret Little, Olivia Shaw</i>
17:45-17:55	BSHI Honorary Membership Award <i>Chair: James Robinson</i>
17:55-18:10	HLA Award <i>Chair: Steven Marsh</i>
18:10-18:35	Julia Bodmer Award <i>Chair: Luca Vago</i>
18:35-18:45	Special Ceppellini Award <i>Chair: Luca Vago</i>
18:45-19:30	Ceppellini Lecture <i>Chair: Marco Andreani</i>
19:30-19:45	Traditional Scottish Welcome!
19:45-21:30	Cromdale
	Welcome Drink Reception

Wednesday 22 April 2026				
08:30-10:00	Pentland Suite			
	Plenary Session I – Haematopoietic Stem Cell Transplantation <i>Chairs: Neema Mayor, Esteban Arrieta-Bolaños</i>			
08:30-09:00	The evolving landscape of donor selection: HLA and beyond Bronwen Shaw, USA			
09:00-09:30	Cord blood as an HLA-mismatched Stem Cell Source: Past Present and Future Rob Wynn, UK			
09:30-10:00	Old dogmas and new opportunities for HLA in Donor selection: Lessons learned from bench to bedside Katharina Fleischhauer, Germany			BSHI Award (Festenstein)
10:00-10:30	Refreshments, Poster and Exhibition Viewing			
10:30-12:00	Pentland	Sidlaw	Fintry	
	Teaching Session 1: Non-HLA antibodies in SOT <i>Chairs: Deborah Pritchard, Raphael Carapito</i> Deborah Pritchard, UK Raphael Carapito, France Clare Collins, UK	Oral Abstract Session 1: Population genetics, infection & disease <i>Chairs: Joannis Mytilineos, Natasja de Groot</i>	Oral Abstract Session 2: Bioinformatics <i>Chairs: Michaela Agapiou, Martin Maier</i>	
12:00-14:00	Lunch BREAK, Poster and Exhibition Viewing			
12:00-13:00		Sidlaw		
		Industry Symposium 1 Thermo Fisher Scientific		
13:00-14:00			Fintry	Ochil 2
			Industry Symposium 2 Werfen	EFI EDC session: EFI Educational Drop In Session
14:00-15:00	Pentland	Sidlaw	Fintry	Kilsyth
	Teaching Session 2: HLA and Cancer: From HLA antigen presentation modeling to personalized tumor vaccines <i>Chairs: Timo Olieslagers, Anders Hedin</i> Nicola Ternette, UK Morten Nielsen, Denmark	Oral Abstract Session 3: HSCT <i>Chairs: Antonij Slavčev, Sharon Vivers</i>	Industry Symposium 3 Hansa Biopharma	Industry Symposium 4 Insight Molecular Diagnostics (IMDx)
15:00-15:30				
15:30-16:00	Refreshments, Poster and Exhibition Viewing			
16:00-17:30	Pentland Suite			
	Plenary Session II – Cell Therapies and Regenerative Medicine (Pentland Suite) <i>Chairs: Constanca Figueiredo, Jean Villard</i>			
16:00-16:30	Dopamine cell therapies for Parkinson’s Disease- Is it ready for primetime? Roger Barker, UK			
16:30-17:00	Tissue Engineered Heart Repair Wolfram-Hubertus Zimmermann, Germany			
17:00-17:30	Reducing immunogenicity in bile-duct cellular therapies Sandra Petrus-Reurer, UK			
17:30-19:00	Wine & Cheese Poster Session			

Thursday 23 April 2026				
08:30-10:00	Pentland Suite			
	Plenary Session III – Joint With Esot: Increasing Access To Transplantation <i>Chairs: Lorna Marson, Jean-Luc Taupin</i>			
08:30-09:00	Organ perfusion: local service or centralised national facilities? Gabriel Oniscu, Sweden			
09:00-09:30	Xenotransplantation, the European approach Eckhard Wolf, Germany			
09:30-10:00	Optimising islet transplantation for Type 1 diabetes Shareen Forbes, UK			
10:00-10:30	Refreshments, Poster and Exhibition Viewing			
10:30-12:00	Pentland	Sidlaw	Fintry	
	Teaching Session 3: Non-HLA and non-classical HLA genes in the MHC <i>Chairs: Lotte Wieten, Katarzyna Bogunia-Kubik</i> Lotte Wieten, Netherlands Katarzyna Bogunia-Kubik, Poland Michael Eikmans, Netherlands	Oral Abstract Session 4: Solid organ transplantation <i>Chairs: Catherine Hastie, Richard Battle</i>	Oral Abstract Session 5: Antigen processing & NK cells <i>Chairs: Paul Norman, Eric Spierings</i>	
12:00-14:00	Lunch Break, Poster and Exhibition Viewing			
12:00-13:00	Pentland			
	Industry Symposium 5 GenDx			
13:00-14:00		Sidlaw		Kilsyth
		Industry Symposium 6 CareDx		EBTI Assembly
14:00-15:00	Pentland	Sidlaw	Fintry	
	Teaching Session 4: New methods for post transplant monitoring in SOT <i>Chairs: Jakob Nilsson, Manuel Muro</i> Manuel Muro, Spain Jakob Nilsson, Switzerland Stefan Schaub, Switzerland	Oral Abstract Session 6: Immunotherapy <i>Chairs: Arthi Anand, Rainer Blasczyk</i>	Industry Symposium 7 Bag Diagnostics	
15:00-15:30				
15:30-16:00	Refreshments, Poster and Exhibition Viewing			
16:00-17:30	Pentland Suite			
	Plenary Session IV – HLA and Disease (Pentland Suite) <i>Chairs: Olivia Shaw, Jill Hollenbach</i>			
16:00-16:30	Evolutionary origin of risk to multiple sclerosis Lars Fugger, UK			
16:30-17:00	HLA-B27 and Spondyloarthritis, back to the future? Paul Bowness, UK			BSHI Award (Terasaki)
17:00-17:30	Exploring somatic evolution and immune escape in lung cancer Nicholas McGranahan, UK			
17:30-19:00	Pentland Suite			
	EFI General Assembly, EFI Medal Ceremony			
19:30-01:00	National Museum of Scotland			
	Networking Event			

Friday 24 April 2026	
09:00-10:30	Pentland Suite Best Oral Abstract Session <i>Chairs: Marco Andreani, Luca Vago</i>
10:30-11:00	Refreshments
11:00-12:30	Pentland Suite Plenary Session V – Antigen Presentation, Neoantigens and MiHAs <i>Chairs: Sebastiaan Heidt, Pietro Crivello</i>
11:00-11:30	Minor Histocompatibility Antigens to Monitor, Predict, and Shape Immune Responses After HLA-Matched Allogeneic Stem Cell Transplantation Marieke Griffioen, Netherlands
11:30-12:00	The Secret Messengers: Extracellular Vesicles in Transplant Rejection Carla Baan, Netherlands
12:00-12:30	From discoveries to therapy: overcoming challenges in neoantigen-driven cancer immunotherapy Michal Bassani-Sternberg, Switzerland
12:30-13:30	Pentland Suite Closing Ceremony <i>Chairs: Marco Andreani, David Turner</i>
12:30-12:45	Jon van Rood Award, Best Abstract Awards
12:45-13:15	Closing Lecture: The cost of a comprehensive immune defence Prof John Trowsdale
13:15-13:25	19th IHIWS Presentation
13:25-13:30	Welcome to Essen and final remarks



FINAL PROGRAMME

ASSOCIATED MEETINGS, WORKSHOPS

SUNDAY 19 APRIL 2026

09:00-17:00	Data Standards Hackathon(DaSH) meeting	Glamis, Sheraton Hotel Ochil 1 + 3
09:00-16:30	ESHI Candidate Preparation Rooms	

MONDAY 20 APRIL 2026

09:00-17:00	Data Standards Hackathon(DaSH) meeting	Glamis, Sheraton Hotel Tinto + Moorfoot Carrick 1 + 3
09:00-17:00	EFI Accreditation Inspectors' Workshop	
09:00-16:00	ESHI Diploma Examination	

TUESDAY 21 APRIL 2026

08:30-16:30	Executive Committee Meeting	Carrick 2
09:30-14:00	EPT Committee Meeting	Harris 2
08:30-17:00	Accreditation Committee Meeting	Ochil 1 + 2
08:30-17:00	Standards Committee Meeting	Carrick 1
13:30-17:00	Education Committee Meeting	Carrick 3
11:00-14:00	IT & Bioinformatics Committee Meeting	Harris 1
14:00-16:00	Scientific Committee Meeting	Ochil 3
16:00-17:30	EFI Population Genetics Working Group	Harris 1 + 2

WEDNESDAY 22 APRIL 2026

12:00-13:30	Executive Committee and Co-ordinators meeting	Carrick 2
12:00-14:00	Bioinformatics Hands On Session 1	Harris 1
13:00-14:00	EFI Educational drop in session	Ochil 2

THURSDAY 23 APRIL 2026

12:00-14:00	Bioinformatics Hands On Session 2	Harris 1
13:00-14:00	EBTI General Assembly	Carrick 2

SCIENTIFIC PROGRAMME

TUESDAY 21 APRIL 2026

17:30-19:30	Opening Ceremony and Awards	Pentland Suite
17:30-17:45	Welcome addresses <i>Chairs: Marco Andreani, David Turner, Ann-Margaret Little, Olivia Shaw</i>	
17:45-17:55	BSHI Honorary Membership Award <i>Chair: James Robinson</i>	
17:55-18:10	HLA Award <i>Chair: Steven Marsh</i>	
18:10-18:35	Julia Bodmer Award <i>Chair: Luca Vago</i>	
18:35-18:45	Special Ceppellini Award <i>Chair: Luca Vago</i>	
18:45-19:30	Ceppellini Lecture <i>Chair: Marco Andreani</i>	
19:30-19:40	Traditional Scottish Welcome!	
19:40	Welcome Reception	Cromdale Hall

WEDNESDAY 22 APRIL 2026

08:30-10:00	Plenary Session I – Haematopoietic Stem Cell Transplantation <i>Chairs: Neema Mayor, Esteban Arrieta-Bolanos</i>	Pentland Suite
08:30-09:00	The evolving landscape of donor selection: HLA and beyond <i>Prof Bronwen Shaw, USA</i>	
09:00-09:30	Cord blood as an HLA-mismatched Stem Cell Source: Past Present and Future <i>Prof Rob Wynn, UK</i>	
09:30-10:00	Old dogmas and new opportunities for HLA in Donor selection: Lessons learned from bench to bedside <i>Prof Katharina Fleischhauer, Germany</i>	
09:30-10:00	BSHI Award (Festenstein)	
10:00-10:30	Refreshments, Poster and Exhibition Viewing	
10:30-12:00	Teaching Session 1: Non-HLA antibodies in SOT <i>Chairs: Deborah Pritchard, Raphael Carapito</i> <i>Deborah Pritchard, UK</i> <i>Raphael Carapito, France</i> <i>Clare Collins, UK</i>	Pentland

10:30-12:00

Oral Abstract Session 1: Population genetics, infection & disease

Sidlaw

Chairs: Joannis Mytilineos, Natasja de Groot

O10 Mycobacterium tuberculosis PPE2 protein-derived peptide ameliorates DSS-induced colitis by depleting mast cells

Pooja Kushwaha, Sangita Mukhopadhyay

O11 Self-reported health history reveals the role of HLA variation in antibiotic allergy

Juliano Boquett, Sean Lin, Karoline Guthrie, Martin Maiers, Jill Hollenbach

O12 Genetic imprinting of HLA-DP variability on cellular and humoral immunity to cytomegalovirus

Luisa Betke, Pietro Crivello, Fabienne Maassen, Marie-Sophie Eppler, Sarah Flossdorf, Esteban Arrieta-Bolanos, Thuja Arrieta-Bolanos, Werner Bochtler, Hans-Peter Eberhard, Corinna Siegmund, Vu Thuy Khanh Le-Trilling, Astrid Westendorf, Peter A. Horn, Joannis Mytilineos, Mirko Trilling, Katharina Fleischhauer

O13 HLA leader peptides and CMV define a unified mechanism of early rejection after solid organ transplantation

Berber Zweers, Lieke Westerholt, Emma Peereboom, Thijs Hoffman, Elize Berg, Dieuwertje Ruigrok, Susan Braithwaite, Linda de Heer, Bart Luijk, Eric Spierings

O14 Population-Scale Analysis Reveals High Conservation of the NKG2 Gene Family Worldwide

Viviane Aparecida de Oliveira Ciriaco, Erick C. Castelli

O15 Liquid Biopsy Meets Immunotherapy: Detecting HLA-I Loss of Heterozygosity to Predict BCG Response in Bladder Cancer

Alba Navarro-Ocón, César García-López, Rocío Lozano-Abad, Hernani Gil-Julio, Mónica Bernal, José Manuel Cózar-Olmo, Francisco Ruiz-Cabello, Natalia Aptsiauri

O16 LILR gene cluster: Structural diversity and allelic polymorphism in humans and macaques

Natasja G. de Groot, Marit K.H. van der Wiel, Susan E. Ott, Nanine de Groot, Corrine M.C. Heijmans, Annemiek J.M. de Vos-Rouweler, Ngoc Giang Le, Jesse Bruijnesteijn

O17 Pregnant individuals with chronic histiocytic intervillitis display HLA-DR expression on fetal trophoblasts in the placenta

Qianwen Lu, Floortje van Ankeren, Stijn Makkus, Hanneke Kapsenberg, Lotte van der Meeren, Marie-Louise van der Hoorn, Michael Eikmans

O18 Once upon a time in the Americas: How 16th Century epidemics reshaped Indigenous immunogenetic diversity

Rodrigo Barquera, Iseult Jackson, Gunnar Neumann, András Szolek, Kathrin Nägele, Adriana C. Zamora Herrera, Raffaella A. Bianco, Diana I. Hernández Zaragoza, Adam Ben Rohrlach, Patxi Pérez Ramallo, Jorge A. Gómez Valdés, Víctor Acuña Alonzo, Lourdes Márquez Morfín, Alexander Herbig, Christina Warinner, Johannes Krause

10:30-12:00

Oral Abstract Session 2: Bioinformatics

Fintry

Chairs: Michaela Agapiou, Martin Maiers

O19 DAQS: Adaptive serum antibody quantification corrects for technical bias yet conserving biological variability

Henry Loeffler-Wirth, Thomas Schacker, Ramona Landgraf, Claudia Lehmann, Ilias Doxiadis

O20 Interpretable AI Embeddings Improve Contextual Modelling of HLA polymorphism and sequence error

Richard Natarajan, Thomas Turner, Neema Mayor, James Robinson

O21 Phenome-wide analysis of non-classical HLA and MIC alleles reveals

MICA*007:01 association with ankylosing spondylitis independent of HLA-B*27

Silja Tammi, Jukka Partanen, Jarmo Ritari

O22 Extending BIGDAWG Analyses to New Categories of Variation

Livia Tran, Michael Chase Peters, Steven Mack

O23 Novel Alternative Splicing Events Identified Across Human Leukocyte Antigen Class I Genes

Ipsa Mittra, Jill Hollenbach

O24 Imputation Programs are Inaccurate in Ethnically Diverse Populations

Katrina Spensley, Michelle Willicombe, Nicola Gunby, Arthi Anand, Eva Santos

O25 Inheritance of HLA-DRB1 via extrachromosomal DNA

Noah Cline, Michael Carter, Al Malki, Ketevan Gendzekhadze, Paul Norman

O26 Machine Learning Outperforms Traditional Methods in Predicting Kidney Transplant Outcomes: A Multicenter Cohort Study

Seyed Amir Tabatabaei Hosseini, Hamad Dheir, Ülkem Çakır, Hüseyin Koçak, Aygül Çeltik, Ayse Sinangil, Gizem Kumru, Tuba Elif Özler, Feyza Bayrakdar Çaglayan, Tolga Yıldırım, Bahar Gürlek Demirci, Ergun Parmaksız, Halil Yıldız, Vural Taner Yılmaz, Yağmur Tahillioğlu, Mevlüt Tamer Dinçer, Arzu Velioglu, Ramazan Daniş, Ebru Sevinç Ok, Mehmet Emin Demir, Özgür Akın Oto, Şebnem Karakan, Zeynep Akçalı, Abdülmecit Yıldız, İbrahim Berber, Adem Uslu, Gülay Aşçı, Alaattin Yıldız, Siren Sezer, Kenan Keven, Huseyin Toz, Nurcan Tunçbağ, Aydın Türkmen, Caner Süsal, Erol Demir

O27 Recombination hot spots in pangenome MHC sequences

Nickolai Alexandrov, Ting Wang, Lindley Blair, Dave Lowe, David Sayer

12:00-14:00

Lunch, Poster and Exhibition Viewing

12:00-13:00

**Industry Symposium 1
Thermo Fisher Scientific**

Sidlaw

13:00-14:00

**Industry Symposium 2
Werfen**

Fintry

13:00-14:00

EFI EDC session (Deb)

Ochil 2

14:00-15:30

Teaching Session 2: HLA and Cancer: From HLA antigen presentation modeling to personalized tumor vaccines

Pentland

Chairs: Timo Olieslagers, Anders Hedin

Nicola Ternette, UK

Morten Nielsen, Denmark

14:00-15:30

Oral Abstract Session 3: HSCT

Sidlaw

Chairs: Antonij Slavčev, Sharon Vivers

O28 Relevance of Non-HLA Region Differences Beyond HLA Molecular Mismatches in Haplo-HSCT with PTCy

Jairo Niño, Marta Fonseca, Pilar Terradillos, Ariadna Vicente Parra, Isabel Jimenez Hernaz, Nuria Calzada, Juan López-Pérez, Estefania Pérez-López, Almudena Navarro-Bailón, Fermin Sánchez-Guijo, Ramón García-Sanz, Lucía López-Corral, Miguel Alcoceba, Amalia Tejeda Velarde, Francisco Javier Gil-Etayo

O29 The interaction strength between NKG2D and MICA molecules exhibits allele specificity

Xuan You, Sudan Tao, Qimin Wu, Faming Zhu

O30 A machine learning approach combining HLA and non-HLA factors for the selection of the "best" stem cell donor: a nation-wide analysis on 7,609 transplants and an interactive tool for clinical use

Roberto Crocchiolo, Raffaele Scorza, Stefania Cacace, Elena Oldani, Davide Chizzoniti, Luca Castagna, Michele Malagola, Barbara Sarina, Simona Piemontese, Nicola Polverelli, Giovanni Rombolà, Nicoletta Sacchi, Quirico Semeraro, Massimo Martino

O31 A comprehensive integration and analysis of in-silico algorithms for 9/10 donor matching

Francisco Javier Gil-Etayo, Rodrigo Gil-Manso, Juan López Perez, Jairo Eduardo Niño Ramírez, Nuria Calzada Nieto, Isabel Jimenez, Pilar Terradillos, Ariadna Vicente, Estefania Pérez, Sara Marcos, Lourdes Vazquez, Lucía López-Corral, Amalia Tejeda Velarde

O32 Cell-free DNA methylation analysis identifies potential novel tissue-specific biomarkers for graft-versus-host disease

Angelo Corso Faini, Monica Sorbini, Francesco Edoardo Vallone, Giuseppe Lia, Alessia Melis, Luisa Giaccone, Benedetto Bruno, Tiziana Vaisitti, Silvia Deaglio

O33 Protective Effect of Carrying HLA Alleles A*02:07-C*01:02-B*46:01 on Outcomes Following Haploidentical Stem Cell Transplantation in AML Patients

Yijie Wang, Xiaobo Li, Da Di, Yimei Feng, Weijie Zhang, Liping Dou, Yanhui Luo, Yuelin He, Jing Chen, Xian Zhang, Maoquan Qin, Jingbo Wang, Daihong Liu, Xi Zhang, Xiangjun Liu

O34 THE IMPACT OF HLA-DQ HETERODIMER MATCHING IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: LOOKING BEYOND THE AMINO ACID SEQUENCE

Katarina Stingl Jankovic, Zorana Grubic, Marija Burek Kamenaric, Nadira Durakovic, Lana Desnica, Radovan Vrhovac, Mirta Mikulic, Renata Zunec

O35 Macrophage migration inhibitory factor associations in graft versus host disease

Aviran Aharon, Rian Sitbon, Batia Avni, Sigal Grisariu, Gil Benedek

O36 Serology 2026 project for the 19th International HLA and Immunogenetics Workshop

Kazutoyo Osoegawa, Lin Wang, Marcelo Fernández-Viña

14:00-15:30

**Industry Symposium 3
Hansa Biopharma**

Fintry

14:00-15:30

**Industry Symposium 4
Insight Molecular Diagnostics (iMDx)**

Kilsyth

15:30-16:00

Refreshments, Poster and Exhibition Viewing

16:00-17:30	Plenary Session 2 – Cell Therapies and Regenerative Medicine <i>Chairs: Constanca Figueiredo, Jean Villard</i>	Pentland Suite
16:00-16:30	Dopamine cell therapies for Parkinson’s Disease- Is it ready for primetime? <i>Prof Roger Barker, UK</i>	
16:30-17:00	Tissue Engineered Heart Repair <i>Prof Wolfram-Hubertus Zimmermann, Germany</i>	
17:00-17:30	Reducing immunogenicity in bile-duct cellular therapies <i>Dr Sandra Petrus-Reurer, UK</i>	
17:30-19:00	Scientific Poster Session	
19:00	Speakers’ and Ceppellini Dinner	Playfair Library, University of Edinburgh

THURSDAY 23 APRIL 2026

08:30-10:00	Plenary Session Iii – Joint With Esot: Increasing Access to Transplantation <i>Chairs: Lorna Marson, Jean-Luc Taupin</i>	Pentland Suite
08:30-09:00	Organ perfusion: local service or centralised national facilities? <i>Prof Gabriel Oniscu, Sweden</i>	
09:00-09:30	Xenotransplantation, the European approach <i>Prof Eckhard Wolf, Germany</i>	
09:30-10:00	Optimising islet transplantation for Type 1 diabetes <i>Prof Shareen Forbes, UK</i>	
10:30-12:00	Teaching Session 3: Non-HLA and non-classical HLA genes in the MHC <i>Chairs: Lotte Wieten, Katarzyna Bogunia-Kubik</i> <i>Lotte Wieten, Netherlands</i> <i>Katarzyna Bogunia-Kubik</i> <i>Michael Eikmans</i>	Pentland

10:30-12:00

Oral Abstract Session 4: Solid organ transplantation

Sidlaw

Chairs: Catherine Hastie, Richard Battle

O37 First genomic study of chronic lung allograft dysfunction discovers two novel associations

Simon Brocard, Vincent Mauduit, Martin Morin, Léo Boussamet, Nayane dos Santos Brito Silva, Axelle Durand, COLT consortium, Laureline Berthelot, Nicolas Vince, Adrien Tissot, Sophie Limou

O38 Genome-wide survival study identifies a novel non-HLA donor-recipient genetic mismatch associated with kidney allograft survival

Vincent Mauduit, Axelle Durand, Martin Morin, Kane E. Collins, Matej Roder, Peter J. van der Most, Nayane SB Silva, Magali Giral, Nicolas Vince, Martin H de Borst, Ondrej Viklicky, Peter J Conlon, Sophie Limou

O39 Active concentration of de novo anti-HLA-DQ donor specific antibodies measured by surface plasmon resonance is associated with chronic lung allograft dysfunction

Frédéric Jambon, Carmelo Di Primo, Claire Dromer, Xavier Demant, Antoine Roux, Jérôme Le Pavec, Olivier Brugiere, Vincent Bunel, Romain Guillemain, Julien Goret, Marion Duclaut, Marine Cargou, Mamy Ralazamahaleo, Elodie Wojciechowski, Gwendaline Guidicelli, Virginie Hulot, Magali Devriese, Jean-Luc Taupin, Jonathan Visentin

O40 Assessment of circulating and lymph node-derived HLA-specific B cell memory in highly sensitized patients undergoing desensitization

Gonca Karahan, Yvonne de Vaal, Kim de Voogt-Bakker, Nicolle Litjens, Dave Roelen, Michiel Betjes, Jacqueline van de Wetering, Annelies de Weerd, Sebastiaan Heidt

O41 Microvascular inflammation is influenced by the KIR peripheral repertoire and CMV infection in kidney transplanted patients

Valérie Olivier, Julien Prados, Stephane Bulher, Sylvie Ferrari-Lacraz, Stefan Schaub, Julien Vionnet, Michael Horn, Jakob Nilsson, Fadi Haidar, Kata Sunic-Augustinovic, Norman Paul, Jean Villard

O42 Can HLA selected reds cell reduce sensitisation in transplanted and wait-List renal patients?

Kirti MEPANI, Katrina Spensley, Eva Santos, Michelle Willicombe, David Roberts, Colin Brown

O43 Combination of non-invasive biomarkers for immunological risk stratification of graft failure

Richard Danger, Nicolas Degauque, Clarisse Kerleau, Gaëlle Tilly, Thi-Van-Ha Nguyen, Emmanuelle Papuchon, Hoa Le Mai, Delphine Kervella, Christophe Masset, Karine Renaudin, Åsberg Anders, Oriol Bestard, Magali Giral, Sophie Brouard

O44 Repeat HLA mismatches are not associated with an increased risk of rejection and graft loss in second kidney transplant recipients: a contemporary nationwide retrospective cohort study

Lissa Pipeleers, Hans de Ferrante, Juliette Moreau, Tom Darius, Steffi De Pelsmaeker, Anton Evenepoel, Giuseppe Gambino, Rachel Hellemans, Vanda Holovska, Johan Kerkhofs, Maarten Naesens, Justine Schmitt, Corentin Strel, Ineke Tiekens, Steven Van Laecke, Laurent Weekers, Marie-Paule Emonds, Karl Martin Wissing

O45 Combining human leukocyte antigen epitope mismatch load and epitope immunogenicity to support alloimmune risk stratification and post-transplant management

Eva Santos, Nicola Gunby, Arthi Anand, Michelle Willicombe

10:30-12:00

Oral Abstract Session 5: Antigen processing & NK cells

Fintry

Chairs: Paul Norman, Eric Spierings

O46 Population-scale analysis of loss of function variants reveals extensive undetected diversity in the human KIR3DL1 gene

Stefania Nappo, Laura Auriemma, Martina Esposito, Donato Madalese, Roberta Penta de Vera D'Aragona

O47 Integrated peptide-level scoring reveals functional asymmetry between HLA-A*02:01, B*07:02 and B*35 and supports allele-informed management of antiviral prophylaxis in transplant recipients

Antonio Milano, Roberto Crocchiolo, Chiara Mariadele Scollo

O48 Polymorphism in HLA and KIR impacts NK cell sensitivity to HLA loss

Philippa Saunders, Andrew Brooks, Clare Oates

O49 Transcriptomic Signatures in MS Associated HLA Alleles

Anshikaa Srivastava, Jill A. Hollenbach

O50 Endothelial HLA-DR and HLA-DQ independently drive CD4+ T cell alloproliferation and activation: relevance to transplant rejection

Emad Abed Alkhalidi, Neil Sheerin, Simi Ali

O51 Mapping functional diversity of human leukocyte antigens using their peptide-binding motifs

Pietro Crivello, Mario Hetzel, Julien Racle, David Gfeller, Esteban Arrieta-Bolaños, Katharina Fleischhauer

O52 The natural killer cell receptor KIR2DS4*001 with its HLA ligand is associated with protection against multiple sclerosis

Jacqueline Williams, Katherine Kichula, Noah Kline, Kerry Kizer, Rayo Suseno, Juliano Boquett, Danillo Augusto, Paul Norman, Jill Hollenbach

O53 Potent NK cell alloreactivity evaluated by missing licensing HLA-A3/A11 protects against relapse in haploidentical hematopoietic stem cell transplantation

Xiang-Feng Tang, Hai-Fei Zhou, Xiang-Jun Liu

O54 ERAP2 Depletion Remodels the HLA Class I Immunopeptidome and Potentiates NK Cell Responses in Leukemia

Valentina Scaldaferrri, Paula Gragera, Filipa Da Silva De Vasconcelos, Kirti Pandey, Maria Troiano, Anthony W Purcell, Marco Andreani, Doriana Fruci

12:00-14:00

Lunch, Poster and Exhibition Viewing

12:00-13:00

**Industry Symposium 5
GenDx**

Pentland

13:00-14:00

**Industry Symposium 6
CareDx**

Sidlaw

13:00-14:00

EBTI Assembly

Kilsyth

14:00-15:30

Teaching Session 4: New methods for post transplant monitoring in SOT

Pentland

Chairs: Jakob Nilsson, Manuel Muro

Manuel Muro, Spain

Jakob Nilsson, Switzerland

Stefan Schaub, Switzerland

14:00-15:30

Oral Abstract Session 6: Immunotherapy

Sidlaw

Chairs: Arthi Anand, Rainer Blasczyk

O55 H3K4me3/H3K27me3 mediated epigenetic reprogramming of permissive CpG islands regulates the HLA class II gene expression in IFN- γ primed Mesenchymal Stromal Cells

Panagiotis Mallis, Efstathios Michalopoulos, Eirini-Faidra Sarri, Alexandra Siorenta, Katerina Roumelioti, Alexandros Spyridonidis, Catherine Stavropoulos-Giokas

O56 Reconstitution of hypogammaglobulinemia and specific antibodies is associated with less infection in a randomized trial of IV immunoglobulin in solid organ transplantation with antibody deficiency

Elizabeth Sarmiento, Ikram Ezzahouri, Carlos Ortiz-Bautista, Magdalena Salcedo, Maria Luisa Rodriguez-Ferrero, Jose Cifrian, Rosalia Laporta, Carles Bravo, Jose Gonzalez-Costello, Javier Segovia, Alicia de Pablos, Javier Carbone

O57 Transfusion-Scale Production of Functional Megakaryocytes from iPSCs with Preserved Safety for Civilian and Military Use

Rabea Dettmer, Alice Rovai, Rico Müller, Rainer Blasczyk, Constanca Figueiredo

O58 Generation of low Immunogenic livers by lentiviral vector-mediated genetic engineering delivered during ex vivo liver perfusion

Ali Ahmadi, Lisa Fell, Sevval Besli, Zoltan Czigany, Mariane Fráguas-Eggenschwiller, Rainer Blasczyk, Constanca Figueiredo

O59 PAK4 Gene Augmentation Restores Impaired T-Cell Activation in a Primary Immunodeficiency Model

Feyza Kostak, Ismail Reisli, Ozge Burcu Sahan, Sukru Nail Guner, Sevgi Keles, Suray Pehlivanoglu

O60 Anti-CD19 CAR-T Cell Therapy as a Novel Long-Term Desensitization Strategy for Highly Sensitized Kidney Transplant Candidates

Isabella Guzzo, Marco Becilli, Andrea Cappoli, Pietro Merli, Raffaella Labbadia, Francesca Del Bufalo, Nicola M Tomas, Manuela Colucci, Tobias B Huber, Marco Busutti, Antonio Giuseppe Bianculli, Mattia Algeri, Marco Andreani, Francesco Emma, Franco Locatelli

O61 Combined CD38-mAb and CTLA4-Ig Therapy Enables Effective Desensitization and Transplantation in Highly Sensitized Kidney Candidates with CPRA \geq 99%.

Rajalingam Raja, Stalinraja Maruthamuthu, Sindhu Chandran, Tom Martin, Sue Robertson, Justin Detweiler, Geo Gaile, Cynthia Breeden, Juliete Silva, Megan Morsheimer, Paul Price, Flavio Vincenti

O62 Novel precision immunotherapy for celiac disease with T cells expressing chimeric HLA-DQ-gliadin complexes

Ilse Gille, Renate S. Hagedoorn, Hannah C. M. Schenk, Dennis F. G. Remst, Kim H. Voogt-Bakker, Ellen M.W. van der Meer-Prins, Cynthia S. M. Kramer, Dave L. Roelen, Sebastiaan Heidt, Frits Koning, Mirjam H. M. Heemskerk

O63 HLA-DP-Targeted CAR T-Cells for Selective Elimination of Post-Transplant Leukemia

Mahshad Karimifard, Maren Soldierer, Hannah Breiter, Marie-Sophie Eppler, Anja Rieb, Sebastiaan Heidt, Dirk Reinhardt, Naghmeh Niktoreh, Katharina Fleischhauer, Aniththa Thivakaran, Helmut Hanenberg, Pietro Crivello

14:00-15:30

**Industry Symposium 7
 Bag Diagnostics**

Fintry

15:30-16:00

Refreshments, Poster and Exhibition Viewing

16:00-17:30	Plenary Session Iv - HLA and Disease <i>Chairs: Olivia Shaw, Jill Hollenbach</i>	Pentland Suite
16:00	Evolutionary origin of risk to multiple sclerosis <i>Prof Lars Fugger, UK</i>	
16:30	HLA-B27 and Spondyloarthritis, back to the future? <i>Prof Paul Bowness, UK</i>	
17:00	Exploring somatic evolution and immune escape in lung cancer <i>Prof Nicholas McGranahan, UK</i>	
16:30-17:00	BSHI Award (Terasaki)	
17:30-18:00	EFI Medal Ceremony	Pentland Suite
18:00-19:00	EFI General Assembly	Pentland Suite
19:30	Networking Event	National Museum of Scotland



FRIDAY 24 APRIL 2026

09:00-10:30

Best Oral Abstract Session

Pentland Suite

Chairs: Marco, Luca

O1 Dynamic states of a disulfide-bond engineered MHC I-tapasin complex upon peptide release

Alexandra Mitlehner, Moritz Becker, Tarek Hilal, Bernhard Loll, Christian Freund

O2 HLA-DQ Chimeric HLA Antibody Receptor (CHAR) T cells target HLA-specific B cells to treat HLA sensitisation in solid organ transplantation

Hannah Schenk, Ilse Gille, Carolt Arana, Renate Hagedoorn, Ainhua Garcia-Busquets, Sergi Betriu, Jordi Rovira, Ellen van der Meer-Prins, Eduard Palou, Fritz Diekmann, Dave Roelen, Mirjam Heemskerk, Sebastiaan Heidt

O3 Tolerant Kidney Transplanted Patients Display an Increase of an Anergic Naive B Cell Population

Louison Girodon, François Brinas Brinas, Gaelle Tilly, Thi-Van-Ha Nguyen, Nicolas Sailliet, Laurence Delbos, Clarisse Kerleau, Magali Giral, Nicolas Degauque, Sophie Brouard, Richard Danger

O4 Discovery of a highly promiscuous HLA-A*02:01 specific TCR underpinning CD8+ T cell-mediated allorecognition

Hayley Tucker, Gourav Choudhary, A.K.M Muradmuzzaman, Patricia Illing, Kerry Mullan, Ricardo Fernandes, Kristen Koopmans, Luke Tennant, Dene Littler, Jamie Rossjohn, Anthony Purcell, Nicole Mifsud

O5 Rare but Recurring: Defining the Landscape of HLA Copy Number Variation Through Large-Scale NGS Genotyping

Stefanie Tietze, Madeleine Walker, Schmiedeke Frieder, Schau Isabell, Kathrin Putke, Anja Klußmeier, Jürgen Sauter, Vinzenz Lange

O6 Regulatory B cell Extracellular Vesicles (Breg-EVs): A Novel Cell-Free Therapy to Promote Transplant Tolerance

Amandine DUPUY, Thi-Van-Ha Nguyen, Amélie Rousselière, Nicolas Sailliet, Léo Drapeau, Jérôme Han-Yee-Yu, Alice Grangier, Sylvain Cam, Eugénie Durand, Nathalie Gérard, Véronique Nerrière-Daguin, Richard Danger, Nicolas Degauque, Fabienne Haspot, Magali Giral, Amanda Brun, Florence Gazeau, Sophie Brouard, Hoa Lê Mai

O7 Establishing the rules governing KIR3DL1 recognition of self- and cancer-derived peptides presented by HLA-A*24:02

Shaghik Barani, Andrew Brooks, Jamie Rossjohn

O8 Isolation and identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect

Katharina Korn, Tabea Koch, Vanessa Lang, Katharina Götz, Simone Thomas, Julia Winkler, Anja Wagner, Simon Völkl, Heiko Bruns, Lisa Denzin, Kilian Schober, Carolin Moosmann, Kai Hildner, Andreas Mackensen, Anita Kremer, Hannah Reimann

O9 ERAP1 Inhibition Reprograms the Tumor Microenvironment through Immunopeptidome Remodeling and NK Cell Activation

Paula Gragera, Valentina Scaldaferrì, Kirti Pandey, Martha Nikopaschou, Susanna Dolci, Martina Samiotaki, Yaroslav Kaminskiy, Rui Branca, Efstratios Stratikos, Anthony W. Purcell, Doriana Fruci

10:30-11:00

Refreshments

11:00-12:30	Plenary Session V – Antigen Presentation, Neoantigens and MiHAs	Pentland Suite
	<i>Chairs: Sebastiaan Heidt, Pietro Crivello</i>	
11:00-11:30	Minor Histocompatibility Antigens to Monitor, Predict, and Shape Immune Responses After HLA-Matched Allogeneic Stem Cell Transplantation	
	<i>Prof Marieke Griffioen, the Netherlands</i>	
11:30-12:00	The Secret Messengers: Extracellular Vesicles in Transplant Rejection	
	<i>Prof Carla Baan, the Netherlands</i>	
12:00-12:30	From discoveries to therapy: overcoming challenges in neoantigen-driven cancer immunotherapy	
	<i>Prof Michal Bassani-Sternberg, Switzerland</i>	
12:30-13:30	Closing Ceremony	Pentland Suite
	<i>Chairs: Marco Andreani, David Turner</i>	
12:30-12:40	Jon Van Rood award & Best abstracts award	
12:40-12:45	Best Poster Award	
12:45-13:15	Closing Lecture: The cost of a comprehensive immune defence	
	<i>Prof John Trowsdale</i>	
13:15-13:25	19th IHIW presentation	
13:25-13:30	Welcome to Essen and final remarks	



LIST OF POSTERS

Bioinformatics / Artificial Intelligence

P1 Development of Tools for Combined Sequencing of HLA and Chimerism Libraries on the MGI Platform

Lucas Silva¹, Christopher Pereira¹, Ariane Simm¹, Lucas Pereira¹, Marcelo Mion¹, Wilson Silva²

¹HLA, Biometrix Diagnóstica, Curitiba, Brazil; ²Bioinformatics, MGI Latam, São Paulo, Brazil

P2 Streamlining kidney transplant data: from manual entry to automated donor-recipient compatibility visualization

Iris Van Eeckhout¹, Sonja Verheyden¹, Hideo Imamura², Anton Evenepoel¹

¹Clinical laboratory, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; ²Brussels Interuniversity Genomics High Throughput core (BRIGHTcore) platform, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

P3 Regional HLA Diversity in European Cord Blood Units: Implications for Collaboration in Induced Pluripotent Stem Cell Haplobanking

Martin Maiers¹, Sergio Querol², Helen Latsoudis³, David M Turner⁴

¹CIBMTR (Centre for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN, United States; ²REDMO (Spanish Bone Marrow Registry), Barcelona, Spain; ³Institute of Computer Sciences, Foundation for Research and Technology (FORTH), Crete, Greece; ⁴H&I Lab, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

P4 Advyser Inference: A Machine-Learning-Driven Approach to Quantify Donor-Derived cfDNA Without Pre-Transplant Genotyping

Hamid Ramezani, August Jangerstad, Francesco Vezzi, Naeimeh Taheri, Caitlin Haughey, Yulia Lizneva, Elinor Loverli, Venkat Talla, Silje Abrante

Devyser AB, Stockholm, Sweden

P5 Predictive utility of the HaploStats tool in determining allelic variants in the Polish population.

Dominika Moskalik-Kierat, Martyna Brzoza, Anna Wasilewska, Wiktoria Wypych, Mateusz Mrozowski, Michał Rudek, Aleksandra Konieczna, Marcelina Grabowska

Laboratory of Immunogenetics, University Centre of Laboratory Medicine, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland

P6 Removing barriers to IPD-IMGT/HLA Database submission: data brokering between the IPD-IMGT/HLA and European Nucleotide Archive Databases

Dominic J Barker^{1,2}, Sebastian JF Hopper¹, Andrew D Yates³, Steven GE Marsh², James Robinson^{1,2}

¹Anthony Nolan Research Institute, London, United Kingdom; ²UCL Cancer Institute, Royal Free Campus, London, United Kingdom; ³European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom

P7 An automated, HLA-specific, analysis pipeline for PacBio's long-read sequencing platform - Vega

Matthew Gordon¹, Richard HL Natarajan¹, Thomas R Turner^{1,2}, Michaela Agapiou^{1,2}, Neema P Mayor^{1,2}, James Robinson^{1,2}

¹Anthony Nolan Research Institute, London, United Kingdom; ²UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P8 Evaluating the impact of HLA typing quality on haplotype frequency estimation

Michaela Agapiou^{1,2}, Richard HL Natarajan¹, José Nunes³, James Robinson^{1,2}

¹Anthony Nolan Research Institute, London, United Kingdom; ²UCL Cancer Institute, Royal Free Campus, London, United Kingdom; ³Department of Genetics and Evolution, University of Geneva, Geneva, Switzerland

P9 Development of an ABO genotyping pipeline using statistical phasing of short read sequencing data

Iwan Tebbs

Stem Cell Donor Registry, NHSBT, Bristol, United Kingdom

P10 Advanced Machine Learning and Bioinformatic Modelling for a High-Resolution Population Analysis of the Non-Classical MHC Loci MICA and MICB

Luis Ramalhoto^{1,2,3}, Paula Almeida¹

¹Centro de Sangue e da Transplantação de Lisboa- área da transplantação, Instituto Portugues do Sangue e da Transplantação, Lisboa, Portugal; ²NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal; ³NOVA4Health—Advancing Precision Medicine, Núcleo de Investigação em Doenças Renais, NOVA Medical School, Lisboa, Portugal

P11 Introducing hla-mapper 5, a unified framework for HLA allele calling, copy number determination, and hg38-referenced variant genotyping from short and long-read sequencing data

Erick Castelli^{1,2}, Nayane dos Santos Brito Silva², Heloisa Andrade³, Mohamed Benzahi⁴, Laure Gineau⁵, Sonia Bourguiba-Hachemi⁴, Nicolas Vince⁴, Diogo Meyer³

¹Department of Pathology, School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil; ²Molecular Genetics and Bioinformatics Laboratory, Experimental Research Unit, School of Medicine, São Paulo State University (UNESP), Botucatu, Brazil; ³Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brazil; ⁴Center for Research in Transplantation and Translational Immunology, Nantes Université, INSERM, Nantes, France; ⁵IRD, Inserm, MERIT F-75006, Université Paris Cité, Paris, France

P12 An artificial intelligent model for donor-recipient matching: optimizing deceased-donor kidney allocation

Fatmah MA Naemi¹, Nahed Alowaidi²

¹Histocompatibility and Immunogenetics Laboratory, King Fahd General Hospital, Jeddah, Saudi Arabia; ²Department of Computer Science, Faculty of Computing and Information Technology, King Abdulaziz University, Jeddah, Saudi Arabia

P13 Deep learning based automated interpretation of complement dependent cytotoxicity assays in histocompatibility testing

Cassian Afting¹, Anna-Lena Semmler¹, Salim Oulghazi¹, Julia Ries¹, Torsten Tonn^{1,2}, Hanns-Martin Lorenz³, Christian Seidl¹, Tarik Exner^{3,4}

¹Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Donation Service Baden-Württemberg-Hessen, Frankfurt, Germany; ²Goethe University Hospital Medical School, Frankfurt, Germany; ³Division of Rheumatology, Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; ⁴Heidelberg International Biosciences Graduate School HBIGS, Heidelberg, Germany

P14 Imputing HLA-DRB1 allele group from exomes using hla-mapper and HIBAG

Rafaela Barbosa¹, Erick Castelli², Diogo Meyer³, Leandro Colli⁴, Michel Naslavsky^{3,5}, Nicolas Vince⁶, Eduardo Donadi¹

¹Basic and Applied Immunology Graduate Program, University of São Paulo, Ribeirão Preto, Brazil; ²Department of Pathology, School of Medicine, University Estadual Paulista, Botucatu, Brazil; ³Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brazil; ⁴Department of Medical Imaging, Haematology and Oncology, University of São Paulo, Ribeirão Preto, Brazil; ⁵Hospital Israelita Albert Einstein, São Paulo, Brazil; ⁶Center for Research in Transplantation and Translational Immunology, Nantes Université, Nantes, France

P15 Population study of HLA genes in six West African ethnic groups (Benin) and their impact on HLA imputation in African populations

Nicolas Vince¹, Mohamed Benzahi¹, Jacqueline Milet², Nayane Dos Santos Brito Silva^{1,3}, Gabriela Sato Paes^{1,3}, Sonia Bourguiba-Hachemi¹, David Courtin², Sophie Limou¹, André Garcia², Audrey Sabbagh², Laure Gineau²

¹CR2TI, Nantes Université – Inserm, Nantes, France; ²MERIT, IRD, Paris, France; ³Molecular Genetics and Bioinformatics Laboratory, UNESP, Botucatu, Brazil

P16 An Open-Source Tool for Extracting HLA Typing Data from the HistoTrac Laboratory Information System to Facilitate Molecular HLA Mismatch Analysis with the PIRCHE TxPredictor Platform

Andrés Jaramillo¹, Matthias Niemann²

¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, United States; ²PIRCHE AG, Berlin, Germany

P17 A semi-automated approach to Oxford Nanopore sequencing for on-call organ transplant procedure

Mathijs Groeneweg^{1,2}, Timo Olieslagers^{1,2}, Christien Voorter^{1,2}, Lotte Wieten^{1,2}

¹Transplantation Immunology, Maastricht University Medical Centre, Maastricht, Netherlands; ²GROW, Research Institute for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, Netherlands

P18 Unlocking the Potential of Banked ADCUs: A Matching Modelling Approach

Jürgen Sauter¹, Ute V Solloch¹, Deborah Buk², Henning Baldauf³, Johannes Schetelig³, Alexander Platz⁴

¹DKMS Group, Tübingen, Germany; ²DKMS Donor Centre, Tübingen, Germany; ³DKMS Group, Dresden, Germany; ⁴DKMS Stem Cell Bank, Dresden, Germany

P19 Beyond Single Eplets: Introducing epletPairFinder for Pairwise Analysis of HLA Immunogenicity

Arwa Kamoun^{1,2}, Imen Daoud¹, Aida Charfi¹, Hanen Abid^{2,3}, Mondher Masmoudi^{2,3}, Soumaya Yaich^{2,3}, Lilia Gaddour¹, Faiza Hakim¹, Dhouha Ben Abdallah¹, Ines Kamoun¹, Fedia Oualha¹, Bakhta Mallek¹, Khawla Kammoun^{3,2}, Nadia Mahfoudh¹

¹Immunology Department, Hedi Chaker Hospital, Sfax, Tunisia; ²Renal Pathology Research Laboratory LR19ESI1, Hedi Chaker Hospital, Sfax, Tunisia; ³Nephrology Department, Hedi Chaker Hospital, Sfax, Tunisia

P20 New Bioinformatics Tool for HLA Antigen Delisting to improve Transplant Access in Highly Sensitized Kidney Transplant Candidates

Jean-Baptiste Baudey Baudey^{1,2}, Théo Marchal¹, Thomas Thorrignac¹, Pascal Pedini^{1,2}, Lucas Hubert^{1,2}, Agnes Basire¹

¹Immunogenetics Laboratory, EFS PACA Corse, Marseille, France; ²ADES UMR 7268, Aix Marseille Univ, Marseille, France

P21 Assessment in Athens, Greece, of the performance of SAgA, the Paris tool dedicated to high throughput interpretation of single antigen anti-HLA antibody patterns

Angeliki Vittoraki¹, Valentin Clichet², Chrysanthi Tsirligkani¹, Eleni Stergiopoulou¹, Alexandra Siorenta¹, Andria Yiaskouri¹, Eleni Diamantopoulou¹, Cédric Usureau², Jeremy Siemowski^{2,3}, Romain Lhotte³, Jean-Luc Taupin²

¹Immunology Department and National Tissue Typing Centre, 'G.Gennimatas' Hospital, Athens, Greece; ²Laboratory of Immunology and Histocompatibility, Hôpital Saint-Louis APHP, Paris, France; ³SiLho, Toulouse, France

P22 Unveiling Molecular Drivers of HLA Antibody Reactivity: A Combinatorial Machine Learning Approach to Refine Cross-Reactive Groups

João Henrique Campos¹, Alberto Cardoso Martins Lima¹, Gustavo Alves¹, Maria Gerbase-DeLima¹, Renato de Marco^{1,2,3}

¹Immunogenetics Institute - IGEN, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil; ²Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil; ³Nephrology Division, Universidade Federal de São Paulo, São Paulo, Brazil

P23 Power Query Automation of the Virtual Crossmatch for Low-Risk Kidney Transplant Candidates

Ruby Siegel¹, Timothy Wellerritter¹, Katelyn Johnson², Danielle Troop¹, Justin House¹, Katrin Hacke¹, Jill Adamski¹, Andrés Jaramillo¹

¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, United States; ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States

Cancer Immunogenetics

P24 HLA, MIC, and KIR cooperate to shape immune surveillance in JAK2 V617F+ and CALR-Mutant MPNs

Milena Ivanova¹, Angelina Mladenova¹, Gergana Tsvetkova², Ilina Micheva³, Evgueni Hadjiev², Anela Ivanova⁴, Galja Madjarova⁴, Velizar Shivarov⁵

¹Clinical Immunology, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria; ²Clinical Haematology, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria; ³Clinical Haematology, Saint Marina University Hospital, Varna, Bulgaria; ⁴Physical Chemistry, Department of Physical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University "St. Kl. Ohridski", Sofia, Bulgaria; ⁵Experimental Research, Medical University, Pleven, Bulgaria

P25 Loss of HLA heterozygosity in the haematopoietic stem cell transplant candidate with primary myelofibrosis: a case report

Frantisek Mrazek¹, Nikola Mojtkova¹, Jana Onderkova¹, Veronika Liebscher¹, David Buffa², Petra Richterova²

¹HLA laboratory, Department of Immunology, University Hospital, Olomouc, Czechia; ²Department of Haemato-oncology, University Hospital, Ostrava, Czechia

P26 Escape from synthetic T-cell activator tebentafusp by genomic HLA loss

Halime Kalkavan¹, Andreas Heinold², Gaurav M. Borse¹, Siyang Liu¹, Falko M. Heinemann², Thomas Dertnig³, Jörg Hense¹, Marc Ingenwerth⁴, Fung-Yi Cheung⁵, Georgia Antonopoulou⁵, Ina Pretzell¹, Katharina Fleischhauer⁶, Nikolaos E. Bechrakis⁷, Martin Schuler¹

¹Department of Medical Oncology, University Hospital Essen, Essen, Germany; ²Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany; ³Institute for Diagnostic and Interventional Radiology und Neuroradiology, University Hospital Essen, Essen, Germany; ⁴Institute of Pathology, University Hospital Essen, Essen, Germany; ⁵Bridge Institute of Experimental Tumour Therapy, University Hospital Essen, Essen, Germany; ⁶Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany; ⁷Department of Ophthalmology, University Hospital Essen, Essen, Germany

Haematopoietic Stem Cell Transplantation (HSCT)

P27 Ultra-rapid genetic diagnosis of hemophagocytic lymphohistiocytosis: a decisive breakthrough for emergency genomic medicine

Pascal Pedini^{1,2}, Claire Goudet³, Nisem Cherouat¹, Emma Rateau¹, Théo Marchal¹, Coralie Frassati^{1,2}, Christophe Picard^{1,2}, Nadhir Youfi⁴, Mélanie Corcuff⁵, Christophe Beroud^{5,6}, Thomas Robert⁵, Vincent Barlogis^{3,7}

¹Immunogenetics Laboratory, EFS PACA Corse, Marseille, France; ²UMR 7268 ADES, Aix-Marseille Univ, Marseille, France; ³Department of Paediatric Haematology, Immunology and Oncology, APHM, Timone Children's Hospital, Marseille, France; ⁴INSERM U1155, Sorbonne University, Paris, France; ⁵INSERM, INRAE, C2VN, Aix-Marseille Univ, Marseille, France; ⁶Department of Medical Genetics, APHM, Timone Children's Hospital, Marseille, France; ⁷CERESS, Aix-Marseille Univ, Marseille, France

P28 The impact of HLA evolutionary divergence on the graft failure after HLA-identical allogeneic hematopoietic stem cell transplantation

Ekaterina Khamaganova¹, Mikhail Drovov², Evgeniy Leonov¹, Stanislav Khizhinskiy¹, Olga Pokrovskaya², Larisa Kuzmina², Tatiana Gaponova³, Elena Parovichnikova²

¹Tissue Typing, National Medical Research Centre for Haematology, Moscow, Russia; ²Bone Marrow Transplantation, National Medical Research Centre for Haematology, Moscow, Russia; ³Transfusiology, National Medical Research Centre for Haematology, Moscow, Russia

P29 HLA evolutionary divergence in HLA-incompatible allogeneic hematopoietic stem cell transplantation

Ekaterina Khamaganova¹, Mikhail Drovov², Evgeniy Leonov¹, Stanislav Khizhinskiy¹, Olga Pokrovskaya², Larisa Kuzmina², Tatiana Gaponova³, Elena Parovichnikova²

¹Tissue Typing, National Medical Research Centre for Haematology, Moscow, Russia; ²Bone Marrow Transplantation, National Medical Research Centre for Haematology, Moscow, Russia; ³Transfusiology, National Medical Research Centre for Haematology, Moscow, Russia

P30 Minor histocompatibility antigen database and the effect of minor histocompatibility antigens on the outcome of hematopoietic stem cell transplantation

Julia Nihtilä¹, Urpu Salmenniemi², Maija Itälä-Remes³, Rachel E Crossland⁴, David Gallardo⁵, Maria Bieniaszewska⁶, Sebastian Giebel⁷, Katarzyna Bogunia-Kubik⁸, Kati Hyvärinen¹, Jukka Partanen¹, Jarmo Ritari¹

¹Finnish Red Cross Blood Service, Helsinki, Finland; ²Comprehensive Cancer Centre, Stem Cell transplantation Unit, Helsinki University Hospital, Helsinki, Finland; ³Turku University Hospital, Turku, Finland; ⁴Translational and Clinical Research Institute, Faculty of Medical Science, Newcastle University, Newcastle, United Kingdom; ⁵Department of Haematology, Institut Català d'Oncologia - Hospital Dr. Josep Trueta, Girona, Spain; ⁶Department of Haematology and Transplantation, Medical University of Gdansk, Gdansk, Poland; ⁷Department of Bone Marrow Transplantation and Haematology-Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland; ⁸Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

P31 Controlled Alloreactivity and Survival Advantage in Core-Permissive HLA-DPB1 Mismatched Allogeneic Haematopoietic Stem Cell Transplantation

Reece Mabbett, Luke Foster

Histocompatibility & Immunogenetics, NHS Blood & Transplant, Birmingham, United Kingdom

P32 Results of chimerism analysis in patients with acute lymphoblastic leukaemia who received unrelated HSC transplantation

Aida Turganbekova¹, Zhulduz Zhanzakova¹, Zhazira Saduakas¹, Dana Baimukasheva¹, Didara Khamitova¹, Saniya Abdrakhmanova¹, Balzhan Umirbekova²

¹HLA-laboratory, Scientific and Production Centre for Transfusiology, Astana, Kazakhstan; ²Department Bone marrow transplant for children, The University Medical Centre Corporate Fund, Astana, Kazakhstan

P33 Virtual crossmatching for haematopoietic stem cell transplantation

Rebecca McGuire, Zoe Thomas, Mark Hathaway, Luke Foster

H&I, NHS Blood and Transplant, Birmingham, United Kingdom

P34 NK cells after HSCT and the occurrence of aGvHD in ALL patients

Agnieszka Witkowska¹, Beata Krzymieniewska², Barbara Nsiłowska-Adamska³, Agnieszka Malinowska¹, Magdalena Ołdak¹, Kazimierz Hałaburda⁴, Jacek Nowak¹

¹Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ²Department of Haematology Diagnostics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ³Department of Haematological System Diseases, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ⁴Department of Hematopoietic Cell Transplantation, Institute of Haematology and Transfusion Medicine, Warsaw, Poland

P35 HLA-donor-recipient matching probability estimation on French Bone Marrow Registry data

Igor Faddeenkov¹, Pierre-Antoine Gourraud¹, Gwendaline Guidicelli², Nicolas Vince¹, Sonia Bourguiba-Hachemi¹, Marine Jeantet³, Federico Garnier³, Catherine Faucher³

¹Nantes Université, CHU Nantes, INSERM, CR2TI, UMR 1064, ITUN, Nantes, France; ²CHU de Bordeaux, Bordeaux, France; ³Agence de la Biomédecine, Saint-Denis, France

P36 Role of Multiple Lineage Short Tandem Repeat Testing to Confirm Engraftment and Remission Post-HPCT in Acute Myeloid Leukaemia

Katharine Keyworth¹, Maria Irvine¹, Jennifer Lord¹, Alison Logan¹, Robert Wynn², Srividhya Senthil², Helena Lee¹

¹Transplantation Laboratory, Manchester Royal Infirmary, Manchester, United Kingdom; ²Paediatric Bone Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, United Kingdom

P37 Extending Chimerism Monitoring: Performance characteristics of Devyser's new NGS system for monitoring chimerism levels in stem cell transplantation samples

Emil Nygren¹, Linnea Pettersson^{1,2}, Francesco Vezzi¹, Rikard Eckerud¹, Hamid Ramezani¹, Caitlin Haughey¹, Naeimeh Taheri¹, Yulia Lizneva¹, Julia Paschke¹, Silje Abrante¹, Michael Uhlin^{1,2}

¹Devyser AB, Stockholm, Sweden; ²Department of Medicine, Karolinska Institute, Stockholm, Sweden

P38 Successful Removal of Historic Donor-Specific HLA Antibodies in Haematopoietic Stem Cell Transplantation: A Case Report

Zoe Thomas, Emily Ryan, Mark Hathaway, Luke Foster

NHS Blood and Transplant, Birmingham, United Kingdom

P39 Detection of HLA loss using an NGS-based MHC chimerism method in patients who relapsed post-allogeneic hematopoietic cell transplantation

Fei Ye¹, Wyatt Nelson², Jinjuan Yao¹, Xiuwei Tang¹, Jonathan Barone¹, Charlotte Hughes³, Andromachi Scaradavou⁴, Brian Shaffer³, Daniel Geraghty^{2,5}, Amanda Blouin¹

¹Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Centre, New York, United States; ²Scisco Genetics Inc., Seattle, United States; ³Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, United States; ⁴Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Centre, New York, United States; ⁵Fred Hutchinson Cancer Centre, Seattle, United States

P40 Link between non donor-specific anti-HLA Antibodies and Inferior Key outcomes after Allogeneic stem cell transplantation -The "LAIKA" study-

Davide Chizzoniti^{1,2}, Barbara Sarina², Davide Bernasconi^{3,4}, Lorenzo Del Castello³, Adela Sulejmani⁵, Giuliana Lando⁵, Giovanni Grillo⁵, Stefania Bramanti², Elena Longhi⁶, Patrizia Chiusolo⁷, Sabrina Giammarco⁸, Filippo Frioni⁸, Luisa Giaccone⁹, Silvia Deaglio⁹, Cristiana Caorsi¹⁰, Salvatore Leotta¹¹, Valentina Cappuzzo¹¹, Giovanni Rombolà¹², Roberto Crocchiolo⁵

¹Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy; ²Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; ³Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; ⁴Division of Research Innovation and Technology Transfer, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ⁵Immunohematology and Transfusion Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; ⁶Laboratory of Transplant Immunology, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital Milan, Milan, Italy; ⁷Dipartimento di Scienze di laboratorio ed Ematologiche, Fondazione Policlinico Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy; ⁸Department of Haematology, Università Cattolica del Sacro Cuore, Rome, Italy; ⁹Stem Cell Transplant Program, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy; ¹⁰Immunogenetics and Transplant Biology Service, AOU Città della Salute e della Scienza di Torino, Turin, Italy; ¹¹Division of Haematology, BMT Unit, AOU Policlinico G Rodolico S Marco, Catania, Italy; ¹²Transplant Immunogenetics, AOU Parma, Parma, Italy

P41 HLA allele frequency survey using a Next-generation sequencing platform in Iranian hematopoietic stem cell donors

Amirsalar Nikkhah Bahrami¹, Fatemeh Sabaghi¹, Ebadolah Salek Moghadam², Fatemeh Mohamadali³, Ahad Zare^{4,5}, Hamid Reza Azhideh⁵, Bijan Mahdizadeh⁵, Maryam Zamanvaziri¹

¹HLA typing, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; ²High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; ³Hematology, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; ⁴Microbiology and Immunology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; ⁵HLA typing, Egha Specialized Laboratory, Tehran, Iran

P42 The Power of Verification: Revealing a Hidden HLA Loss

Lilach Gutter Kapon, Amani Anabtawi, Mouna Khateeb Sabbah, Jiana Sbeit

Rambam Medical Centre, Haifa, Israel

P43 Historical evolution of unrelated bone marrow donor recruitment from the Murcia region into the Spanish Bone Marrow Donor Registry and the different conditioning social events between 1992-2025

Manuel Muro-Perez¹, Maria Rosa Moya-Quiles¹, Carmen Botella¹, Jose Antonio Galian¹, Helios Martinez-Banaclocha¹, Marina Fernandez-Gonzalez¹, Maria Jose Alegria¹, Alicia Hita¹, Rosana González López¹, Claudia Rosique¹, Javier Muro¹, Alfredo Minguela¹, Isabel Legaz², Manuel Muro¹

¹Immunology, University Clinical Hospital Virgen de la Arrixaca, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain; ²Legal and Forensic Medicine, University of Murcia, Murcia, Spain

P44 HLA-DRB3/4/5 mismatches in unrelated haematopoietic stem cell transplantation - a single-centre study

Lucie Zemánková, Marie Vallo, Adéla Havelková, Sara Nazarova, Radek Plachý, Anna Dobrovolná, Milena Vraná

Institute of Haematology and Blood Transfusion, Prague, Czechia

P45 Assessment of Quality and Number of Effective Donors Improvement in the Bone Marrow Donor Registry in the Murcia Región in the Southeast of Spain with full HLA typing by Next-Generation Sequencing

Manuel Muro-Perez¹, Maria Rosa Moya-Quiles¹, Carmen Botella¹, Jose Antonio Galian¹, Helios Martinez-Banaclocha¹, Marina Fernandez-Gonzalez¹, Maria Jose Alegria¹, Alicia Hita¹, Rosana González López¹, Claudia Rosique¹, Javier Muro¹, Alfredo Minguela¹, Isabel Legaz², Manuel Muro¹

¹Immunology, University Clinical Hospital Virgen de la Arrixaca, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain; ²Department of Legal and Forensic Medicine, University of Murcia, Murcia, Spain

P46 Clinical impact of the newly reclassified HLA-C*04:09L low-expression allele in allogeneic hematopoietic stem cell transplantation

Francisco Javier Gil Etayo^{1,2}, Rodrigo Gil-Manso^{1,2}, Juan López-Pérez¹, Jairo Eduardo Niño Ramírez¹, Pilar Terradillos Sánchez^{1,2}, Isabel Jiménez Hernanz^{1,2}, Ariadna Vicente Parra^{1,2}, Nuria Calzada Nieto¹, Daniel Arroyo-Sánchez¹, Antonio Costa Anzola¹, Sara Marcos Asensio¹, Estefanía Pérez López^{1,2}, Lourdes Vázquez^{1,2}, Lucía López-Corral^{1,2}, Amalia Tejeda Velarde^{1,2}

¹Haematology Department, University Hospital of Salamanca, Salamanca, Spain; ²IBSAL, Salamanca, Spain

P47 NKG2E, NKG2F, KLRG1 receptors and the CD107a molecule in outcome and regulation of immune response after allogeneic hematopoietic stem cell transplantation

Jagoda Siemaszko¹, Łukasz Tokarski¹, Agnieszka Szeremet², Maciej Majcherek², Anna Czyż², Małgorzata Sobczyk-Kruszelnicka³, Wojciech Fidyk³, Barbara Nasiłowska-Adamska⁴, Patrycja Skowrońska⁵, Maria Bieniaszewska⁶, Agnieszka Tomaszewska⁷, Grzegorz W. Basak⁷, Sebastian Giebel³, Tomasz Wróbel², Katarzyna Bogunia-Kubik¹

¹Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ²Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland; ³Department of Bone Marrow Transplantation and Haematology-Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland; ⁴Institute of Haematology and Blood Transfusion Medicine, Warsaw, Poland; ⁵Cell and Tissue Bank, University Medical Centre in Gdansk, Gdańsk, Poland; ⁶Department of Haematology and Transplantology, Medical University of Gdansk, Gdańsk, Poland; ⁷Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland

P48 The Role of Immunogenetic, Biological and Organizational Factors in Unrelated Hematopoietic Stem Cell Donors Searches for Patients with Hematological Diseases

Klaudia Nestorowicz Kaluzna¹, Jacek Nowak², Malgorzata Dudkiewicz^{3,4}, Jaroslaw Czerwinski^{1,5}, Artur Kamiński^{4,6}

¹Central Bone Marrow Donor Registry, Polish Transplant Coordinating Centre Poltransplant, Warsaw, Poland; ²Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ³Department of Biochemistry and Microbiology, Warsaw University of Life Sciences, Warsaw, Poland; ⁴Polish Transplant Coordinating Centre Poltransplant, Warsaw, Poland; ⁵Department of Emergency Medicine, Medical University of Warsaw, Warsaw, Poland; ⁶Department of Transplantology and Central Tissue Bank, Medical University of Warsaw, Warsaw, Poland

P49 ONtrack: a Prototype kit for chimerism monitoring employing third-generation sequencing

Jolinde van Strien, Maaïke Rijkers, Lisa Rond, Pascal van der Weele

GenDx, Utrecht, Netherlands

P50 Development of a digital PCR-based chimerism monitoring assay

Jolinde van Strien, Bram Luiken, Styn Franken, Pascal van der Weele

GenDx, Utrecht, Netherlands

P51 A new HLA-A allele in an onco-haematological patient

Lucia Assunta Longa¹, Laura Perotti¹, Maristella Pucca¹, Barbara Bruno¹, Rachele Bruggiafreddo¹, Luisa Mariangela Calcagno¹, Federica Piovano¹, Ilaria Avonto¹, Laura Maddalena¹, Giulia Bondielli¹, Lorenzo Comba¹, Nicola Mordini², Roberto Sorasio², Paola Maria Manzini¹

¹SCI Immunohematology and Transfusion Medicine Service, S. Croce e Carle Hospital, Cuneo, Italy; ²SC Haematology, S. Croce e Carle Hospital, Cuneo, Italy

P52 Insights into the Suitability of Bulgaria's Hematopoietic Donor Pool for Producing Hla-Homozygous Induced Pluripotent Stem Cells for Future Haplobanks

Bushra Al Hadra¹, Valentina Atanasova¹, Snezhanka Slavkova¹, Tsvetelin Lukanov^{1,2}, Anastasiya Mihaylova¹, Elissaveta Naumova¹

¹Clinic of Clinical Immunology and Stem Cell Bank, University Hospital Alexandrovska, Sofia, Bulgaria; ²Department of Clinical Immunology, Medical Faculty, Medical University, Sofia, Bulgaria

P53 Application of the new MiSeq i100 Plus Illumina device to detect HLA loss using the Devyser NGS assay

Agnieszka Witkowska, Agnieszka Malinowska, Magdalena Ołdak, Ewa Sztangierska, Jacek Nowak

Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland

P54 Unrelated 'haploidentical' HSCT donor selection criteria for TCR αβ/CD19+ depletion and T memory cell addback for children with inborn errors of immunity

Ruth Chisman¹, Jane Matthews¹, Jarmila Spegarova², Kay Carruthers³, Helen Watson⁴, David Bourn⁵, Lulu Wang², Angela Grainger², Rebecca Payne², Arash Akbarzad-Yousefi¹, Mary Slatter^{2,6}, Su Han Lum⁶, Sophie Hambleton^{2,6}

¹Histocompatibility and Immunogenetics, NHS Blood and Transplant, Newcastle upon Tyne, United Kingdom; ²Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; ³Newcastle Advanced Therapies, Newcastle University, Newcastle upon Tyne, United Kingdom; ⁴Blood Sciences, Newcastle Hospitals Laboratories, Newcastle upon Tyne, United Kingdom; ⁵Newcastle Genetics Laboratory, Institute of Genetic Medicine, Newcastle upon Tyne, United Kingdom; ⁶Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

P55 Dynamics of HLA antibody development after HLA mismatched hematopoietic stem cell transplantation

Marija Burek Kamenaric¹, Lucija Jukic¹, Katarina Stingl Jankovic¹, Nadira Durakovic², Mirta Mikulic², Lana Desnica², Radovan Vrhovac², Zorana Grubic¹, Renata Zunec¹

¹Tissue Typing Centre, Clinical Department for Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia; ²Department of Haematology, Internal Clinic, University Hospital Centre Zagreb, Zagreb, Croatia

P56 Results of immunogenetic selection of donor-recipient pairs accepted for hematopoietic stem cell transplantation in 2022-2025.

Agnieszka Rzeszotarska, Alicja Parszewska, Patrycja Hepnar, Katarzyna Leszczyńska, Jolanta Korsak

Department of Clinical Transfusion Medicine, Military Medical Institute National Research Institute, Warsaw, Poland

P57 Unmasking Homozygosity: Comprehensive Full MHC Sequencing Defines a Rare HLA-B Locus Deletion Uncovered During a Stem Cell Transplant Evaluation

Noureddine Berka¹, Dimitrios Monos², Michael Ponisciak¹, Jonathon Glover¹, Melanie Hagerty¹, Carly Carozza¹, Eric Pimpinella¹, Melina Ntinou², Timothy Mosbrugger², Abdelhamid Liacini¹

¹Histocompatibility, American Red Cross, Philadelphia, United States; ²Clinical Immunology Laboratory, Children Hospital of PhiladelphiaOP, Philadelphia, United States

P58 Impact of Pre-Transplant Methotrexate Use on Immune Response: A case report

Sevim Gonen¹, Ulker Kocak², Zuhre Kaya², Oguz Soylemezoglu³

¹HLA Laboratory, Gazi, Ankara, Turkey; ²Pediatric Haematology, Gazi, Ankara, Turkey; ³Pediatrics, Gazi, Ankara, Turkey

P59 Monitoring of HLA Loss in a group of adult patients after Haploidentical HSCT

Tiziana Galluccio¹, Antonio Novelli², Federica Frenza³, Raffaella Cerretti⁴, Gottardo De Angelis³, Enrico Santinelli⁵, Viola Alesi², Mariarosa Battarra¹, Andrea Di Luzio¹, Annalisa Guagnano¹, Franco Locatelli⁶, Marco Andreani¹

¹Transplant Immunogenetics Laboratory, Oncohematology and Cellular and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; ²Cytogenetic Research Unit, Medical Genetics Laboratory, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; ³Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy; ⁴Stem Cell Transplantation Unit, Tor Vergata Policlinic Foundation, Rome Transplant Network, Rome, Italy; ⁵Hematology, Campus Bio-Medico University Hospital Foundation, Rome, Italy; ⁶Department of Paediatric Haematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy

P60 Analysis of HLA-DPBI epitopes and assessment of immunological risk in a patient candidate for HSCT

Fabio Viggiani¹, Floriana Giorgio¹, Patrizia Grazia Castellaneta¹, Antonio Mellone¹, Mario Vito Monteleone¹, Francesca Bellini¹, Alex Latorre¹, Federica Matera¹, Antonio Spinelli¹, Paola Carluccio², Immacolata Attolico², Alessandro Marinelli¹, Giovanna Mongelli¹

¹O.U. Tissue Typing and Transplant Immunology, Policlinico of Bari, Bari, Italy; ²Department of Emergency - Section of Haematology, Policlinico of Bari, Bari, Italy

P61 The challenges of transplanting a highly sensitised AML patient undergoing haematopoietic cell transplant.

Hannah Turnbull¹, James Peat¹, Franco Tavarozzi¹, Raymond Fernando^{2,1}, Neema P Mayor^{3,4}, Lisa Walsh¹, Sharon Vivers^{1,4}, Sandra Frater¹

¹H&I Laboratory, Anthony Nolan, London, United Kingdom; ²H&I Laboratory, Royal Free Hospital, London, United Kingdom; ³Anthony Nolan Research Institute, London, United Kingdom; ⁴UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P62 Retrospective Analysis Reveals an Effect of Donor Kir Haplotype on Clinical Outcomes in Patients with Haematological Malignancies Following Haploidentical Transplantation

Tsvetelin Lukanov^{1,2}, Anastasiya Mihaylova¹, Yavor Petrov³, Andriyana Bankova⁴, Krasen Venkov⁴, Kameliya Kostadinova⁴, Antoaneta Nediyaalkova¹, Lidia Tsitselkova¹, Angelina Mladenova¹, Iliana Micheva³, Georgi Mihaylov⁴, Elissaveta Naumova¹

¹Clinic of Clinical Immunology with Stem Cell Bank, University Hospital "Alexandrovskya", Sofia, Bulgaria; ²Department of Clinical Immunology, Medical University-Sofia, Sofia, Bulgaria; ³University Hospital "St. Marina", Varna, Bulgaria; ⁴Specialized Hospital For Active Treatment Of Haematological Diseases, Sofia, Bulgaria

P63 Beyond the 10/10 Match: A Clinically Significant HLA-DPBI Mismatch in a Sibling Donor

Amal Algharably¹, Ali Tariq¹, Hana Alkhabbaz², Moheeb Awwami¹

¹Kidney and Pancreas Health Centre, King Faisal Specialist Hospital, Riyadh, Saudi Arabia; ²Riyadh University, Riyadh, Saudi Arabia

P64 Eplet mismatches, DSA and rejection in paediatric patients affected by malignant and non-malignant haematological diseases treated with haploidentical hematopoietic stem cell transplantation

Paola Giustiniani¹, Federica Galaverna², Pietro Merli², Antonio Giuseppe Bianculli¹, Francesco Quagliariella², Chiara Rosignoli², Marco Becilli², Roberto Carta², Emilia Boccieri², Maria Troiano¹, Rita Maria Pinto², Mariarosa Battarra¹, Marco Andreani¹, Franco Locatelli^{2,3}

¹Laboratory of Transplant Immunogenetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; ²Department of Paediatric Haematology/Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; ³Catholic University of the Sacred Heart, Rome, Italy

P65 CD3+ T-cell versus peripheral blood chimerism for relapse risk prediction after allogeneic haematopoietic stem cell transplantation

Bonni Pieterse^{1,2}, Robyn Marshall¹, Michael S Pepper²

¹Oncolab Diagnostics, Pretoria, South Africa; ²Department of Immunology, University of Pretoria, Pretoria, South Africa

P66 A Challenging Donor Selection for HSCT Involving Plasma exchange, with both HLA-specific and Blood Group specific antibodies.

Leigh Keen¹, Anthony Calvert¹, Maria Burton¹, Lorraine Flores¹, Kirti Mepani², Anthony Poles¹

¹Histocompatibility and Immunogenetics, NHS Blood and Transplant, Bristol, United Kingdom; ²Histocompatibility and Immunogenetics, NHS Blood and Transplant, Colindale, United Kingdom

HLA Antigen Processing and Presentation

P67 Molecular Mechanisms and Immunological Significance of HLA Antigen Processing and Presentation in Health, Disease, and Transplantation

Ehtuish Ehtuish

Surgery, Libyan Transplant Authority LTA, Tripoli, Libya

P68 Optimization of the Luminex® single antigen bead assay protocol

Christina Merk^{1,2}, Elisa Amann^{1,2}, Amelie Schmid-Möglich^{1,2}, Melanie Gerster^{1,2}, Aysenur Arslan^{1,2}, Christine Neuchel^{1,2}, Teresa Saal^{1,2}, Hubert Schrezenmeier^{1,2}, Daniel Fürst^{1,2}

¹Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, Ulm, Germany; ²Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

P69 Analysis of celiac disease frequency in DQ8 subtypes in the Basque Country: Comparison between HLA-DQB1*03:02 and HLA-DQB1*03:05

Nerea Muñoz Llanes, Daniel Sala Fernández, Sandra Guiral Foz, Nerea Olivares Beobide, Marta Alonso Varela, Paula Arana Berganza, Bernabé Dávila De Las Fuentes, Alexandre Bosch Martinez, Aránzazu Pacho de Lucas

Immunology, Osakidetza, Barakaldo, Spain

P70 Eplet mismatch: a new determinant of the occurrence of de novo DSA in heart transplantation

Dan Adrian Luscalov¹, Ana-Maria-Cristina Drella², Carole Saison¹, Philippe Moskovtchenko¹, Catherine Giannoli¹, Sarah Hamada¹, Xavier Fournel¹, Lamis Haider², Flora Kochly², Valerie Dubois¹, Laurent Sebbag²

¹Laboratoire HLA, EFS, Lyon, France; ²Service d'Insuffisance Cardiaque, Hôpital Louis Pradel, HCL Lyon, Lyon, France

P71 HLA as a biomarker for susceptibility to bullous pemphigoid and gliptin- associated bullous pemphigoid in a highly HLA heterogeneous population.

Helen Latsoudis^{1,2}, Eirini Kavvalou³, Sabine-Elke Krüger-Krasagakis³, Paraskevi Xekouki⁴, Vasiliki Daraki⁴, Irene Mavroudi², Helen A. Papadaki², Maria Polina Konstantinou³, Konstantinos Krasagakis³

¹Institute of Computer Sciences, Foundation for Research and Technology Hellas, Heraklion, Greece; ²Hematopoiesis Laboratory, School of Medicine, University of Crete, Heraklion, Greece; ³Department of Dermatology, University General Hospital of Heraklion, Heraklion, Greece; ⁴Department of Endocrinology, University General Hospital of Heraklion, Heraklion, Greece

P72 Unexpected Negative Crossmatch in a kidney Transplant Candidate with Multiple class II DSA

Amal Algharably¹, Ali Tariq¹, Hassan Aleid¹, Hana Alkhabbaz², Moheeb Awwami¹

¹Kidney and Pancreas Health Centre, King Faisal specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ²Riyadh University, Riyadh, Saudi Arabia

P73 Towards understanding the requirement of HLA-G typing for post-transplant management strategies

Laura Haberder, Funmilola Haukamp, Wiebke Hiemisch, Rainer Blasczyk, Christina Bade-Döding

Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany

Immunogenetics and Infections

P74 Higher HLA-E expression at the placenta: a potential mechanism for combating SARS-CoV-2 infection?

Suelen Zeck¹, Monica Goldstein², Newton Sergio Carvalho², Maria Graça Bicalho¹

¹LIGH-Genetics, Federal University of Paraná, Curitiba, Brazil; ²PGTOCO-Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil

P75 Clinical and Immunological Characteristics of Paediatric Haemolytic Uremic Syndrome: a Case Control Egyptian Study

Shereen Mahmoud Shawky^{1,2}, Walaa Abdel Fattah³, FatmaH Abdel Raouf³, Mai Emamm², Amina Abdelsalam², Neveen A Soliman²

¹Clinical & Chemical pathology, Faculty of Medicine, Cairo University, Cairo, Egypt; ²Pediatric Department, Faculty of Medicine, Cairo University, Cairo, Egypt; ³Clinical & Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

P76 Molecular study of the mannose-binding lectin gene to predict infection in heart transplantation

Ikram Ezzahouri¹, Elizabeth Sarmiento¹, Francisco Lozano², Carmen Rodriguez-Sainz³, Patricia Muñoz⁴, Carlos Ortiz-Bautista⁵, Javier Carbone^{1,6}

¹Immunology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ²Servicio de Inmunología, Hospital Clinic de Barcelona, Barcelona, Spain; ³Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁴Microbiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁵Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁶Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Madrid, Spain

P77 HLA alleles in patients with juvenile idiopathic arthritis in North Macedonia

Meri Kirijas¹, Marija Neshkovska Shumenkovska², Gorjan Milanovski¹, Dejan Trajkov¹, Teodora Brnjarchevska Blazevska¹, Tamara Savevska Milanovska¹, Stefan Nedelkoski¹, Sanja Kajevik¹, Aleksandar Petlichkovski¹

¹Institute of Immunobiology and Human Genetics, Medical Faculty Skopje, Skopje, North Macedonia; ²University Clinic for Paediatric Diseases, Faculty of Medicine Skopje, Skopje, North Macedonia

P78 Lack of association between HLA-C alleles and alcoholic liver cirrhosis: insights from a case control study

Celia Maria Carrillo-Palazon¹, Manuel Muro-Perez², Javier Muro², Maria Rosa Moya-Quiles², Manuel Muro², Isabel Legaz¹

¹Department of Legal and Forensic Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Murcia, Spain; ²Immunology, University Clinical Hospital "Virgen de la Arrixaca" - IMIB, Murcia, Spain

P79 HLA haplotypes would not explain the HLA-Multiple Sclerosis association

Anna Serova-Erard^{1,2}, Igor Faddeenkov¹, Laury Nicolas³, Stanislas Demuth⁴, Sonia Bourguiba-Hachemi¹, Laureline Berthelot¹, Pierre-Antoine Gourraud^{1,5}, Nicolas Vince¹, François Cornélis^{1,2,6}

¹CR2T1 - Centre for Research in Transplantation and Translational Immunology UMR1064, Nantes Université, INSERM, Nantes, France; ²Génétique - Oncogénétique Adulte - Prévention (GENOAP), CHU Clermont-Ferrand, Clermont-Ferrand, France; ³Génétique Médicale - Oncogénétique Adulte - Prévention (GENOAP), CHU Guadeloupe, Pointe-à-Pitre, France; ⁴Neurologie, CHU Orléans, Orléans, France; ⁵Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM CIC 1413, Nantes Université, CHU Nantes, Nantes, France; ⁶UFR de Médecine et des professions paramédicales, Université Clermont Auvergne, Clermont-Ferrand, France

P80 HLA Genotype and Autoantibody Intensity in Individuals Evaluated for Celiac Disease

Vasiliki Kitsiou, Christina Salamaliki, Petros Mantzios, Elissavet Kontou, Theofilos Athanassiades, Stella Pomoni, Diamanto Kouniaki, Katerina Tarassi, Alexandra Tsirogianni

Immunology-Histocompatibility Dept., Evangelismos Hospital, Athens, Greece

P81 Identification of the DQB1*03:289 allele associated with the DRB4*01:03:01:02N null allele in DR4-positive cells

Cristina Abad Molina¹, Vinicius Stelet², Sandra García-Jiménez¹, Rafael Cita³, Alberto Torio⁴, Armando Coca-Rojo⁵, Francisco Boix⁶

¹Servicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ²Laboratório de Imunogenética, Instituto Nacional de Câncer, Rio de Janeiro, Brazil; ³Laboratório de Imunologia de Transplantes, Fundação Pio XII Barretos, São Paulo, Brazil; ⁴Sección de Inmunología, Hospital Regional Universitario de Málaga, Málaga, Spain; ⁵Servicio de Nefrología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ⁶Laboratorio de Histocompatibilidad, Centro de Transfusion de la Comunidad Valenciana, Valencia, Spain

P82 NG-Mix Plus, HLA typing reagent for 2nd and 3rd sequencing generation

Sophie Rose, Florence Bennasar, Yannic Danger, Franck Vérité

EFS Réactifs, EFS, Rennes, France

P83 Distribution of DRB1*04, DRB1*07, and DRB1*09 Alleles in Cadaveric Donors and Their Association with DRB4*01:03:01:02N in the Spanish Population

Cristina Abad Molina¹, Francisco Boix², Mario Cádaba-Arranz¹, Miriam Vilches-Moreno³, Elena Bustamante-Munguira⁴, José María Eiros-Bouza¹, Armando Coca-Rojo⁵

¹Servicio de Microbiología e Inmunología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ²Laboratorio de Histocompatibilidad, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain; ³UGC Hematología, Inmunología y Genética, Hospital Universitario Puerta del Mar, Cádiz, Spain; ⁴Servicio de Medicina Intensiva, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ⁵Servicio de Nefrología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

P84 HLA-G allelic diversity and its association with COVID-19 severity in a German cohort

Nina Grünen¹, Yannik Busch¹, Sabine Schramm², Mona Otte³, Margarethe Konik³, Krystallenia Paniskaki³, Sarah Jansen³, Johanna Reinold³, Anja Gäckler³, Adalbert Krawczyk³, Benjamin Wilde³, Birte Möhlendick⁴, Winfried Siffert⁴, Thorsten Brenner⁵, Peter A. Horn², Oliver Witzke³, Marco Schäfer¹, Wolfgang Peter¹, Vera Rebmann², Hana Rohn³

¹Stefan Morsch Stiftung, Birkenfeld, Germany; ²Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ³Department for Infectious Diseases and Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ⁴Institute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ⁵Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Immunological Tolerance, Immunotherapy and Gene Therapy

P85 Presence of HLA-DRB3 is Associated with Distinct Antibody Profiles in Patients with Suspected Immune-Mediated Platelet Disorders

Sarah Petermann, Inga Stellmacher, Monika Steitz, Antje Ströhm, Friedrich Arndts, Alexander Carbol, Lambros Kordelas

German Red Cross Blood Donation Service West, Ratingen, Germany

P86 Soluble co-signalling molecules as a non-invasive diagnostic tool to predict graft injury after kidney transplantation

Alessandra Panarese^{1,2}, Fabio Vistoli^{1,2}, Ivana Abruscio¹, Pierluigi Sebastiani³, Gabriele Turacchio³, Alessia Colanardi³, Tiziana Del Beato³, Carla Cervelli⁴, Franco Papola⁴, Angelica Canossi³

¹Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, Coppito 2, L'Aquila, Italy; ²Division of General and Transplant Surgery, San Salvatore Hospital ASL1 Abruzzo, San Salvatore Hospital ASL1 Abruzzo, L'Aquila, Italy; ³Biomedical Sciences, CNR Translational Pharmacology, Via Giosuè Carducci 32C, L'Aquila, Italy; ⁴San Salvatore Hospital, Organs Transplantation and Immunology, L'Aquila, Italy

P87 Shared HLA Allelic Signatures in Myasthenia Gravis and Spondyloarthritis: Insights into Common Autoimmune Mechanisms

Mariana Pavel-Tanasa, Ruxandra Nagit, Cristina Croitoru, Corina Cianga, Daniela Constantinescu, Petru Cianga

Department of Immunology, Grigore T. Popa University of Medicine and Pharmacy Iasi, Iasi, Romania

P88 Eplet-Level Donor-Specific HLA Antibody Formation After Local Allogeneic MSC Injection in Ulcerative Colitis: The Impact of Structural Surface Exposure of the Eplets

Stine Fischer Fogsgaard¹, Anaïs Marie Julie Moeller², Suzanne Reitsma Bianchi², Rasmus Roost Aabling², Anders Dige³, Jørgen Steen Agnholt³, Klaus Krogh³, Bjarne Kuno Moeller^{2,1}

¹Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; ²Center for Gene and Cellular Therapy, Aarhus University Hospital, Aarhus, Denmark; ³Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

This poster will not be presented on site

P89 Anti-cytomegalovirus immunoglobulin increases specific CD8 anti-CMV responses in high-risk thoracic recipients

Elizabeth Sarmiento^{1,2}, Rocio Alonso³, Ikram Ezzahouri³, Irene Algaba³, Rosalia Laporta⁴, Myriam Aguilar⁴, Carlos Ortiz-Bautista⁵, Javier Segovia⁶, Manuel Gomez-Bueno⁶, María Alejandra Mejía¹, Jose Cifrian⁷, Victor Mora⁷, Javier Carbone^{3,1,8}

¹Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²Immunology, Hospital Central de la Defensa Gomez Ulla, Madrid, Spain; ³Immunology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ⁴Pulmonology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ⁵Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁶Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ⁷Pulmonology, Hospital Universitario Marques de Valdecilla, Santander, Spain; ⁸Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Madrid, Spain

P90 Advancing HLA-G Based Regulatory T-Cell Therapy: Clinical-Scale Optimization and Novel Sources for Next-Generation iG-Treg Products

Chryso Pierides¹, Maria Kyriakou¹, Memnon Lysandrou², Dionysia Kefala², Xeni Beli², Nikolaos Savvopoulos², Alexandros Spyridonidis², Paul Costeas¹

¹The Centre for the Study of Haematological Malignancies, Karaiskaki Foundation, Nicosia, Cyprus; ²Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Rio, Greece

P91 Comparative Functional Profiling of CAR-T and TCR-T Cells in Haematological Malignancies

Emilia Jaskuła^{1,2}, Anna Andrzejczak¹, Robert Mroczek¹, Krystian Sarat¹, Anna Tomkiewicz³, Katarzyna Koscińska⁴, Jagoda Mierzejewska¹, Monika Jasek¹, Marta Wagner¹, Julia Depta¹, Monika Chaszczewska-Markowska¹, Agnieszka Szczygieł¹, Anna Rudawska¹, Katarzyna Węgierek-Ciura¹, Bożena Szermer-Olearnik³, Michalina Gos¹, Lidia Karabon¹

¹Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ²Lower Silesian Oncology Haematology and Pulmonology Centre, Wrocław, Poland; ³Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ⁴Lower Silesian Oncology Haematology and Pulmonology Centre, Wrocław, Poland

MHC, Evolution, Anthropology, Population Genetics

P92 High Frequency of Full Parental HLA Matches in a Consanguineous Population: A Large-Scale Study from the Kurdistan Region of Iraq

Rawand Al-Qadi, Saadallah Fareeq Salih, Heleen Jalal

Duhok's Specialized Laboratory Centre, Duhok, Iraq

P93 HLA-B leader genotypes in the Russians of Southern Region of Russia

Elena Kuzmich, Irina Pavlova, Tatiana Glazanova, Alina Egorova, Ludmila Bubnova

Research laboratory of immunology, Russian Research Institute of Haematology and Transfusiology, Saint Petersburg, Russia

P94 Allelic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 in Central Anatolia, Türkiye

Mustafa Yavuz Köker

Immunology, Erciyes Medical School, Kayseri, Turkey

P95 New associations between HLA-DQA1 and DPB1 alleles and aplastic anaemia in the population of Kazakhstan

Aida Turganbekova^{1,2}, Zhulduz Zhanzakova¹, Dana Baimukasheva¹, Zhazira Saduakas¹, Didara Khamitova¹, Saniya Abdrakhmanova¹, Zhaksylyk Masalimov²

¹HLA-laboratory, Scientific and Production Centre for Transfusiology, Astana, Kazakhstan; ²The Faculty of Natural Sciences, L.N. Gumilyov Eurasian National University, Astana, Kazakhstan

P96 Ultra-high resolution allele and haplotype frequencies of classical HLA class II genes in a UK cohort

Thomas R Turner^{1,2}, Michaela Agapiou^{1,2}, Albert JE French¹, James Robinson^{1,2}, Neema P Mayor^{1,2}

¹Anthony Nolan Research Institute, London, United Kingdom; ²UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P97 Associations of HLA-A, -B and -DRB1 alleles in patients with Sjögren's syndrome in population of south Croatia

Sonja Jaman^{1,2}, Barbara Stanić^{1,2}, Matea Tarabene^{1,2}, Lucija Meštrović¹, Esma Čečuk-Jeličić²

¹Tissue Typing Laboratory, University Hospital of Split, Split, Croatia; ²Faculty of Health Sciences, University of Split, Split, Croatia

P98 An unusual DRB1*08 (DR8) HLA class II haplotype carrying a DRB3- (DR52) and a DRB2- (Ψ) pseudogene observed in so far five unrelated European families

Thomas Binder¹, Reinhard Kelsch², Antje Siegl¹, Peter Diegel³, Yannik Busch³, Marco Schäfer³, Wolfgang Peter³, Thomas H Eiermann⁴

¹HLA-Laboratory, University Medicine Rostock, Rostock, Germany; ²HLA-Laboratory, University Medicine Münster Medicine Rostock, Münster, Germany; ³HLA-Laboratory, Stefan Morsch Foundation (SMS), Birkenfeld, Germany; ⁴Home, Ulm, Germany

P99 Ultra-high resolution HLA-DMA, -DMB, -DOA and -DOB allele and haplotype frequencies in a cohort of UK haematopoietic cell transplant donors

Albert JE French¹, Michaela Agapiou^{1,2}, Thomas R Turner^{1,2}, James Robinson^{1,2}, Neema P Mayor^{1,2}

¹Anthony Nolan Research Institute, London, United Kingdom; ²UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P100 Pharmacogenomically relevant HLA alleles in two defined ethnic groups from North India

Uma Kanga¹, Abhishweta Saxena^{1,2}, Gaurav Sharma³, Shweta Tyagi¹, Poonam Coshic⁴

¹Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, New Delhi, India; ²Department of Health Research, Ministry of Health & Family Welfare, New Delhi, India; ³Department of Translational & Regenerative Medicine, PGIMER, Chandigarh, India; ⁴Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, New Delhi, India

P101 HLA-B*27 allele distribution and agreement between PCR and SSO Typing in Patients with Ankylosing Spondylitis

Karla Escobar Castro^{1,2}, Alicia Yupe^{3,4}, Dulce Luna Muñoz⁴, Adolfo Santizo^{1,4}, Juan Carlos Castillo⁴, Silvia Archila^{1,4}, Juan Barillas Navas⁴, Elioencal Perez¹

¹Nephrology & transplant, Hospital General San Juan De Dios, Guatemala; ²Centro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala; ³Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala; ⁴Dirección General de Investigación, Universidad de San Carlos de Guatemala, Guatemala

P102 Three-field allele and haplotype frequencies, and linkage disequilibrium of HLA-DQA1, -DQB1 and -DRB1 in 603 Chinese Han families

Pan Zhang¹, Maoquan Qin², Junbo He³, Xiang-Jun Liu³

¹Department of Stem cell Transplantation, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, China; ²Department of Stem cell Transplantation, Beijing Children's Hospital, Capital Medical University, Beijing, China; ³Beijing BoFuRui Gene Diagnostics Co., Ltd., Beijing, China

P103 Neanderthals and HLA: the African signature of an ancient immune system

Pascal Pedini^{1,2}, Théo Marchal^{1,2}, Coralie Frassati^{1,2}, Silvana Condemni¹, Jacques Chiaroni^{1,2}, Stéphane Mazières¹

¹GENGLOB UMR 7268 ADES, Aix-Marseille Univ, Marseille, France; ²Immunogenetics Laboratory, EFS PACA Corse, Marseille, France

P104 The Regional HLA Heterogeneity: A Determining Factor for a Future Haplobank in Greece

Helen Latsoudis¹, Prodromos Papadopoulos¹, Jürgen Sauter², Irene Mavroudi^{3,4}, Aggeliki Xagorari⁵, Alexandros Spyridonidis^{6,7}, Maria Smaili⁷, Anastasios Manolis⁸, Damianos Sotiropoulos⁵, Catherine Stavropoulos-Giokas⁶, Pavlos Costeas⁹, Pavlos Pavlidis¹, Helen A. Papadaki^{3,4}

¹Institute of Computer Sciences, Foundation for Research and Technology Hellas, Heraklion, Greece; ²DKMS Group, Tübingen, Germany; ³Public Cord Blood Bank of Crete, University Hospital of Heraklion, Heraklion, Greece; ⁴Haematopoiesis Research Laboratory, School of medicine, University of Crete, Heraklion, Greece; ⁵Department of Haematology, Papanikolaou General Hospital, Thessaloniki, Greece; ⁶Hellenic Cord Blood Bank, Hellenic Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece; ⁷The Centre to Advance Public Awareness & Recruitment of Bone Marrow Donor Volunteers (CBMDP) – "Save a Life", Patras, Greece; ⁸Hellenic Transplant Organisation (HTO), Athens, Greece; ⁹Public Cord Blood Registry, Karaiskaki Foundation, Nicosia, Cyprus

P105 Novel insights into HLA-B*27 alleles and haplotype polymorphisms through Next-Generation Sequencing

Zorana Grubic, Katarina Stingl Jankovic, Lucija Jukic, Marija Burek Kamenaric, Renata Zunec

Tissue Typing Centre, Clinical Department for Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia

P106 High resolution 11-Loci HLA Typing to Improve Renal and HSCT Outcomes in diverse North India Population

Yoginder Pal Singh¹, Ajay Kumar Baranwal², Narinder Kumar Mehra¹

¹Centre of Excellence for HLA and Transplant Immunology, Agilus Diagnostics Limited, Gurgaon, India; ²Dept. of Lab Sciences & Molecular Medicine, Army Hospital Research & Referral, New-Delhi, India

P107 Presence of Rare HLA Alleles in Bone Marrow Donors from Apulia and Comparison with International Frequencies

Patrizia Grazia Castellaneta, Fabio Viggiani, Floriana Giorgio, Francesca Bellini, Alex Latorre, Alessandro Marinelli, Federica Matera, Antonio Mellone, Mario Vito Monteleone, Antonio Spinelli, Giovanna Mongelli

O.U. Tissue Typing and Transplant Immunology, Policlinico of Bari, Bari, Italy

P108 A DR51 Haplotype with DRB1*15:03~DRB5 null is a recombinant of a DR51 and DRB1*01:02 DRI haplotype

Lindley Blair, Nikolai Alexandrov, Ting Wang, Dave Lowe, David Sayer

Research & Development, ThermoFisher Scientific, West Hills, CA, United States

P109 Pan-Genomic Analyses Reveal the Immunogenetic and Demographic History of an Isolated Amazonian Community.

Antonia Walter¹, Diana-Iraíz Hernández-Zaragoza¹, Ana-María Tito-Álvarez², Emilia Vásquez-Domínguez³, Angie Camila Cadena Ramos¹, Trija Nag Chowdhury¹, Adam Ben Rohlach¹, Chiara Barbieri^{4,5}, Camilo Zurita⁶, Johannes Krause¹, Rodrigo Barquera¹

¹Archaeogenetics, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany; ²Nursing Program, Universidad de las Américas (UDLA), Quito, Ecuador; ³Biotechnology, Universidad de las Américas (UDLA), Quito, Ecuador; ⁴Life and Environmental Sciences, University of Cagliari, Cagliari, Italy; ⁵Evolutionary Biology and Environmental Studies, University of Zurich, Zurich, Switzerland; ⁶Biomedicine Research Unit, Zurita & Zurita Laboratorios, Quito, Ecuador

P110 HLA-J and HLA-E as markers for sequence variability within the HLA class I region

Ting Wang, Nikolai Alexandrov, Lindley Blair, Dave Lowe, David Sayer

Specialty Diagnostics Group, Thermo Fisher Scientific, West Hills, United States

P111 Immunogenetic and Population Genetics Analyses of the Yaqui (Northwestern Mexico)

Trija Nag Chowdhury¹, Diana-Iraíz Hernández-Zaragoza¹, Abraham Aguilar², Ricardo Serrano-Osuna³, Adam Ben Rohlach¹, Angie Cadena-Ramos⁴, Johannes Krause¹, Rodrigo Barquera¹

¹Department of Archaeogenetics, Max Planck Institute of Evolutionary Anthropology, Leipzig, Germany; ²Blood Bank, Hospital General de Zona #30, IMSS, Mexicali, Mexico; ³Central Laboratory, UMAE-IMSS, Ciudad Obregón, Mexico; ⁴Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil

P112 Using Immunogenetic Markers to Estimate Genetic Admixture in the Americas

Diana-Iraíz Hernández-Zaragoza^{1,2}, Victor Acuña-Alonzo², Esteban Arrieta-Bolaños^{3,4}, Rodrigo Barquera¹

¹Archaeogenetics, Max-Planck Institute for Evolutionary Anthropology (MPI-EVA), Leipzig, Germany; ²Molecular Genetics Laboratory, Escuela Nacional de Antropología e Historia (ENAH), Mexico City, Mexico; ³Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany; ⁴German Cancer Consortium (DKTK), Essen, Germany

New Technologies, Various

P113 Post-transplant chimerism: third-generation sequencing serving reactivity and precision

Pascal Pedini^{1,2}, Sandrine Maioli¹, Nisem Cherouat¹, Coralie Frassati^{1,2}, Agnes Basire¹, Vincent Barlogis³, Christophe Picard^{1,2}

¹Laboratory of Immunogenetics, Reference Laboratory "Chimerism", French Blood Establishment, Marseille, France; ²ADES UMR 7268, Aix-Marseille University, Marseille, France; ³Department of Haematology, Immunology and Paediatric Oncology, APHM, Timone Children's Hospital, Marseille, France

P114 Full-Length-Characterization of more than 120 Novel HLA-DRB3/4/5 Alleles for Submission to the IPD-IMGT/HLA Database

Annett Heidl, Christin Paech, Kathrin Putke, Vinzenz Lange, Anja Klussmeier

DKMS Life Science Lab, Dresden, Germany

P115 Rapid ABO genotyping assay in combination with HLA genotyping

Steve Chang¹, Hao Wang², Bobbie S Rhodes-Clark³, Cathy Gebhart⁴, Valia Bravo-Egana⁵, Dan Dou²

¹CareDx, CO, United States; ²CareDx, Stockholm, Sweden; ³Department of Advance Cardiopulmonary Therapies and Transplantations, McGovern Medical School /UTHealth Houston, TX, United States; ⁴LifeLink Transplantation Immunology Lab, FL, United States; ⁵Histocompatibility/Immunology Laboratory, Medical College of Georgia/Augusta University, GA, United States

P116 Rethinking Contamination Controls in clinical NGS Testing: Why No-Template Controls Fall Short

Jesse Cox¹, Shelly Williams¹, Shannen Bishop¹, Sophie Hauxwell¹, Narin Tangprasertchai², Thierry Viard²

¹Department of Pathology and Microbiology, University of Nebraska Medical Centre, Omaha, United States; ²R&D Department, CareDx, Inc, Brisbane, United States

P117 The effect of IVIG on the Single Antigen Bead analysis interpretation

Katerina Jaklova¹, Matej Roder¹, Aneta Glosova¹, Marketa Novakova¹, Tereza Jancuskova¹, Antonij Slavcev¹, Filip Hruby²

¹Immunogenetics, IKEM, Prague, Czechia; ²IT, IKEM, Prague, Czechia

P118 Evaluation of NGS-Pronto® Oxford Nanopore Long-Read Workflow for Routine Clinical HLA Typing

Simon Mathers, Michelle Carr, Claire Seymour, Jennifer Lord, Alison Logan, Anna Barker

Transplantation Laboratory, Manchester University Foundation Trust, Manchester, United Kingdom

P119 A single-centre experience in identifying novel HLA alleles through next-generation sequencing

Amalia Tejada Velarde^{1,2}, Juan López-Pérez¹, Jairo Eduardo Niño Ramírez¹, Pilar Terradillos Sánchez^{1,2}, Ariadna Vicente Parra^{1,2}, Isabel Jiménez Hernaz^{1,2}, Nuria Calzada Nieto^{1,2}, Antonio Costa Anzola¹, Daniel Arroyo-Sánchez¹, Francisco Javier Gil Etayo^{1,2}

¹Haematology Department, University Hospital of Salamanca, Salamanca, Spain; ²IBSAL, Salamanca, Spain

P120 Optimising HistoTrac as a quality control and quality assurance tool for HLA antibody screening assays

Steven Jervis, Marcus Russell-Lowe, Julie Johnson, Natalia Diaz Burlinson

Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, United Kingdom

P121 Application of the new MiSeq i100 Plus Illumina device for HLA typing using AlloSeq Tx CareDx tests

Agnieszka Witkowska, Agnieszka Malinowska, Magdalena Ołdak, Ewa Sztangierska, Jacek Nowak

Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland

P122 Spectral Profiling of Pre-Transplant Serum Identifies Biochemical Patterns Associated with Kidney Allograft Rejection

Luis Ramalhe^{1,2,3}, Rúben Araujo³, Anibal Ferreira^{4,3,2}, Cecilia Calado⁵

¹Centro de Sangue e da Transplantação de Lisboa-Área da Transplantação, Instituto Portugues do Sangue e da Transplantação, Lisboa, Portugal;

²iNOVA4Health—Advancing Precision Medicine, Núcleo de Investigação em Doenças Renais, NOVA Medical School, Lisboa, Portugal; ³NOVA

Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal; ⁴Serviço de Nefrologia, Hospital Curry Cabral, Unidade Local de Saúde de São

José, Lisboa, Portugal; ⁵Engineering & Health Laboratory, Instituto Superior de Engenharia de Lisboa, Lisboa, Portugal

P123 AlloSeq Nano: Reliable High-Resolution HLA and ABO Genotyping with ONT Sequencing

Thomas Morris¹, Amanda Willis², Beata Kmiec², Jessica Edwards², Damian Goodridge², Curt Lind²

¹Research & Development, CareDx Inc., West Chester, United States; ²CareDx Inc., West Chester, United States

P124 Proof of concept of epitope-specific immunoadsorption of Anti-HLA class I Antibodies in Highly Sensitized Patients

Juliana Pires^{1,2}, Charlene Evain³, Blandine Maitre², Marie-Joëlle Apithy^{3,1}

¹Immunology and Haematology, EFS, Strasbourg, France; ²Research Department, EFS, Strasbourg, France; ³Histocompatibility, EFS, Strasbourg, France

P125 NGSgo-ProntoFLX: Single or Duplex HLA Amplifications for Confirmatory Typing or Disease Association

Mattijs Punt, Michelle de Ridder, Bo Rood, Pascal van der Weele

GenDx, Utrecht, Netherlands

P126 Comparison of Anti-HLA Antibody Detection Using Luminex 200 and FlexMap 3D Platforms

Taha Ben Merzouk¹, Guilaine Hell¹, Baptiste Panaget¹, Célia Gebel¹, Veronique Renner¹, Christine Heylen², Céline Retkowski³, Marie-Joëlle Apithy^{1,4}

¹Histocompatibility, EFS, Strasbourg, France; ²Waukesh, Werfen, Waukesh, Belgium; ³Transplantation, Werfen, Lille, France; ⁴Immunology and Haematology, EFS, Strasbourg, France

P127 Beyond Gender: Determining Sex-Linked Markers for Donor Registries by Genomic Sequencing

Robert Grosse¹, Moritz Langer¹, Daniel Schefzyk², Katharina Daniel¹, Kathrin Putke¹, Thilo Mengling², Jan A. Hofmann², Vinzenz Lange¹, Anja Klussmeier¹, Jürgen Sauter²

¹DKMS Life Science Lab, Dresden, Germany; ²DKMS Group, Tübingen, Germany

P128 An Ultra-High Throughput Platform for Rapid HLA Typing in Response to Large-Scale Donor Mobilizations

Coralie Frassati^{1,2}, Arnaud Lagarde³, Anne Barlier³, Amira Mohamed³, Nisem Cherouat¹, Sandrine Maioli¹, Emma Rateau¹, Agnes Basire¹, Christophe Picard^{1,2}, Sophie Simon¹, Jacques Chiaroni^{1,2}, Pascal Pedini^{1,2,3}

¹Immunogenetics Laboratory, EFS PACA Corse, Marseille, France; ²ADES UMR 7268, Aix Marseille Univ, Marseille, France; ³M2GM Molecular biology platform, APHM, Marseille, France

P129 Comparative Performance of NGS and ddPCR in Detecting HLA Loss

Pascal Pedini^{1,2}, Sandrine Maioli¹, Agnes Basire¹, Sophie Simon¹, Maude Avias¹, Esteban Arrieta-Bolaños³, Thuja Arrieta-Bolaños³, Andreas Heinold⁴, Raynier Devillier⁵, Coralie Frassati^{1,2}

¹Laboratory of Immunogenetics, Reference Laboratory "Chimerism", EFS PACA Corse, Marseille, France; ²ADES UMR 7268, Aix-Marseille University, Marseille, France; ³Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany; ⁴Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany; ⁵Department of Haematology, IPC, Marseille, France

P130 Assessing the clinical utility of HISTO SPOT HLA AB antibody detection system in comparison to the LIFECODES single antigen test

Aseem Kumar Tiwari¹, Rajni Chauhan¹, Shweta Bhardwaj², Kristin Launhardt², Mohammad Zahid²

¹Department of Transfusion Medicine & Transplant Immunology, Medanta-The Medicity, Gurugram, India; ²Shiva Scientific Life Sciences, Shiva Scientific Life Sciences, New Delhi, India

P131 The magic of DNA fragmentation

Yannik Busch¹, Stefan Scheuermann², Martin Rothhaar^{3,2}, Ulrich Ackermann², Ralf Ackermann², Craig Funnell³, Marco Schaefer¹, Wolfgang Peter¹

¹HLA-Laboratory, Stefan Morsch Foundation, Birkenfeld, Germany; ²Alpina Scientific GmbH, Neckargemuend, Germany; ³Axon Labortechnik GmbH, Kaiserslautern, Germany

P132 Audit of HLA-B*27 tests requested from Jan 2020 to Dec 2024 at the Clinical Transplantation Laboratory

Claudia Andrew, Katy Derbyshire, Delordson Kallon

Clinical Transplantation, Barts Health NHS Trust, London, United Kingdom

P133 Four years of experience in HLA typing using hybrid capture-based NGS

Chiara Sindici, Donatella Londero, Elisa Cecchini, Celeste Cervellin, Ilaria Sandron, Erika Testa, Giovanni Barillari

Transfusion Medicine, ASUFC-Udine, UDINE, Italy

P134 Evaluation of Long-Read Nanopore Sequencing for High-Resolution (HLA) Typing

Ludovica Chidichimo, Elena Longhi, Nemanja Suvajac, Viviana Sioli, Denise Bertola, Vittoria Caporale, Francesca Drago, Alejandro Espadas de Arias, Marco Guarene, Alessia Balzano, Caterina Brambilla, Ermenenziana Soccio, Mara Tivelli

Laboratorio Immunologia dei Trapianti, S.C. Trapianti Lombardia NITp, IRCSS Ospedale Maggiore Policlinico Ca' Granda, Milan, Italy

P135 High-Resolution 11-Locus HLA Typing with an Accelerated AlloSeq Tx11 Workflow on the MiSeq i100

Fiona Yamamoto¹, Thomas Morris¹, Amanda Willis¹, Beata Kmiec², Curt Lind¹

¹CareDx, West Chester, United States; ²CareDx, Stockholm, Sweden

NK Cells, KIR and Other

P136 Two 29-parameter Spectral Flow Cytometry Panels for Functional Immunophenotyping of Human Natural Killer Cells

Nicky Beelen^{1,2,3}, Steven Koetzier³, Amber Lombardi^{2,3}, Ilse Houba³, Lotte Wieten^{3,2}

¹Internal Medicine, Division of Haematology, Maastricht University Medical Centre+, Maastricht, Netherlands; ²GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands; ³Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Centre, Maastricht, Netherlands

P137 High-resolution full-length typing of LILR and LAIR genes using hybrid capture and long-read sequencing

Kazuyoshi Hosomichi¹, Seik-Soon Khor^{2,3}, Kouyuki Hirayasu⁴, Masao Nagasaki^{5,6}, Yosuke Kawai³, Katsushi Tokunaga³

¹School of Life Science, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; ²Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore; ³Genome Medical Science Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan; ⁴Environmental Stress Research Centre (eSRC), Kanazawa University, Kanazawa, Japan; ⁵Medical Research Centre for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan; ⁶Department of Centre for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

P138 Enriched KIR2DL3/C2C2 and KIR2DS4/C2C2 combinations in alcoholic cirrhosis: evidence of genotype-specific risk patterns

Celia Maria Carrillo-Palazon¹, Javier Muro², Manuel Muro-Perez², Maria Rosa Moya-Quiles², Manuel Muro², Isabel Legaz¹

¹Department of Legal and Forensic Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Murcia, Spain; ²Immunology, University Clinical Hospital "Virgen de la Arrixaca" - IMIB, Murcia, Spain

P139 Association of extended KIR haplotypes with MDS, PNH, and SAA

Jacek Nowak¹, Agnieszka Witkowska¹, Agnieszka Malinowska¹, Ewa Sztangierska¹, Magdalena Ołdak¹, Magdalena Bajorek-Muzyczka¹, Agnieszka Gawron¹, Agata Kowalczyk¹, Elżbieta Graczyk-Pol¹, Robert Ziętek², Urszula Szlendak¹

¹Department of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; ²Laboratory of Cytogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland

P140 Markers of NK cell cytotoxicity (NCR3, Perforin, Granzyme B) in rheumatoid arthritis

Ioulia Gavriilidi-Sosna¹, Sylwia Biały¹, Jerzy Świerkot², Katarzyna Kolossa³, Sławomir Jeka^{3,4}, Katarzyna Bogunia-Kubik¹

¹Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ²Department of Rheumatology and Internal Medicine, Wrocław Medical University, Wrocław, Poland; ³Department of Rheumatology and Connective Tissue Diseases, Jan Biziel University Hospital No. 2, Bydgoszcz, Poland; ⁴Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland

P141 Incorporating Killer Immunoglobulin Like Receptor Based Parameters into Donor Selection in Allogeneic Hematopoietic Stem Cell Transplantation

Hasan Yalım Akin¹, Ezgi Anlıaçık², Rıdvan Göksel Anlıaçık², Sevim Dalva Aydemir³, Filiz Akal⁴, Suat Sertel², Güldane Cengiz Seval⁴, Selami Koçak Toprak⁴, Klara Dalva²

¹Cord Blood Bank Faculty of Medicine, Ankara University, Ankara, Turkey; ²Tissue Typing Laboratory, Faculty of Medicine, Ankara University, Ankara, Turkey; ³Biotechnology Institute, Ankara University, Ankara, Turkey; ⁴Department of Haematology, Faculty of Medicine, Ankara University, Ankara, Turkey

P142 The non-steroidal anti-inflammatory drug ibuprofen suppresses HLA-E-controlled NK cell phenotypes by upregulating NKG2A

Mats Köster^{1,2}, Johanna Reinold^{1,3}, Justine Schmidt³, Harald Engler⁴, Benjamin Wilde¹, Sabine Schramm², Peter A. Horn², Oliver Witzke¹, Sven Benson³, Hana Rohn¹, Vera Rebmann²

¹Department for Infectious Diseases and Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ²Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ³Institute for Medical Education, Centre for Translational and Behavioural Neuroscience (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ⁴Institute of Medical Psychology and Behavioural Immunobiology, Centre for Translational and Behavioural Neuroscience (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

P143 Improving the imputation of KIR2DS4 5-digit alleles using both multi-ancestry and ancestry-specific reference panels

Gabriela Sato Paes^{1,2,3}, Raphaella Neto Pereira^{2,3,4}, Ícaro Scalisse de Freitas Santos^{2,4}, Sonia Bourguiba-Hachemi³, Sophie Limou³, Fabienne Haspot³, Nicolas Vince³, Erick C. Castelli^{1,2,5}

¹Graduate Program in Pathology, School of Medicine, São Paulo State University (Unesp), Botucatu, Brazil; ²Molecular Genetics and Bioinformatics Laboratory Experimental Research Unit, School of Medicine, São Paulo State University, Botucatu, Brazil; ³UMR 1064, Nantes Université, Nantes, France; ⁴Institute of Biosciences, São Paulo State University, Botucatu, Brazil; ⁵Department of Pathology, School of Medicine, São Paulo State University (Unesp), Botucatu, Brazil

P144 Frequencies of KIR genes in healthy controls and transplanted patients, Medellín, Colombia

Marlon Castrillón, Cristian Álvarez

Laboratorio de Inmunología de Trasplantes, LIME, GICIG, Universidad de Antioquia, Medellín, Colombia

P145 Human Neutrophil Antigen Genotyping and Antibody Specification: Results from the UK NEQAS for H&I Pilot External Quality Assessment Schemes

Amy De'Ath, Deborah Pritchard

H&I, UK NEQAS, Cardiff, United Kingdom

P146 No Time to Wait: Bringing the LIFECODES® Single Antigen Bead Assay up to Speed

Rebecca Almond, Steven Jervis, Marie Hampson, Judith Worthington, Kay Poulton

Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, United Kingdom

P147 Association of myelin basic protein and 18 kDa translocator protein gene polymorphisms with multiple sclerosis risk and phenotypes in relation to HLA-DRB1*15 in Eastern Croatia

Saška Marčić^{1,2}, Mirna Glegji¹, Mirjana Suver Stević^{1,3}, Tea Mirošević Zubonja⁴, Anđelka Bugarin¹, Stana Tokić⁵, Martin Petrek⁶, Marina Samardžija^{1,5}

¹Department of HLA Typing and Genomic Diagnostics, University Hospital Centre Osijek, Osijek, Croatia; ²Department of Medicinal Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; ³Department of Biology, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; ⁴Department of Neurology, University Hospital Centre Osijek, Osijek, Croatia; ⁵Department of Laboratory Medicine and Pharmacy, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; ⁶Department of Pathophysiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czechia

P148 Hidden Polymorphism in HLA-DRA

Althea Malik^{1,2}, Yannik Busch¹, Peter Diegel¹, Liane Hey¹, Heike Bauer¹, Anne Schweizer², Claudia Lehmann³, Ilias Doxiadis⁴, Marco Schäfer¹, Wolfgang Peter¹

¹HLA-Laboratory, Stefan-Morsch-Foundation, Birkenfeld, Germany; ²Process engineering, Environmental Campus Birkenfeld, Hoppstädten-Weiersbach, Germany; ³HLA-Laboratory, Institute for Transfusion Medicine, University Hospital Hamburg-Eppendorf, Birkenfeld, Germany; ⁴Laboratory for Transplantation Immunology, Institute for Transfusion Medicine, University Hospital Leipzig, Leipzig, Germany

P149 Immunogenetic Signatures: Tγδ-Cell Phenotype and Genetic Polymorphisms in Rheumatoid Arthritis

Sylwia Biały¹, Joanna Wielińska^{2,3}, Kinga Maria Tyczyńska⁴, Łukasz Tokarski³, Jerzy Świerkot⁴, Katarzyna Bogunia-Kubik³

¹Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ²Department of General Biochemistry, University of Lodz, Lodz, Poland; ³Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; ⁴Department and Clinic of Rheumatology and Internal Diseases, Wrocław Medical University, Wrocław, Poland

P150 Implementation of reduced paper workflow to increase efficiency and improve sustainability for HLA antibody testing by Luminex, using LEAN methodology

Hanna Lane, Lisa Wood, Adrian Handley, David Atkinson, Luke Foster

H&I, NHSBT, Birmingham, United Kingdom

P151 The Central Bone Marrow Donor Registry (CBMDR) Poltransplant

Klaudia Nestorowicz Kaluzna¹, Malgorzata Dudkiewicz^{1,2}, Anna Łęczycka³, Marcin Macher⁴, Jaroslaw Czerwinski^{5,6}, Artur Kamiński^{5,7}

¹Central Bone Marrow Donor Registry, Polish Transplant Coordinating Centre Poltransplant, Warsaw, Poland; ²Department of Biochemistry and Microbiology, Warsaw University of Life Sciences, Warsaw, Poland; ³Central Bone Marrow Donor Registry, Poltransplant, Warsaw, Poland; ⁴Poltransplant, Warsaw, Poland; ⁵Polish Transplant Coordinating Centre Poltransplant, Warsaw, Poland; ⁶Department of Emergency Medicine, Medical University of Warsaw, Warsaw, Poland; ⁷Department of Transplantology and Central Tissue Bank, Polish Transplant Coordinating Centre Poltransplant, Warsaw, Poland

P152 An HLA association study in South Tunisian patient with acute myeloid leukaemia

Imen Daoud¹, Aida Charfi¹, Abid Ons¹, Maha Charfi², Faiza Hakim¹, Lilia Gaddour¹, Ines Kamoun¹, Fedia Oualha¹, Dhouha Ben Abdallah¹, Moez Elloumi², Arwa Kamoun¹, Nadia Mahfoudh¹

¹Immunology and Histocompatibility Department, University Hedi Chaker Hospital, Sfax, Tunisia; ²Hematology Department, University Hedi Chaker Hospital, Sfax, Tunisia

P153 Unmasking a Hidden Donor-Specific Antibody: Importance of Extended Antigen and Epitope Analysis in a Highly Sensitized Kidney Transplant Candidate

Amal Algharably¹, Ali Tariq¹, Hassan Aleid¹, Hana Alkhabbaz², Moheeb Awwami¹

¹Kidney and Pancreas Health Centre, King Faisal specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ²Riyadh University, Riyadh, Saudi Arabia

P154 Comparison of testing methods for the detection of HPA antibodies

Emma Ross¹, Angela Abel¹, Sylvia McConnell¹, Richard Battle¹, Anthony Calvert², Anthony Poles², David M Turner¹

¹H&I, SNBTS, Edinburgh, United Kingdom; ²Histocompatibility and Immunogenetics, NHS Blood and Transplant, Bristol, United Kingdom

P155 Allelic Variants of the Thiopurine S-Methyltransferase Enzyme which Catalyses the Immunomodulatory Thiopurine Drugs and Identification of a novel TPMT 323C>G allele in the Turkish Population

Ozlem Goruroglu Ozturk^{1,2}, Petek Curuk¹, Tamer Inal¹, Akif Curuk^{1,3}

¹Department of Clinical Biochemistry, Cukurova University, Adana, Turkey; ²Department of Translational Medicine, Cukurova University, Adana, Turkey; ³Department of Biotechnology, Cukurova University, Adana, Turkey

P156 Assessment of the LIFECODES® LMX XP kits for HLA antibody screening in potential Haematopoietic Stem Cell Transplant recipients with HLA-DP mismatch donor

Tony Man, Bindu Rana, Sejal Morjaria, Eamonn Cudworth, Katy Derbyshire, Delordson Kallon

Clinical Transplantation Laboratory, Barts Health, London, United Kingdom

P157 HLA-G 14 bp ins/del and Celiac Disease Severity: Allelic and Genotypic Analysis in an Italian Cohort

Annamaria Pasi¹, Ilaria Sbarsi¹, Margherita Torchio¹, Annalisa De Silvestri², Paola Bergamaschi¹, Chiara Bottazzi¹, Maria Cristina Monti¹, Silvia Caimmi³

¹Servizio di Immunoematologia e Trasfusione, Fondazione IRCCS Pol. San Matteo, Pavia, Italy; ²SSD Biostatistica e Clinical Trial Centre -Direzioe Scientifica, Fondazione IRCCS Pol. San Matteo, Pavia, Italy; ³Dipartimento di Pediatria, Fondazione IRCCS Pol. San Matteo, Pavia, Italy

Reproductive Immunity

P158 Prevalence of high-risk KIR haplotypes associated with HLA-C ligands in couples with recurrent reproductive failure

Manuel Serrano¹, Paulette Walo¹, Boris Karanovic², Raquel Alenda³, Antonio Balas³, Jose Luis Vicario³, María Alejandra Mejía⁴, Ana Vionnet¹, Javier Carbone^{1,5}

¹Immunology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ²Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia; ³Centro de Transfusiones de la CAM., Madrid, Spain; ⁴Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁵Immunology Department, Hospital Universitario Viamed Santa Elena, Madrid, Spain

P159 Evaluation of the Efficacy of Low-Dose Prednisone in Recurrent Reproductive Failure with Immunological Abnormalities. Multicenter Observational Study

Manuel Serrano¹, Ana Vionnet¹, Paulette Walo¹, María Alejandra Mejía², Tirso Perez Medina³, Reyes de la Cuesta Benjumea³, Francesca Campoverde¹, Kristofer Limay², Víctor Moreno Torres⁴, María Martínez⁴, Susana Mellor⁴, Pablo Tutor⁴, Javier Carbone^{1,2,5}

¹Immunology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ²Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ³Gynecology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ⁴Internal Medicine, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; ⁵Immunology, Hospital Universitario Viamed Santa Elena, Madrid, Spain

P160 Association between KIR/HLA Profile and Recurrent Pregnancy Loss: Analysis in a Cohort of 61 Italian Women

Maria Troiano¹, Michela Falco², Giuseppe Testa¹, Vaquero Elena³, Marco Andreani¹

¹Laboratory of Immunogenetics and Transplant, Department of Oncohematology and Cell and Gene Therapy, IRCCS Bambin Gesù Paediatric Hospital, Rome, Italy; ²Laboratory of Clinical and Experimental Immunology, Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, Genoa, Italy; ³Department of Biomedicine and Prevention, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata, Rome, Italy

P161 Characterization of microchimeric cells of maternal origin in umbilical cord blood by HLA-targeted spectral flow cytometry

Rachel C Quilang¹, Catharina van der Keur¹, Cynthia Kramer¹, Anne Wagenmakers¹, Bernadette L. Bramreiter^{1,2}, Dave Roelen¹, Michael Eikmans¹

¹Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands; ²Division of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria

P162 Histocompatibility does not predict villitis of unknown etiology in oocyte donation pregnancies

Emiel Slaats^{1,2}, Emma Peereboom³, Hanneke Kapsenberg², Marie-Louise van der Hoorn⁴, Eric Spierings³, Thomas van den Akker^{4,5}, Thomas Kroneis¹, Michael Eikmans²

¹Gottfried Schatz Research Centre, Department of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; ²Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands; ³Center for Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; ⁴Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, Netherlands; ⁵Athena Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Solid Organ Transplantation

P163 Characteristics and causes of de novo donor-specific anti-HLA antibodies after the first renal transplantation from a single centre study in eastern China

Qinqin Pan, Xiaoyu Zhou, Xiao Ma, Yajie You, Yuejiao Yu, Xinye Han

HLA Lab, Department of Transfusion, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

P164 Investigation of Major Histocompatibility Complex Class I Chain-related Molecule A (MICA) antibodies in patients on the renal transplant wait list.

Kerry Liney¹, Andrew Blair¹, Jonathan AM Lucas², Neema P Mayor², Catherine Hastie¹, Ann-Margaret Little¹

¹Histocompatibility and Immunogenetics Laboratory, Gartnavel General Hospital, Glasgow, United Kingdom; ²Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P165 Prediction of antibody-mediated rejection by quantifying eplets potentially targeted by preformed donor-specific antibodies

Konstantin Doberer¹, Sebastian Kapps¹, Daniela Kriks², Gottfried Fischer², Luis Hidalgo³, Farsad Eskandary¹

¹Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; ²Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria; ³Division of Transplantation, Department of Surgery, University of Alberta, Birmingham, United States

P166 Case-based analysis of HLA-DQ interpretation pitfalls on class II single antigen bead assays

Jiwon Lee, Sol Kim

Department of Laboratory Medicine, Green Cross Laboratories, Yongin, Republic of Korea

P167 Beyond the Standard Kit: Identifying Hiding Donor Specific Antibody Through Multi-Platform Assessment

Amani Mohammed, Hassan Alharbi, Mohammed AlAithan, Saber AlZahrani, Rafah Bamrdouf, Mohammad Awaji

Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia

P168 The Missing A*02 Allele: Assessment of Allele Dropout Frequency in NGS Based HLA Typing

Saber AlZahrani, Mariam Alzahrani, Dalal AlAbduladheem, Shaima Alkebasi, Amal Alaqool, Amani Mohammed, Mohammad Awaji

Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia

P169 Comparative Assessment of cPRA Values Using the Spanish PATHI Calculator and the Eurotransplant cPRA Calculator Tools

Miriam Martín Morales, Marta Aguilar Criado, Azahara Díaz Lozano, María Begoña Vázquez Araújo

Immunology, University Hospital of Badajoz, Badajoz, Spain

P170 Validation of a method for donor-derived cell free DNA analysis in heart transplant patients

Alice Pecoraro¹, Rosalba Bavetta¹, Irene Aiello¹, Serena Mistretta¹, Maria Blando¹, Floriana Bruno¹, Floriana Di Paola¹, Giuseppe Davì¹, Claudia Elisabetta Spinuzza¹, Alessia Nardo¹, Alessandra Fontana², Roberta Fedele¹, Valentina Cappuzzo³

¹UOS HLA, AOOR Villa Sofia-Cervello, Palermo, Italy; ²Cardiologia, ISMETT-IRCCS, Palermo, Italy; ³UOC Medicina TrASFusionale, AOOR Villa Sofia-Cervello, Palermo, Italy

P171 Imlifidase as a desensitization strategy in kidney transplantation at CHU de Liège, Belgium: up to one-year outcomes in two high-risk recipients

Justine Schmitt¹, André Gothot¹, Laurent Weekers², Catherine Bonvoisin², Antoine Bouquegneau²

¹HLA, CHU Liège, Liege, Belgium; ²Nephrology, CHU Liège, Liege, Belgium

P172 The First ABO Incompatible Kidney Transplantation from Living Donor in L'Aquila (Italy) Single centre experience – Increasing Kidney Donors

Olaida Josefina Valdez¹, Maria Grazia Tupone¹, Franco Papola¹, Maria Scimitarra¹, Raffaella Azzarone¹, Anna Rita Lizzi¹, Carla Battistoni¹, Stefano Scipione¹, Daniela Pulcinelli¹, Simona Scacchi¹, Barbara Spaziani¹, Vittoriano Torrelli¹, Valentina Del Grecco², Orietta Staltari², Anna Rughetti², Laura Lancione³, Fabio Vistoli³, Carla Cervelli¹

¹U.O.C. Centro Regionale di Immunoematologia e Tipizzazione tissutale CRITT, ASL1 – Avezzano, Sulmona, L'Aquila, San Salvatore Hospital, L'Aquila, Italy; ²U.O.C. Servizio di Immunoematologia e TrASFusionale S.I.T, ASL1 – Avezzano, Sulmona, L'Aquila, San Salvatore Hospital, L'Aquila, Italy; ³U.O.C. Chirurgia Generale e dei Trapianti., ASL1 – Avezzano, Sulmona, L'Aquila, San Salvatore Hospital, L'Aquila, Italy

P173 From dialysis to crossmatch: serum management challenges in Argentina's kidney transplant system

Manuel Quirno Costa, Micaela Russo, Mariel Abovich

Hospital General de Agudos "Carlos G Durand", Buenos Aires, Argentina

P174 Does prioritization improve access for highly sensitized kidney transplant candidates? An Argentinian experience

Belén Balekjian, Manuel Quirno Costa

Hospital General de Agudos "Carlos G. Durand", Buenos Aires, Argentina

P175 IVDR-Compliant Performance Verification of One Lambda Devyser Chimerism and Accept cfDNA DNA Kits on Illumina MiSeq and MiSeq i100 Sequencing Systems

Rikard Eckerud¹, Linnea Pettersson^{1,2}, Sofia Westerling¹, Michael Uhlin^{1,2}

¹Devyser AB, Stockholm, Sweden; ²Department of Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden

P176 Non-classical HLA and MIC risk score is associated with acute kidney transplant rejection beyond classical HLA matching

Silja Tammi¹, Salla Markkinen¹, Ilkka Helanterä², Marko Lempinen², Jukka Partanen¹, Kati Hyvärinen¹, Jarmo Ritari¹

¹Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland; ²Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

P177 A Cell is out There; Value Added Third party Crossmatching - a case study

Miceal Cole¹, Ashley Meenagh¹, Tanya Shovlin¹, Aisling Courtney², Fotini Partheniou¹

¹H&I Laboratory, Belfast City Hospital, Belfast, United Kingdom; ²Renal Unit, Belfast City Hospital, Belfast, United Kingdom

P178 Validation of EasySep™ Direct Human Total Lymphocyte Isolation Kit for Flow Cytometry crossmatching in solid organ transplantation

Sophia Rowlston, Patrick Flynn, Anna Barker

Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, United Kingdom

P179 One Of These HLA-A*24s Is Not like The Other

Jayasree Hariharan, Wendy Gonzalez, Anthony Burand, Justin Mostecky, Bryan Ray

Werfen, Waukesha, United States

P180 Clinical application of the memory B cell assay in immunological risk assessment: A case series

Marie Skougaard¹, Ida Schwartz Bobach¹, Line Aas Mortensen², Gitte Rye Hinrichs², Claus Bistrup², Tor Skibsted Clemmensen³, Pernille Koefoed-Nielsen¹

¹Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; ²Department of Nephrology, Odense University Hospital, Odense, Denmark; ³Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

P181 Mandatory Immunological Risk Assessment and donor-derived cell-free DNA Monitoring: Lesson from a Paediatric Heart Transplant Case.

Marcelina Grabowska¹, Karolina Postek¹, Weronika Zarychta-Wiśniewska¹, Iwona Sobierajska¹, Agnieszka Jałbrzykowska¹, Małgorzata Sobieszcząńska-Małek², Diana Dudek², Anna Rożnowska-Wójtowicz³, Radosław Pietrzak³, Anna Prowotorow-Iwaniukowicz³

¹Laboratory of Immunogenetics, University Centre of Laboratory Medicine, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland; ²Department of Cardiac, Thoracic and Transplant Surgery, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland; ³Department of Paediatric Cardiology and Paediatrics, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland

P182 Relevant Individual Luminex Antibody Reactivity: Effect of 37 degrees Celsius Incubation

Claudia Lehmann^{1,2}, Ramona Landgraf², Ilias Doxiadis²

¹University Hospital Hamburg-Eppendorf, Institute for Transfusion Medicine, HLA Laboratory, Hamburg, Germany; ²University Hospital Leipzig, Institute for Transfusion Medicine, Laboratory for Transplantation Immunology, Leipzig, Germany

P183 Implementation of a Donor Derived Cell Free Dna Assay Into Routine Post-Transplantation Diagnostics - The Immunogenetics Laboratory Perspective

Weronika Zarychta-Wiśniewska, Karolina Postek, Aleksandra Dołęga, Aleksandra Marciniak, Małgorzata Siembor, Agata Balińska, Joanna Wojtczak, Marcelina Grabowska

Laboratory of Immunogenetics, University Centre of Laboratory Medicine, University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland

P184 Multiplex Bead immunoassay Increases Eligibility of ABO-A2 Incompatible Kidney Transplants Compared to a Hemagglutination Method: A Single Centre Study

Nilasma Shrestha¹, Anne Halpin², Tambi Jarmi¹, Elizabeth Godbey¹, Wassim Toomah¹, Mohamad Amir Balloura¹, Caishun Li², Bruce Motyka², Lori West², Mohamed Elrefaei¹

¹Mayo Clinic, Jacksonville, United States; ²University of Alberta, Edmonton, Canada

P185 Strength of HLA Donor-Specific Antibodies in 1:16 Diluted Pre-Transplant Serum Predicts Early HLA Antibody Persistence and Kidney Allograft Dysfunction After Simultaneous Liver-Kidney transplant

Mohamed Elrefaei¹, Dong Li², Tambi Jarmi¹, Jasmine Kendrick¹, Nilasma Shrestha¹, Alexander Gilbert², Raffaele Girlanda², Alexander Kroemer², Rohit Satoskar², Thomas Fishbein², Cal Matsumoto², Sandra Rosen-Bronson², Olga Timofeeva^{2,3}

¹Mayo Clinic, Jacksonville, United States; ²MedStar Georgetown University Hospital, Washington DC, United States; ³UCLA, Los Angeles, United States

P186 Optimization of Flow Cytometry Crossmatch: Improved Sensitivity, Accuracy, and Clinical Outcomes

Amani Anabtawi, Lilach Gutter Kapon, Mouna Khateeb Sabbah

Rambam Medical Centre, Haifa, Israel

P187 Using engineered variants and MagSort in dissecting the complex reactivities of an alloserum targeting all HLA-A antigens evaluated except for A*02:02 and A*02:05

Magali Devriese^{1,2}, Xiaoliang Yao³, Hsiao-Min Chang³, Fred Quiroz³, Eric Ka-Wai Hui³, David Suh³, Dave Lowe³, Jean-Luc Taupin^{1,2}, Tina Meng³

¹Laboratoire D'immunologie et Histocompatibilité, Hôpital Saint Louis, Paris, France; ²Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France; ³Department of Research and Development, Thermo Fisher Scientific Inc, West Hills, United States

P188 Concentration dependent reactivity of a human monoclonal antibody recognizing HLA-DQB1*04/05/06 and cross-reacting at a reduced intensity to DQB1*03

Tina Meng¹, Ujjwala Singh¹, Naiiry Petrosyan¹, Fred Quiroz¹, Xiaoliang Yao¹, Helen Han¹, Hsiao-Min Chang¹, Eric Ka-Wai Hui¹, David Suh¹, Vincent Ma¹, Elaina Rybak¹, Quansheng Zhu¹, Zhifang Wang², James Jones³, Dave Roelen⁴, Cynthia Kramer⁴, Sebastiaan Heidt^{4,5}, Dave Lowe¹

¹Research and Development, Thermo Fisher Scientific Inc., West Hills, United States; ²Software Engineering, Thermo Fisher Scientific Inc., West Hills, United States; ³Customer Experience, Thermo Fisher Scientific Inc., West Hills, United States; ⁴Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands; ⁵Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands

P189 Identification of amino acid residues, distal to peptide-binding groove, that confer serological distinctions within each HLA-DQB1*02, 03, 05, and 06 group

Tina Meng¹, Ujjwala Singh¹, Naiiry Petrosyan¹, Fred Quiroz¹, Xiaoliang Yao¹, Helen Han¹, Hsiao-Min Chang¹, Eric Ka-Wai Hui¹, David Suh¹, Vincent Ma¹, Elaina Rybak¹, Quansheng Zhu¹, Zhifang Wang², James Jones³, Dave Roelen⁴, Cynthia Kramer⁴, Sebastiaan Heidt^{4,5}, Dave Lowe¹

¹Research and Development, Thermo Fisher Scientific Inc., West Hills, United States; ²Software Engineering, Thermo Fisher Scientific Inc., West Hills, United States; ³Customer Experience, Thermo Fisher Scientific Inc., West Hills, United States; ⁴Immunology, Leiden University Medical Centre, Leiden, Netherlands; ⁵Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands

P190 In-solution determination of HLA antibody concentration and affinity - an alternative to Single Antigen Bead Assay derived MFI

Nikolina Veljancic¹, Matthias Reist¹, Nicolas Chanton², Jasmin Jermann², Dominik Meinel², Rico Buchli³, Sean R.A. Devenish⁴, Reuben Reed⁴, Dave Lowe⁵, Sean Carey⁵, Sebastiaan Heidt⁶, Dave Roelen⁶, Cynthia S.M. Kramer⁶, Joerg Halter⁷, Stefan Schaub⁸, Gideon Hoenger¹

¹Department of Biomedicine, University Hospital Basel, Basel, Switzerland; ²School of Life Sciences, University of Applied Sciences, Muttenz, Switzerland; ³Department of Research and Development, HLA Protein Technologies Inc., Oklahoma City, United States; ⁴Fluidic Sciences, 27-29 Jarman Way, Royston, United Kingdom; ⁵Department of Research and Development, OneLambda Inc., West Hills, United States; ⁶Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands; ⁷Hematology Division, University Hospital Basel, Basel, Switzerland; ⁸Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland

P191 Utility of an Assay to Evaluate Reactivity of Bw6 Antibodies to Swine Leukocyte Antigens

Holly Haver, Jayasree Hariharan, Bryan Ray, Justin Mostecky

R&D, Werfen, Waukesha, United States

P192 Reevaluating the definition of a "Current" serum sample for re-transplant candidates following early loss of a first graft

Ina Skaljic, Aneesha Shetty, Erin Christian, Danielle N Cisneros, Maria Oppermann, Renata Foerstel, Robert A Bray, Howard M Gebel

Rush University Medical Centre, Chicago, United States

P193 Beyond HLA antibodies: Involvement of Anti-P2RY11 and Anti-LGALS3 Antibodies in HLA-DSA-Negative Chronic Antibody-Mediated Rejection After Kidney Transplantation

Lei Liu¹, Ning Li², Di Guan³, Xiaobo Li³, Junbo He³, Mingjun Wang², Huanxi Zhang⁴, Jinghong Tan⁴, Xiantian Pan⁴, Guorong Liao⁵, Shaoyong Zhuang⁶, Xiaodong Yuan⁶, Xiaoming Zhang⁷, Ming Zhang⁶, Yongguang Liu⁵, Longshan Liu⁴, Changxi Wang⁴, Wenjun Shang¹, Xiang-Jun Liu³

¹The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ²The Second People's Hospital of Shanxi Province, Taiyuan, China; ³Beijing BFR Gene Diagnostic Technology Co., Ltd, Beijing, China; ⁴The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ⁵Zhujiang Hospital of Southern Medical University, Guangzhou, China; ⁶Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; ⁷The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, China

P194 Comparative Analysis of Illumina MiSeq and Nanopore MinION Sequencing for Third-Field HLA Typing of 11 Classical HLA Class I and II Genes for 100 Danish Patients and Donors

Frederikke Byron Pedersen, Helena Utzon, Amanda Tine Ry, Anne Werner Hauge

Department of Clinical Immunology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

P195 Non-HLA Antibodies Are Associated With Active Antibody-Mediated Rejection in DSA-Negative Recipients After Kidney Transplantation

Longshan Liu¹, Ning Li², Lei Liu³, Guorong Liao⁴, Di Guan⁵, Xiaobo Li⁵, Junbo He⁵, Shaoyong Zhuang⁶, Xiaodong Yuan⁶, Xiaoming Zhang⁷, Huanxi Zhang¹, Jinghong Tan¹, Xiantian Pan¹, Mingjun Wang², Ming Zhang⁶, Yongguang Liu⁴, Wenjun Shang³, Changxi Wang¹, Xiang-Jun Liu⁵

¹The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²The Second People's Hospital of Shanxi Province, Taiyuan, China; ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; ⁴Zhujiang Hospital of Southern Medical University, Guangzhou, China; ⁵Beijing BFR Gene Diagnostic Technology Co., Ltd, Beijing, China; ⁶Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; ⁷The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, China

P196 Antibody reactivity patterns restricted to single antigen beads bearing specific combination of DQA1*03 and DQB1*03 chains

Alba Exposito-Bey, Miguel Borrego-Martin, Maria Francisca Gonzalez-Escribano, Beatriz Rodriguez-Bayona

Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

P197 Recombinant SLA Class I and II Molecules for Antibody Detection

Clemens Schneeweiß, Anja Zeretzke¹, Philipp Knutzen¹, Murielle Verboom², Rainer Blasczyk²

¹Imusyn GmbH & Co. KG, Hanover, Germany; ²Institut für Transfusionsmedizin und Transplantat Engineering, Medizinische Hochschule Hannover, Hanover, Germany

P198 Identification of a Novel Null HLA-C Allele (C*07:1155N) in a Transplant Candidate: Implications for Allocation and Immunological Follow-up

Sylvie Tourne¹, Philippe Guntz¹, Guilaine Hell¹, Baptiste Panaget¹, Marie-Joëlle Apithy^{1,2}

¹Histocompatibility, EFS, Strasbourg, France; ²immunology and Haematology, EFS, Strasbourg, France

P199 Could preformed non-HLA antibodies cause delayed kidney transplant function?

Roberta Lamanna, Silvia Fornaciari, Veronica De Gregorio, Chiara Biagini, Lidia Felet, Debora Gonella, Michele Curcio

Departmental Section of Immunogenetics, Azienda Ospedaliero Universitaria Pisana, Cisanello Hospital, PISA, Italy

P200 Comparison of Two cell-free DNA (cfDNA) Extraction Methods for NGS-Based Donor-Derived cfDNA measurement in Kidney Transplant Follow up.

Eva González-Roca^{1,2}, Cristina Sánchez-Cárdenas¹, Eva Ekaterina Mistreanu¹, Paula Sánchez-DelVillar¹, Alfredo Mendoza¹, Esther Titos^{1,2}

¹Molecular Biology CORE Laboratory, Hospital Clínic Barcelona, Barcelona, Spain; ²IDIBAPS-FCRB, Barcelona, Spain

P201 Low risk delisting strategy in highly sensitized patients awaiting kidney transplant: experience in a third-level hospital in Spain

Miguel Borrego-Martin¹, Alba Exposito-Bey¹, Francisco Manuel Gonzalez-Roncero², Maria Francisca Gonzalez-Escribano¹, Beatriz Rodriguez-Bayona¹

¹Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain; ²Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

P202 Integrating Absolute and Relative cfDNA Measures to Improve Detection of Lung Allograft Injury

Pascal Pedini^{1,2}, Alizée Sébastian^{1,3}, Benjamin Coiffard⁴, Martine Reynaud-Gaubert⁴, Monique Silvy³, Jacques Chiaroni^{1,2}, Christophe Picard¹

¹ADES UMR 7268, Aix Marseille Univ, Marseille, France; ²Immunogenetics Laboratory, EFS PACA Corse, Marseille, France; ³BeDia, Genomics, Marseille, France; ⁴Lung transplant department, APHM, Marseille, France

P203 Third Generation Sequencing Enables High-Resolution HLA Typing Directly from Allograft Biopsies

Maja Nørgaard, Pernille Koefoed-Nielsen

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark

P204 Advancing the Understanding of cfDNA Through Multiparametric Analysis in Lung Transplantation

Pascal Pedini^{1,2}, Alizée Sebastian^{1,3}, Benjamin Coiffard⁴, Martine Reynaud-Gaubert⁴, Monique Silvy³, Jacques Chiaroni^{1,2}, Christophe Picard^{1,2}

¹ADES UMR 7268, Aix Marseille Univ, Marseille, France; ²Immunogenetics Laboratory, EFS PACA Corse, Marseille, France; ³BeDia, Genomics, Marseille, France; ⁴Lung transplant department, APHM, Marseille, France

P205 151AHE+163R: a new eplet pair involved in anti-HLA reactivity

Imen Daoud¹, Aida Charfi¹, Hanen Abid^{2,3}, Mondher Masmoudi^{2,3}, Soumaya Yaich^{2,3}, Lilia Gaddour¹, Faiza Hakim¹, Dhouha Ben Abdallah¹, Ines Kammoun¹, Fedia Oualha¹, Bakhta Mallek¹, Khaoula Kamoun^{2,3}, Arwa Kamoun^{1,2}, Nadia Mahfoudh¹

¹Immunology and Histocompatibility Department, University Hedi Chaker Hospital, Sfax, Tunisia; ²Renal Pathology Research Laboratory, LR19ES11, University Hedi Chaker Hospital, Sfax, Tunisia; ³Nephrology Department, University Hedi Chaker Hospital, Sfax, Tunisia

P206 Usefulness of the nonself-self paradigm of HLA epitope immunogenicity in the specificity analysis

of HLA antibodies induced during pregnancy

Imen Daoud¹, Aida Charfi¹, Hanen Abid^{2,3}, Mondher Masmoudi^{2,3}, Soumaya Yaich^{2,3}, Lilia Gaddour¹, Faiza Hakim¹, Dhouha Ben Abdallah¹, Ines Kamoun¹, Fedia Oualha¹, Bakhta Mallek¹, Khaoula Kamoun^{2,3}, Arwa Kamoun^{1,2}, Nadia Mahfoudh¹

¹Immunology and Histocompatibility Department, University Hedi Chaker Hospital, Sfax, Tunisia; ²Renal Pathology Research Laboratory LR19ES11, University Hedi Chaker Hospital, Sfax, Tunisia; ³Nephrology Department, University Hedi Chaker Hospital, Sfax, Tunisia

P207 Anti-Rituximab: A Solution for Rituximab-Related Interference in Pre-Transplant Crossmatch Testing

Orjeta Bonaca, Sendi Montanič

Slovenian Institute for Transfusion Medicine, Tissue Typing Centre, Ljubljana, Slovenia

P208 Tracing of residual DNA when reusing MinION flow cells with a barcoded version of NGS-Turbo

Eline ter Steege, Bo Rood, Sjoerd Creutzburg, Pascal van der Weele

GenDx, Utrecht, Netherlands

P209 Exploring the Predictive Value of PIRCHE-T2 in Kidney Transplantation: a cautious interpretation

Chiara Biagini¹, Guido Scatena², Veronica De Gregorio¹, Silvia Fornaciari¹, Roberta Lamanna¹, Domenica Mandarino¹, Francesco Galati¹, Michele Curcio¹

¹Departmental Section of Immunogenetics, Azienda Ospedaliero Universitaria Pisana, Cisanello Hospital, Pisa, Italy; ²Italian Institute, for Environmental Protection and Research (ISPRA), Roma, Italy

P210 Flow cytometry crossmatch, anti-HLA antibodies and epitope analysis: integrating the pieces for donor-recipient compatibility assessment in solid organ transplantation

Veronica De Gregorio, Silvia Fornaciari, Roberta Lamanna, Chiara Biagini, Serena Di Beo, Federica Salvadori, Michele Curcio

Departmental Section of Immunogenetics, Azienda Ospedaliero Universitaria Pisana, Cisanello Hospital, Pisa, Italy

P211 Managing HLA Antibody Workflow Using Control Point Graphs and Business Intelligence Software in a Reduced-Paper HLA Antibody Identification Process

Adrian Handley¹, Hanna Lane¹, Happiness Oguike², David Atkinson¹, Luke Foster¹

¹H&I Lab, NHSBT, Birmingham, United Kingdom; ²NHSBT, Colindale, United Kingdom

P212 Variability in H&I practices supporting cardiothoracic transplant: Results of a UK-wide survey assessing MFI cut-offs, risk stratification and adherence to national guidelines

Aaron Wright, Luke Foster, Hanna Lane, Emily Ryan

H&I laboratory, NHSBT, Birmingham, United Kingdom

P213 SOtrack donor-derived cell-free DNA-based monitoring assay for paediatric heart transplant – the chase of single copy detection

Bram Luiken, Jolinde van Strien, Lara van der Klugt, Cynthia Kramer, Pascal van der Weele

GenDx, Utrecht, Netherlands

P214 Impact of BSHI/BTS-recommended MFI cut-offs in cardiothoracic transplant risk assessment: A local review of virtual crossmatch data and transplant outcomes

Aaron Wright, Luke Foster, Hanna Lane, Emily Ryan

H&I Laboratory, NHSBT, Birmingham, United Kingdom

P215 HNA-3a Antibody Screening: Should Routine Testing be Implemented for all Prospective Kidney Transplant Recipients?

Lisa Wood¹, Luke Foster¹, Emily Ryan¹, Shazia Shabir², Shafi Malik², Surinder Jandu², James Barnes²

¹Histocompatibility and Immunogenetics, NHS Blood and Transplant, Birmingham, United Kingdom; ²Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation trust, Birmingham, United Kingdom

P216 HLA Eplets and Immunological Risk: An Innovative Approach to Improving Graft Survival

Nadia Mahfoudh¹, Aida Charfi¹, Imen Daoud¹, Bilel Barkia¹, Hanen Abid^{2,3}, Mondher Masmoudi^{2,3}, Soumaya Yaich², Lilia Gaddour¹, Faiza Hakim¹, Dhouha Ben Abdallah¹, Ines Kammoun¹, Fedia Walha¹, Bakhta Kamoun¹, Khoula Kamoun^{2,3}, Arwa Kamoun^{1,3}

¹Immunology and Histocompatibility, University Hedi Chaker Hospital, Sfax, Tunisia; ²Nephrology, University Hedi Chaker Hospital, Sfax, Tunisia; ³Renal Pathology Research Laboratory LR19ES11, University Hedi Chaker Hospital, Sfax, Tunisia

P217 Validation of a Rapid TaqMan Real-Time PCR Assay for Emergency HLA Typing in Cadaveric Organ Donors

Diamanto Kouniaki, Theofilos Athanassiades, Vasiliki Kitsiou, Sofia Nikolaou, Christina Salamaliki, Georgia Galaziou, Aikaterini Gkizori, Smaro Aritzaki, Katerina Tarassi, Alexandra Tsirogianni

Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece

P218 Non-HLA antibody trajectories may predict kidney transplant outcomes

Rajalingam Raja¹, Tara Sigdel², Stalinraja Maruthamuthu¹, Bryan Ray³

¹Immunogenetics and Transplantation Laboratory University of California San Francisco, University of California San Francisco, San Francisco, United States; ²Department of Surgery, University of California San Francisco, San Francisco, United States; ³Research and Development, Werfen, Wakesha, United States

P219 Transfusion-induced HLA antibodies are short-lived and rarely recur post-heart transplantation: A single-centre retrospective study with implications for virtual crossmatching

Rajalingam Raja¹, Stalinraja Maruthamuthu¹, Georg Wieselthaler²

¹Immunogenetics and Transplantation Laboratory, University of California San Francisco, San Francisco, United States; ²Department of Surgery, University of California San Francisco, San Francisco, United States

P220 Multilayered molecular immunological risk stratification in paediatric living donor kidney transplantation

Antonio Giuseppe Bianculli¹, Maria Troiano¹, Paola Giustiniani¹, Francesca Besi¹, Andrea Di Luzio¹, Luca Antonucci², Raffaella Labbadia², Marco Busutti², Isabella Guzzo², Marco Andreani¹

¹Laboratory of Immunogenetics and Transplant, Complex Operative Unit of Oncohematology, Hematopoietic Transplantation and Cellular Therapies, Bambino Gesù Children's Hospital, Rome, Italy; ²Division of Nephrology, Dialysis and Renal Transplant Unit, Bambino Gesù Children's Hospital, Rome, Italy

P221 Investigating the causes of an unexpected strongly positive flowcytometry crossmatch in a patient with no donor specific anti-HLA antibodies (HLA-DSA)

Davide Lepore¹, Shem Wallis-Jones^{1,2}, Elizabeth De Mendonca¹, Nicola Thal^{2,1}, Reetinder Grewal¹, Franco Tavarozzi¹, Lisa Walsh¹, Sharon Vivers¹, Neema P Mayor³, Sandra Frater¹, Rhys Evans⁴, Raymond Fernando^{1,2}

¹Histocompatibility Laboratories, Anthony Nolan, London, United Kingdom; ²Renal Transplant Unit, Royal Free London, NHS Foundation Trust, London, United Kingdom; ³Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London, United Kingdom, ⁴UCL Centre for Transplantation, Royal Free London, NHS Foundation Trust, London, United Kingdom

P222 Resolution of atypical reactive patterns in anti-HLA antibody assessment tests using the One Lambda Luminex platform through Epitope analysis

Floriana Giorgio, Fabio Viggiani, Patrizia Grazia Castellaneta, Antonio Mellone, Mario Vito Monteleone, Francesca Bellini, Alex Latorre, Giovanna Mongelli

O.U. Tissue Typing and Transplant Immunology, Policlinico of Bari, Bari, Italy

P223 Advanced epitope analysis in a sample: diagnostic implications and optimization of antigen panels

Floriana Giorgio, Fabio Viggiani, Patrizia Grazia Castellaneta, Antonio Mellone, Mario Vito Monteleone, Francesca Bellini, Alex Latorre, Federica Matera, Antonio Spinelli, Alessandro Marinelli, Giovanna Mongelli

O.U. Tissue Typing and Transplant Immunology, Policlinico of Bari, Bari, Italy

P224 Virtual crossmatch in living donor kidney transplantations: two pilot studies

Dave Roelen¹, Aiko de Vries², Annelies de Weerd³, Tessa van Diemen-Schrama², Hanneke Bouwsma², Jacqueline van de Wetering³, Adriaan van Beek¹

¹Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands; ²Department of Internal Medicine, Leiden University Medical Centre, Leiden, Netherlands; ³Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands

This poster will not be presented on site

P225 Utility of Complement-Binding Antibody Testing as a Tool to Facilitate Lung Transplantation in Alloimmunized Recipients

Manuel José Del Rey^{1,2}, Esther Mancebo^{1,2}, Alfocea Ángel^{1,2}, Juan D Acevedo¹, Paula López-Vizueté¹, María José Castro-Panete¹, Rodrigo Alonso³, Carlos A Quezada³, Alicia de Pablo³, Estela Paz-Artal^{1,2}, Virginia Pérez³

¹Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; ²Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain; ³Pulmonology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

P226 The introduction of HNA genotyping to reduce the risk of antibody mediated rejection caused by HNA-3a antibodies in female transplant recipients

Nicola Speirs, Rebecca Sneddon, Christopher Devine, Kelly Spence, Sylvia McConnell, Richard Battle, David M Turner

H&I Lab, SNBTS, Edinburgh, United Kingdom

P227 Clinical impact of preformed donor-specific anti-HLA-DP antibodies in kidney transplantation

Alba Exposito-Bey¹, Alba Temprado-Collado², Miguel Borrego-Martin¹, Blanca Gasco-Martos³, Francisco Manuel Gonzalez-Roncero³, Maria Francisca Gonzalez-Escribano¹, Beatriz Rodriguez-Bayona¹

¹Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain; ²Servicio de Nefrología, Hospital de Llerena-Zafra, Badajoz, Spain; ³Unidad de Transplante Renal. Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

P228 HLA alleles and anti-HLA antibodies in patients with end-stage renal disease awaiting kidney transplantation in Lower Silesia, Poland

Wanda Niepiekło-Miniewska, Małgorzata Kamińska, Adriana Marcinów, Martyna Maciaś, Katarzyna Bogunia-Kubik

Laboratory of Tissue Immunology, Medical Centre, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

P229 Changes in HLA Sensitization and Sensitizing Events Over Ten Years in Kidney Transplant Candidates

Nataša Katalinić^{1,2}, Hrvoje Rimac¹, Tajana Crnić Marčetić¹, Alisa Linić¹, Sandra Šever Šušnjar¹, Tamara Milojević¹, Sanja Balen^{3,2}

¹Tissue Typing Department, Institution for Transfusion Medicine, Clinical Hospital Centre, Rijeka, Croatia; ²Department of Clinical Laboratory Diagnostics, Faculty of Medicine, Rijeka, Croatia; ³Institution for Transfusion Medicine, Institution for Transfusion Medicine, Clinical Hospital Centre, Rijeka, Croatia

P230 Eplet-level insights into HLA-DQ and HLA-DP sensitization among kidney transplant candidates

Tajana Crnić Marčetić¹, Nataša Katalinić^{1,2}, Hrvoje Rimac¹, Aida Mujic Franic¹, Helena Kurtovic¹, Sanja Balen^{3,2}

¹Tissue Typing Department, Institution for Transfusion Medicine, Clinical Hospital Centre, Rijeka, Croatia; ²Department of Clinical Laboratory Diagnostics, Faculty of Medicine, Rijeka, Croatia; ³Institution for Transfusion Medicine, Clinical Hospital Centre, Rijeka, Croatia

P231 Pilot study – Evaluation of the GraftAssureIQ dd-cfDNA assay in Kidney Transplant Monitoring and Implementation of a pre-analysis sample processing method using the Maxwell RSC Rapid cfDNA kit

Sarinder Day¹, John Ward¹, Ella-Rose Brewer¹, Carla Rosser¹, Ailish Nimmo², Rommel Ramanan²

¹Immunology and Immunogenetics, North Bristol NHS Trust, Bristol, United Kingdom; ²Renal, North Bristol NHS Trust, Bristol, United Kingdom

P232 Detection of erythrocytes with both donor and the patient's original blood group antigens after a successful stem cell transplant. Implications for a subsequent kidney transplant from the same donor

Nicola Thal^{1,2}, Madalina Pinzaru², Kyle Annette-Woodgate², Franco Tavarozzi², Sandra Frater², Lisa Walsh², Neema P Mayor³, Sharon Vivers², Gareth Jones¹, Rhys Evans¹, Raymond Fernando^{1,2}

¹Renal Transplant Unit, The Royal Free London, NHS Foundation Trust, London, United Kingdom; ²H&I Laboratory, Anthony Nolan, London, United Kingdom; ³Anthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P233 Anti-HLA Delisting Strategies in Highly Sensitized Patients: Early Transplant Access Without Compromising Safety

Francisco Javier Gil Etayo^{1,2}, Guadalupe Tabernero³, Pilar Terradillos Sánchez¹, Isabel Jiménez Hernaz¹, Ariadna Vicente Parra¹, Nuria Calzada Nieto¹, Alexandra Lizarazu³, Luis Correa³, Antonio Costa Anzola¹, Juan López-Pérez¹, Daniel Arroyo-Sánchez¹, Irene Tabernero³, Pilar Fraile³, Amalia Tejada Velarde¹

¹HLA Lab, Hospital de Salamanca, Salamanca, Spain; ²Ibsal, Salamanca, Spain; ³Nefrology, Hospital de Salamanca, Salamanca, Spain

P234 Unexpected Negative flow cytometry Crossmatch in a Lung Transplant Candidate with High MFI donor specific antibody

Amal Algharably¹, Rayid Abdulqawi², Hana Alkhabbaz³, Moheeb Awwami¹

¹Kidney and Pancreas Health Centre, King Faisal Specialist Hospital, Riyadh, Saudi Arabia; ²Lung Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital, Riyadh, Saudi Arabia; ³Riyadh University, Riyadh, Saudi Arabia

P235 Interference in PRA Testing Following LVAD Implantation: A Case Report

Sahar Sandoqa¹, Amal Algharably¹, Ali Tariq¹, Hana Alkhabbaz², Moheeb Awwami¹

¹Kidney and Pancreas Health Centre, King Faisal specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ²Riyadh University, Riyadh, Saudi Arabia

P236 A rapid HNA genotyping assay to identify HNA-3b3b patients for subsequent anti-HNA-3 antibody testing

Reetinder Grewal¹, Elizabeth De Mendonca¹, Hannah Docker², Raymond Fernando³, Martin Barnardo², Neema P Mayor^{4,5}, Sandra Frater¹, Sharon Vivers^{1,5}, Michael Hoddinott¹, Lisa Walsh¹, Franco Tavarozzi¹

¹Anthony Nolan H&I Laboratory, London, United Kingdom; ²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; ³Royal Free Hospital, London, United Kingdom; ⁴Anthony Nolan Research Institute, London, United Kingdom; ⁵UCL Cancer Institute, Royal Free Campus, London, United Kingdom

P237 Combined HLA-DPA/B chain antibody reactivity in a patient waiting for kidney retransplant

Sandra Tafulo, Pedro Ramoa, Paula Aires, Vasco Guerra, Susana Oliveira, Maria Peixoto, Rita Ferreira

Histocompatibility and Immunogenetics, Portuguese Institute for Blood and Transplantation, Porto, Portugal

P238 HLA-G and LILRB1: Immunogenetic Determinants in Living Donor Kidney Transplantation

Yannik Busch¹, Julian Hoelzenbein², Nina Grünen¹, Sabine Schramm², Johanna Reinold³, Sarah Jansen³, Anja Gaeckler³, Benjamin Wilde³, Falko M. Heinemann², Andreas Heinold², Peter A. Horn², Oliver Witzke³, Marco Schaefer¹, Wolfgang Peter¹, Hana Rohn³, Vera Rebmann²

¹HLA Laboratory, Stefan Morsch Foundation, Birkenfeld, Germany; ²Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ³Department for Infectious Diseases and Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

P239 Prediction of Flow Cytometry Crossmatch Outcomes Based on DSA MFI Detected by Single-Antigen Bead Assays

Ángel Alfocea-Molina^{1,2}, Sandra García-Jiménez^{1,2}, Carlota Cantonad Ruigomez-Martín^{1,2}, David Gómez-Fernández¹, Francisco Javier Bermejo-Olivera¹, María Isabel García-García¹, Manuel José Del Rey^{1,2}, María José Castro-Panete¹, Estela Paz-Artal^{1,2}, Esther Mancebo^{1,2}

¹Immunology Service, Laboratory of Histocompatibility, 12 de Octubre University Hospital, Madrid, Spain; ²Immunodeficiencies and Transplant Immunology Group, i+12 Institute, Madrid, Spain

P240 Molecular Troublemakers: Defining Immunogenic Eplets and Their Antibody Risk

Richard Battle¹, Gemma Thomson¹, Angela Abel¹, Trijntje JW Rennie², Paul Phelan², Sylvia McConnell¹, David M Turner¹

¹Histocompatibility and Immunogenetics, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom; ²Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

P241 Optimizing EDTA treatment of serum samples for HLA antibody analysis

Gema González Martínez, Eva Rivas García, Santiago Sánchez Alonso, Isabel González Henríquez, Esperanza Rodríguez Torres, Chamaida Sosa González, Natalia Salgado González

Immunology, CHUIMI, Las Palmas de Gran Canaria, Spain

P242 Validation of a recipient age and HLA-DR and -DQ molecular mismatch score to support donor-specific antibody risk stratification after kidney transplantation

Eva Santos-Nunez¹, Nicola Gunby¹, Arthi Anand¹, Michelle Willicombe²

¹H&I Laboratory, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom; ²Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom

P243 Improved Access and Outcomes in the Spanish Program for Highly Sensitized Kidney Transplant Candidates: A Single-Centre Experience

Ángel Alfocea-Molina^{1,2}, Sandra García-Jiménez^{1,2}, Antonio Sanz-Sánchez¹, Beatriz Romero³, María Isabel García-García¹, David Gómez-Fernández¹, Francisco Javier Bermejo-Olivera¹, Manuel José Del Rey^{1,2}, Estela Paz-Artal^{1,2}, Amado de Andrés-Belmonte³, Esther Mancebo^{1,2}

¹Immunology Service, Laboratory of Histocompatibility, 12 de Octubre University Hospital, Madrid, Spain; ²Immunodeficiencies and Transplant Immunology Group, i+12 Institute, Madrid, Spain; ³Nephrology Service, 12 de Octubre University Hospital, Madrid, Spain

P244 The Utility of Serum Pre-treatment with Foetal Bovine Serum and a Freeze-Thaw Cycle to Reduce High Background in Luminex Single Antigen Bead Assays

Victoria Iveson, Lauren Charlton, Claire Romaines, Keith Giles, Jane Matthews, Ruth Chisman, Arash Akbarzad-Yousefi

H&I Laboratory, NHS Blood & Transplant, Newcastle upon Tyne, United Kingdom

P245 Urinary Chemokines (CXCL9 and CXCL10) and donor-derived cell-free DNA (dd-cfDNA) as Non-Invasive Biomarkers of Kidney Allograft Rejection

Mya Hmun^{1,2}, Nicola Thal³, Ravneet Kaur Bola³, Raymond Fernando³, Alan Salama^{1,2}, Rhys Evans^{1,2}

¹Department of Renal Medicine and Transplantation, Royal Free Hospital NHS Foundation Trust, London, United Kingdom; ²University College of London (UCL) Centre for Kidney and Bladder Health, Royal Free Hospital, London, United Kingdom; ³Solid Organ Transplant Team, Anthony Nolan Research Centre, London, United Kingdom

P246 Comparison of anti-HLA antibody detection capacity between the HISTO SPOT HLA AB assay and two commonly used single bead antigen assays

Asimina Fylaktou¹, Margarita Samali¹, Eleni Iliopoulou¹, Myrto Aikaterini Iosifidou¹, Marianthi Papachristou¹, Anna Boukla¹, Michalis Christodoulou², Ioannis Theodorou³, Maria Stagkou², Georgios Lioulios⁴

¹National Peripheral Histocompatibility Centre, Department of Immunology, Hippokration General Hospital, Thessaloniki, Greece; ²First Department of Nephrology, Aristotle University of Thessaloniki, Hippocration General Hospital, Thessaloniki, Greece; ³Laboratoire d'Immunologie, Hôpital Robert Debre, Paris, France; ⁴Department of Nephrology, Democritus University of Thrace, Alexandroupolis, Greece

P247 Review of Simultaneous Islet and Kidney Transplantation in a Single Centre

Angela Abel¹, Kirsty Duncan², Richard Battle¹, David M Turner¹

¹Edinburgh H&I Lab, SNBTS, Edinburgh, United Kingdom; ²Edinburgh Islet Cell Transplantation Unit, NHS Lothian, Edinburgh, United Kingdom

P248 Acute liver graft antibody mediated rejection during early post-operative period: a case report

Asimina Fylaktou¹, Theodora Oikonomou², Georgios Lioulios³, Konstantina-Eleni Karakasi⁴, Aliko Xochelli¹, Georgios Katsanos⁴, Ioannis Goulis², Georgios Tsoulfas⁴

¹National Peripheral Histocompatibility Centre, Department of Immunology, Hippokration General Hospital, Thessaloniki, Greece; ²Fourth Medical Department, Hippokratia General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; ³Department of Nephrology, Democritus University of Thrace, Alexandroupolis, Greece; ⁴Department of Transplantation Surgery, Hippokratia General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

P249 One year monitoring of kidney graft recipients and association with donor derived cell free DNA: the experience of one centre

Stella Vasiliadou¹, Georgios Lioulios², Margarita Samali³, Aliko Xochelli³, Georgia Chatzika³, Artemis Maria Iosifidou³, Lambros Vagiotas¹, Maria Stagkou⁴, Nikolaos Antoniadis¹, Georgios Tsoulfas¹, Asimina Fylaktou³

¹Department of Transplantation Surgery, Hippokratia General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; ²Department of Nephrology, Democritus University of Thrace, Alexandroupolis, Greece; ³National Peripheral Histocompatibility Centre, Department of Immunology, Hippokration General Hospital, Thessaloniki, Greece; ⁴First Department of Nephrology, Hippokratia General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

P250 Antibodies against Human Neutrophil Antigens in immunological risk assessment, in kidney transplantation

Margarita Samali¹, Georgios Lioulios², Eleni Iliopoulou¹, Artemis Maria Iosifidou¹, Anastasia Stoumpou¹, Aikaterini Anastasiou¹, Despina Asouchidou¹, Marianthi Papachristou¹, Maria Daoudaki³, Maria Stagkou⁴, Asimina Fylaktou¹

¹National Peripheral Histocompatibility Centre, Department of Immunology, Hippokration General Hospital, Thessaloniki, Greece; ²Department of Nephrology, Democritus University of Thrace, Alexandroupolis, Greece; ³Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; ⁴First Department of Nephrology, Aristotle University of Thessaloniki, Hippocration General Hospital, Thessaloniki, Greece

P251 Beyond MFI: Validation of a Normalized Urea-Avidity Assay to Unmask Functional Heterogeneity in HLA specific Antibodies

Gottfried Fischer¹, Daniela Koren², Daniela Kriks², Sebastian Wrighton³, Bernhard Kratzer³, Winfried Pickl¹

¹Department of Transfusion Medicine and Cellular Therapy, Medical University Vienna, Vienna, Austria; ²Department of Transfusion Medicine and Cellular Therapy, General Hospital Vienna, Vienna, Austria; ³Institute of Immunology, Medical University Vienna, Vienna, Austria

P252 Can MHC Class I Chain-Related Gene A Antibody Presence Predict Rejection in Kidney Transplantation?

Ümit Aslanhan¹, Sebahat Usta Akgul¹, Erol Demir¹, Talin Çatalbaşyan¹, Deniz Ece Özcan¹, Demir Kaan Demir¹, Yaren Alan¹, Emre Arpalı², Cemile Pehlivanoğlu³, Mehmet Kanbay⁴, Dilek Ertoy Baydar⁵, Burak Koçak⁶, Sevgi Kalkanlı⁷, Caner Süsa¹, Gülbu Işıtmangil⁸

¹Transplant Immunology Research Centre of Excellence TIREX, Koç University School of Medicine, Istanbul, Turkey; ²Transplant Surgery, Medical College of Wisconsin, Milwaukee, United States; ³Department of Paediatrics, Division of Nephrology, Koç University School of Medicine, Istanbul, Turkey; ⁴Department of Internal Medicine, Division of Nephrology, Koç University School of Medicine, Istanbul, Turkey; ⁵Department of Pathology, Koç University School of Medicine, Istanbul, Turkey; ⁶Organ Transplantation Unit, Koç University School of Medicine, Istanbul, Turkey; ⁷Department of Immunology, University of Health Sciences, Istanbul, Turkey; ⁸Department of Microbiology, University of Health Sciences, Istanbul, Turkey

P253 Neutralization of Thymoglobulin Interference in Flow Cytometry Crossmatch and Luminex Single Antigen

Renata Fantini¹, Renato de Marco^{1,2,3}, Robert Liwski⁴, Isau Noronha¹, Paloma Melo¹, Maria Gerbase-DeLima¹

¹Immunogenetics Institute – IGEN, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil; ²Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil; ³Nephrology Division, Universidade Federal de São Paulo, São Paulo, Brazil; ⁴Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, Canada

P254 The Impact of HLA-DRB1 Alleles on Anti-HLA Class I Antibody formation

Gustavo Alves¹, João Henrique Campos¹, Maria Gerbase-DeLima¹, Renato de Marco^{1,2,3}

¹Immunogenetics Institute – IGEN, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil; ²Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil; ³Nephrology Division, Universidade Federal de São Paulo, São Paulo, Brazil

P255 Validation of HLA class I serotype classification using single antigen bead results

João Henrique Campos¹, Gustavo Alves¹, Alberto Cardoso Martins Lima¹, Maria Gerbase-DeLima¹, Renato de Marco^{1,2,3}

¹Immunogenetics Institute – IGEN, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil; ²Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil; ³Nephrology Division, Universidade Federal de São Paulo, São Paulo, Brazil

P256 Experience with low-risk immunologic delisting protocols in highly sensitized candidates for renal transplantation

David Rodríguez-Martín¹, Juan Francisco Luchoro-Cerdá¹, Juan Manuel Torres-Canizales¹, Caroli Arana-Aliaga², Redondo-Pachon María Dolores³, Nuria Serra-Cabañas⁴, María Molina-Gómez⁵, Edoardo Melilli⁶, Maria Antonia Emilia Meneghini⁷, Eduard Palou¹, Jose Luis Caro-Oleas¹

¹Immunology, Hospital Clínic de Barcelona, Barcelona, Spain; ²Nephrology, Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain; ³Nephrology, Renal Transplant Unit, Hospital del Mar, Barcelona, Spain; ⁴Nephrology, Renal Transplant Unit, Fundació Puigvert, Barcelona, Spain; ⁵Nephrology, Renal Transplant Unit, Hospital Germans Trias i Pujol, Badalona, Spain; ⁶Nephrology, Renal Transplant Unit, Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain; ⁷Nephrology, Renal Transplant Unit, Hospital Vall d'Hebron, Barcelona, Spain

P257 Surrogate Flow Crossmatch Demonstrates False-Positive Anti-HLA Antibody Reactivity in Two Single-Antigen Bead Assays

Claudia Muñoz-Herrera, Hua Zhu, Charles Williams, Rachel E Boasi, Terrence Robinson, Zeying Du, Mohamed Elrefaei

Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, United States

SATELLITE SYMPOSIA

Thermo Fisher, 22 April 2026, 12:00-13:00, Sidlaw Auditorium

Title: Transformative tools in immunogenetics: expanded DQ Single Antigen panel and Hybrid Capture NGS

Chair: Dr. Oliva Shaw, PhD, FRCPath (Synnovis)

ThermoFisher
SCIENTIFIC

The potential contribution of an expanded ExPlex panel to the interpretation of anti-HLA antibodies

Jean Luc Taupin, PharmD, PhD, Saint-Louis Hospital and Diderot University

Comparison of One Lambda HybriType HLA to EFI 8.1 and ISO 15189 Standards

Alice Scarpa, Sr. Biologist, Ospedale di Piacenza

Werfen, 22 April 2026, 13:00-14:00, Fintry Hall

Title: Enhancing Confidence in HLA Decision-Making: Today & Tomorrow

werfen

Two Platforms, Two Suppliers: Evaluating Variability in Anti-HLA Antibody Detection

Marie-Joëlle Apithy, Établissement français du sang, Strasbourg, France

NanoTYPETM HLA-II Plus: A multicenter clinical validation & user experience

Maja Nørgaard, Aarhus Universitetshospital, Denmark

Hansa Biopharma, 22 April 2026, 14:00-15:00, Fintry Hall

Title: Redefining Possibility: Advances and Strategies in HLA Incompatible Kidney Transplantation

Chair: Kay Poulton (Professor & Consultant Scientist Transplantation Laboratory, Manchester Royal Infirmary, UK)


HANSA
BIOPHARMA

Current Outcomes in HLA-Incompatible Kidney Transplantation: Where Are We Today?

Olivia Shaw, Director, Clinical Transplantation Laboratory, Clinical Transplantation Department, UK Guy's Hospital, London, UK

Innovations in HLAi Transplantation: Expanding the Horizons of Delisting

Jean-Luc Taupin, Professor, Immunology & Histo-incompatibility, Saint-Louis Hospital – AP-HP, Paris, France

Navigating Antibody Challenges: Strategies for Transplantation in the Presence of DSA

Eduard Palou, Consultant Immunologist & Head of Transplant Laboratory, Clinic Hospital de Barcelona, Barcelona, Spain

Insight Molecular Diagnostics (iMDx) – Oncocyte, 22 April 2026, 14:00–15:00, Kilsyth
Title: Real-World Evaluation of an In-House dd-cfDNA Assay: A Single-Center Validation Study at One of the World's Largest Kidney Transplant Centers



Comparison of GraftAssureIQ performance to commercially available NGS-based solutions used in post-transplantation monitoring

Study design, implementation considerations, and key findings

The role of in-house dd-cfDNA testing in advancing transplant research

Suzane Silbert, PhD, Director, Esoteric Testing, R&D and Microbiology Laboratories Tampa General Hospital
Luciano Soares, PhD, Clinical Scientist Tampa General Hospital

GenDx, 23 April 2026, 12:00–13:00, Sidlaw Auditorium
Title: From Sequencing to Success: Innovation Across the Transplant Journey



Closing the Gaps in Post Transplant Monitoring: The Power of HLA Loss Testing
Arthi Anand, Consultant Clinical Scientist at Imperial College Healthcare NHS Trust

High-Resolution HLA Typing in Solid Organ Transplantation
Dr. Cynthia Kramer, Scientist at GenDx

CareDx, 23 April 2026, 13:00–14:00, Sidlaw Auditorium
**Title: Together in Patient Care: Advancing
Transplant Outcomes with AlloSeq Nano and AlloSeq cfDNA**



AlloSeq Nano: Robust High-Resolution HLA and ABO Genotyping with Long-read Sequencing

Curtis Lind, VP, Head of Research & Development, CareDx, USA

Donor-Derived cfDNA Testing in the Laboratory Setting for Solid Organ Transplant Monitoring

Anais Certain, MSc, Institute for Transplantation & Organ Regeneration (PITOR) - PARCC - INSERM U970, France

From Test Result to Clinical Decision: Contextualizing dd cfDNA Testing in Kidney Transplantation

Prof. Dr. Maarten Naesens, Clinical Director, Nephrology & Renal Transplantation, University Hospitals Leuven (UZ Leuven), Belgium

Q&A

BAG Diagnostics, 23 April 2026, 14:00–15:00, Fintry Hall

Title: Assessing the BAG Diagnostics HISTO SPOT® HLA AB System for usability and potential integration into the Laboratory's HLA Antibody Screening and Identification Strategy for Solid Organ and Haematopoietic Stem Cell Transplantation

Chair: Dr. Kristin Launhardt



Ella Gorton (Anthony Nolan)

SOCIAL NETWORKING EVENTS

Welcome Drink Reception

Tuesday 21 April 2026, 19:45–21:30

Place: Edinburgh International Conference Centre –
EICC (Conference Venue) – Exhibition Hall



Held on Tuesday evening, open to all conference participants. Come along and have a Welcome Drink Reception and enjoy light refreshments and beverages, catch up with friends, meet new people, make connections, discuss the EFI2026 sessions, and find new insights with great company.

Networking Event

Thursday 23 April 2026, 19:30–01:00

Price: 125 € / per person

Place: National Museum of Scotland,
Chambers Street, Edinburgh, EH1 1JF

Transportation: Transportation will not be provided

Dress code: Business casual/smart casual



There are only a limited number of tickets that can be purchased at the Registration Desk.



GenDx Tulip run

Thursday 23 April 2026

Price: 25 € / per person

Meeting point: main entrance of the Edinburgh International Conference
Centre (EICC) at 6:30



Detailed schedule: 06:45 – Warm-up
07:00 – Start run
08:00 – Tulip run awards & heading back
to the hotel/venue



We are looking forward to welcoming you at GenDx 4–5 Km Tulip Run during EFI 2026. You can join by running or walking if you prefer.

If you would like to make your own way to the start, the start point is at 1 Lonsdale Terrace, EH3 9HN (what3words: sleepy.leaps.woke). Be there at 06:45 for the warm up.

Profits will be donated to a charity of GenDx choice and GenDx will double the amount raised.



Robust and streamlined *long-read based* HLA typing

Simplified end-to-end workflow for high-resolution HLA typing, combining single-step amplification and library preparation with fast analysis in AlloSeq Assign

<3hours Turnaround Time (TAT) - DNA sample to result
<45 min Hand-on Time (HoT) / Single sample

Amplification & Barcoding

11 HLA loci + ABO

- Redundant Coverage
- Single Step Amplification and Library Prep
- No fragmentation

Purification

- Library pooling
- Bead-based purification

Sequencing


- MinION Mk1D

Data Analysis and Reporting

- AlloSeq Assign
- Automatic analysis
- 3 field resolution

Redundant design to *prevent allele dropouts*

AlloSeq Nano redundant coverage of exons encoding antigen recognition sites minimizes the risk of allele dropout and utilises long-read sequencing to resolve phasing ambiguities commonly encountered with short reads.



Configuration

HLA + ABO
24 samples

Product

AlloSeq Nano HLA
ABO (Amplification)

SKU/ Part No.

707.101-24r

HLA + ABO

AlloSeq Purification
Beads (Ancillary)

707.601-50r

Ordering Information and Kit Components

Exons

Long Amplicon

Short Amplicon

To order or request a demo, contact your CareDx representative.


AlloSeq Nano is available as Research Use Only (RUO). RUO products are not to be used for diagnostic procedures. AlloSeq is a trademark or registered trademark of CareDx, Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. © 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

VLP-PRO-11344-v2 Effective 2026-03

Enhance Your Transplant *Rejection Risk* Assessment

AlloSeq cfDNA provides a more accurate, less invasive, solution to surveilling allograft injury

- Minimally invasive compared to biopsy
- Demonstrated ability to detect early injury and rejection when combined with standard of care¹



Many reasons to consider AlloSeq cfDNA surveillance testing



Surveilling for allograft injury



Monitoring rejection treatment response



Supplementing other lab tests



Assessing delayed graft function



Contact a representative,
or visit [caredx.com](https://www.caredx.com)

Ref 1: Bu L, et al. Clinical outcomes from the assessing donor-derived cell-free DNA monitoring Insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. *Kidney Int.* 2022 Apr;101(4):793-803.

AlloSeq cfDNA is available as CE/IVD or Research Use Only. For local regulatory status, please contact CareDx. The CareDx Testing Services Laboratory in Stockholm, Sweden is accredited according to ISO/IEC 17025. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is only available outside the United States. AlloSeq is a trademark or registered trade-mark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. AlloSure is only available within the US. © 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

VLP-PRO-11298-v1 Effective 2026-02

Publication	First Author	Journal	Year
Kidney			
Donor-derived Cell-free DNA as a Noninvasive Biomarker of Kidney Allograft Rejection in Pediatric Kidney Transplantation	Hogan J.	Transplantation	2025
Normalization Dynamics of Donor-derived Cell-free DNA Predicts Future Kidney Transplant Rejection	Cucchiari D.	Nephrology Dialysis Transplantation	2025
Implementation of the In-house Technique for the Determination of Donor-derived Cell-free DNA in Daily Clinical Practice: Experience from the Hospital Clinic of Barcelona [Article in Spanish]	Cuadrado-Payán E.	Nefrología	2025
Evaluation of a Decentralized Donor-derived Cell-free DNA Assay for Kidney Allograft Rejection Monitoring	Loupy A.	Transplant Int.	2024
Early Monitoring of Donor-derived Cell-free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center	Botella C.	Life	2024
Multi-centre Analytical Performance Verification of an IVD Assay to Quantify Donor-derived Cell-free DNA in Solid Organ Transplant Recipient	Casas S.	HLA	2024
Donor-derived Cell-free DNA Predicted Allograft Rejection and Severe Microvascular Inflammation in Kidney Transplant Recipients	Kim H.D.	Frontiers in Immunology	2024
Cell-free DNA for the Detection of Kidney Allograft Rejection	Aubert O.	Nature Medicine	2024
Donor-derived Cell-free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy Results of a Prospective Single-center Trial	Benning L.	Transplant Int.	2023
Cell-free DNA Measurement of Three Genomes After Allogeneic MSC Therapy in Kidney Transplant Recipients Indicates Early Cell Death of Infused MSC	Dreyer J. Geertje	Frontiers in Immunology	2023
Assessment of Donor-derived Cell-free DNA (dd-cfDNA) at Surveillance and at Clinical Suspicion of Acute Rejection in Renal Transplantation	Mantios E.	Transplant Int.	2023
Donor-derived Cell-free DNA at 1 Month after Kidney Transplantation Relates to HLA Class II Eplet Mismatch Load	González-López E.	Biomedicines	2023
Early Kinetics of Donor-derived Cell-free DNA After Transplantation Predicts Renal Graft Recovery and Long-term Function	Cucchiari D.	Nephrology Dialysis Transplantation	2023
Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose	Kühn T.	Transplantation	2023
Humoral Response to SARS-CoV-2 mRNA Vaccination in Previous Non-Responder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid	Benning L.	Frontiers in Medicine	2022
Levels of Donor-derived Cell-free DNA and Chemokines in BK Polyomavirus-associated Nephropathy	Mayer A. K.	Clinical Transplantation	2022
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10	Mayer A. K.	Transplant Direct	2022
A Comparison of Two Different Analytical Methods for Donor-derived Cell-free DNA Quantification	Verhoeven J.G.H.P.	Clinical Biochemistry	2021
Diagnostic Value of Donor-derived Cell-free DNA to Predict Antibody-mediated Rejection in Donor-specific Antibody-positive Renal Allograft Recipients	Mayer A. K.	Transplant Int.	2021
Liver			
Donor-derived Cell-free DNA and miRNA Monitoring for the Early Prediction and Diagnosis of Liver Allograft Rejection and Patient Outcomes	Julian J.	Frontiers in Immunology	2025
Monitoring of Donor-derived Cell-free DNA by Short Tandem Repeats: Concentration of Total Cell-free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation	Fernández-Galán E.	Liver Transplantation	2022
Kidney, Liver			
Comparison of Methods for Donor-derived Cell-free DNA Quantification in Plasma and Urine from Solid Organ Transplant Recipients	Kueng N.	Frontiers in Genetics	2023
Lung			
Detection of Lung Allograft Injury Through a Comprehensive Multidisciplinary Analysis of Donor-derived Cell-free DNA in Plasma and Bronchoalveolar Lavage: a Real-World Single Center Experience	Calabrese F.	Frontiers in Immunology	2025
Donor-derived Cell-free DNA in Chronic Lung Allograft Dysfunction Phenotypes: a Pilot Study	Beeckmans H.	Frontiers in Transplantation	2024
Clinical Relevance of Cell-free DNA Quantification and Qualification During the First Month After Lung Transplantation	Pedini P.	Frontiers in Immunology	2023
Heart			
Donor-derived Cell-free DNA Versus Left Ventricular Longitudinal Strain and Strain-derived Myocardial Work Indices for Identification of Heart Transplant Injury	Teszak T.	Biomedicines	2025
Noninvasive Rejection Surveillance After Solid Organ Transplantations: Analysis of the Donor-derived Cell-free DNA [Article in Hungarian]	Teszak T.	Orvosi Hetilap	2024
Local Laboratory-run Donor-derived Cell-free DNA Assay for Rejection Surveillance in Heart Transplantation - First Six Months of Clinical Experience.	Teszak T.	Clinical Transplantation	2023

AlloSeq cfDNA is available as CE-IVD and Research Use Only. For local regulatory status, please contact CareDx. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is available only outside the US. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. © 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

VLP-PRO-10628-v2 Effective 2026-02

ORDER NOW

NGSgo[®] -ProntoFLX

Single Locus HLA typing to maximize flexibility on ONT



1 min. sequencing /
sample / locus



Compatible with ONT
sequencing platforms

AVAILABLE
AS RUO



Data Analysis with
NGSengine[®]



96-sample
throughput per run



- Currently available: NGSgo-ProntoFLX HLA-A, NGSgo-ProntoFLX HLA-B, NGSgo-ProntoFLX HLA-DQA1, DQB1
- Ready-to-use amplification mixture



Scan to discover more

Contact us for more information at support@gendx.com
GenDx | +1 (312) 815 5006 | www.GenDx.com



Training course

Become an expert in HLA typing


September 30 - October 2, 2026 | Utrecht, Netherlands

Why attend?

- ✔ Theoretical knowledge of HLA typing with NGS.
- ✔ Hands-on training of multiplexed HLA typing: One-Day-Workflow using Illumina sequencing
- ✔ Training on data analysis with NGSengine®: from basics to case studies.
- ✔ Bring your own genomic DNA samples for typing (anonymized samples and data only).
- ✔ ACHI accredited (3 CECs)

You can register on our website or by writing an email to education@gendx.com

Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park
The Netherlands | +31 (0)30 252 3799
www.GenDx.com



From Sequencing to Success: Innovation Across the Transplant Journey



Closing the Gaps in Post Transplant Monitoring: The Power of HLA Loss Testing

Arthi Anand PhD FRCPATH AAHCS

Consultant Clinical Scientist, Laboratory Director
Imperial College Healthcare NHS Trust



High-Resolution HLA Typing in Solid Organ Transplantation

Cynthia Kramer PhD

Scientist at GenDx




GenDx New Developments

Maarten Penning PhD

General Manager at GenDx





39th EFI/BSHI Conference 2026

Don't miss our Industry Symposium

Wednesday, April 22, 2026 | 12:00 – 13:00
Third Floor - Sidlaw Auditorium

Transformative tools in immunogenetics: expanded DQ Single Antigen panel and Hybrid Capture NGS

Moderator

Dr. Oliva Shaw, PhD, FRCPath | Synnovis

Speakers

The potential contribution of an expanded ExPlex panel to the interpretation of anti-HLA antibodies

Jean Luc Taupin, PharmD, PhD | Saint-Louis Hospital and Diderot University

Comparison of One Lambda HybriType HLA to EFI 8.1 and ISO 15189 Standards

Alice Scarpa, Sr. Biologist | Ospedale di Piacenza

One Lambda™ HLA PRO

Automated Pipetting System

Maximizing laboratory efficiency

In a busy and evolving laboratory, efficiency and flexibility are paramount. Our automated pipetting system delivers on both fronts, offering a versatile solution that streamlines multiple workflows.

Designed to support standalone workflows such as NGS library preparation and bead-based assays, this system adapts to your lab's dynamic needs. Easily scalable to accommodate varying sample loads, providing precision and consistency across all assays.

By integrating our automated pipetting system, you can enhance productivity, maintain high standards of accuracy, and adapt swiftly to changing demands, making it an invaluable asset to your laboratory operations.



The system minimizes footprint with an air-displacement pipettor and below-deck storage

Learn more at thermofisher.com/hlapro or contact your Account Manager

This product is intended for General Laboratory Use. It is the customer's responsibility to ensure that the performance of the product is suitable for customers' specific use or application. © 2024 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

June 2024 | Rev 0

HLA Typing Assay

One Lambda HybriType

Hybrid Capture HLA Typing – Simplified

The One Lambda™ HybriType™ NGS Hybrid Capture Assay is designed for HLA laboratories seeking a simplified workflow without compromising data quality. Leveraging hybrid capture enrichment and flexible panel configurations, HybriType delivers broad gene coverage, high-resolution genotyping, and balanced reads—while minimizing ambiguity and enabling deeper analysis through integrated copy number assessment.

Additional Features and Benefits

- **Universal protocol** for blood and buccal swab samples
- **≤ 5.5-hour workflow** enables next day results[†]
- **Unique Dual Indexing (UDI)** for enhanced sample traceability
- **High-resolution genotyping** with minimal ambiguity
- **Automated analysis** via TypeStream™ Visual NGS Software



Learn more at thermofisher.com/hybriType

[†] Timing may vary based on lab expertise and efficiency.



ADAPT.

Are you ready to make a change?

Change can be intimidating, but without change there is limited growth. Differences in MFI values between vendors can be challenging to explain, but they should not be seen as a deterrent. There are many ways to help overcome MFI differences between vendors and with the right partner and tools you can overcome this barrier. As Darwin said, "It is not the strongest that survive, nor the most intelligent, but the ones that are most adaptable to change."

[CLICK HERE](#) to find out what your peers experienced by adapting to change.

[werfen.com](https://www.werfen.com)

Experience the future of HLA Typing



Efficient, reliable, and ready for your lab.

NanoTYPE brings next-generation technology to streamline workflows. Its intuitive design ensures fast, simple, and accessible testing—ideal for laboratories of all sizes, including those handling time sensitive cases.

Join us at the Werfen Booth #3 EFI 2026!

Edinburgh, Scotland
21-24 April 2026

Discover a range of engaging experiences at EFI 2026, from an insightful symposium to interactive demos and bite-sized silent seminars.

Explore our solutions—Book your demo

Throughout EFI, our team will be delivering guided demonstrations of our full product portfolio, including NanoTYPE™ and MatchX™. Walk up or register in advance for a personalised one-to-one experience exploring our latest innovations with our expert.



SCAN HERE
to secure
your demo

Join us for a symposium

Exploring variability in HLA antibody detection and the evolving approaches in HLA typing supporting HLA testing strategies.

>> Enhancing Confidence in HLA Decision-Making: Today & Tomorrow

Date/Time: Wednesday 22 April, 1:00pm-2:00pm

Location: Level 3, Fintry Room, EICC



SCAN HERE
to learn about
our speakers



Plug In for a Silent Seminar

These short, focused sessions are designed to fit perfectly into your coffee break—no crowding, no noise, just clear insights delivered via headsets.



SCAN HERE
to reserve
your headset

[werfen.com](https://www.werfen.com)

Werfen is a trademark of Werfen S.A. NanoTYPE is a trademark of Omixon Biocomputing KFT (d.b.a. Werfen). MatchX is a trademark of Immucor, Inc. (d.b.a. Werfen). All trademarks may have been registered in the United States Patent and Trademark Office and/or in other jurisdictions. Product offerings may differ by region, please check with your local Werfen representative for regulatory status in your area.

werfen

Lynda may never get a compatible kidney offer¹

Now you could change this³

With Idefirix® (imlifidase) you can help transform the lives of your highly sensitised adult patients by enabling HLA-incompatible kidney transplantation.^{2,4}

Age:	41
cPRA:	99.0%
Years on dialysis:	9
Number of organ offers received:	None

idefirix®
(imlifidase)

Image of fictional patient for representative purposes only.

The full Prescribing Information is available on request at the Hansa booth (Booth 15).

ENABLING INCOMPATIBLE TRANSPLANT.¹

Idefirix® Abbreviated Prescribing Information (UK)

Idefirix® (imlifidase) 11 mg powder for concentrate for solution for infusion. After reconstitution and dilution, each mL of concentrate contains 10 mg imlifidase. **Indication:** Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. **Dosage and administration:** The dose is based on patient body weight (kg). The recommended dose is 0.25 mg/kg administered as a single dose preferably within 24 hours before transplantation. Idefirix is for intravenous use only following reconstitution and dilution. The entire, fully diluted infusion should be administered over a period of 15 minutes. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients; Ongoing serious infection; Thrombotic thrombocytopenic purpura (TTP). Patients with this blood disorder may be at risk of developing serum sickness. **Warnings and precautions:** Infusion related reactions have been reported with imlifidase administration. If any serious allergic or anaphylactic reaction occurs, imlifidase therapy should be discontinued immediately and appropriate therapy initiated. An interrupted infusion can be restarted when the symptoms have abated. For kidney transplantation, ongoing serious infections of any origin are considered a contraindication, and chronic infections such as HBV or HIV must be well controlled. The temporary reduction of IgG by imlifidase must be taken into consideration. Therefore, in addition to the standard of care infection prophylaxis in kidney transplantation in general (against *Pneumocystis carinii*, cytomegalovirus and oral *candida*), all patients should also receive prophylactic oral antibiotics covering respiratory tract pathogens for 4 weeks. Due to the reduced IgG levels after treatment with imlifidase, there is a risk for a temporary reduction of vaccine protection for up to 4 weeks following imlifidase treatment. Antibody-mediated rejection (AMR) may occur as a consequence of rebound of donor-specific antibodies (DSA). Management of patients should include

close monitoring of anti-HLA (human leukocyte antigen) antibodies and serum or plasma creatinine as well as readiness to perform biopsies when AMR is suspected. If complement-dependent cytotoxicity crossmatch (CDCXM) is used, the following needs to be considered to avoid false positive results after imlifidase treatment: IgM has to be inactivated to be able to specifically assess the cytotoxic capacity of IgG and the use of an anti-human globulin (AHG) step should be avoided. If used, it should be confirmed that the AHG is directed against the Fc-part and not against the Fab-part of the IgG. Use of AHG, directed against the Fab-part, will not allow correct readout of a CDCXM in an imlifidase-treated patient. **Interactions:** Imlifidase is a cysteine protease that specifically cleaves IgG. As a consequence, IgG-based medicinal products may be inactivated if given in connection with imlifidase. Intravenous immunoglobulin (IVIg) may contain neutralising antibodies against imlifidase, which may inactivate imlifidase if IVIg is given before imlifidase. The half-life of IVIg (3-4 weeks) should be considered before administering imlifidase to patients treated with IVIg. **Pregnancy and lactation:** There are no data from the use of imlifidase in pregnant women since pregnancy is a contraindication to kidney transplantation. **Adverse reactions:** The most common serious adverse reactions were pneumonia and sepsis. Very common adverse reactions include bacterial and viral infection. Common adverse reactions include abdominal infection, adenovirus infection, catheter site infection, infection, influenza, parvovirus infection, pneumonia, post operative wound infection, sepsis, upper respiratory tract infection, urinary tract infection, wound infection, anaemia, transplant rejection, dizziness postural, headache, scleral haemorrhage, visual impairment, sinus tachycardia, flushing, hypertension, hypotension, dyspnoea, rash, myalgia, feeling hot, infusion site pain, alanine aminotransferase increased, aspartate aminotransferase increased and infusion-related reactions. Prescribers should consult the Summary of Product Characteristics for full information on adverse reactions. **Further information:** For more detailed information, please refer to the full

prescribing information. **Price:** Single vial pack: £135,000; 2 vial pack: £270,000. **Legal classification:** Prescription Only. **Marketing Authorisation Number:** PLGB 46323/0002. **Marketing Authorisation Holder:** Hansa Biopharma AB, P.O. Box 785, 220 07 Lund, Sweden. **Date of preparation:** December 2025.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Hansa Biopharma AB at safety@hansabiopharma.com Telephone: 0808 2349964

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the full Prescribing Information on how to report adverse reactions. Please also report adverse reactions to Hansa Biopharma AB at safety@hansabiopharma.com

cPRA, calculated panel reactive antibody; HLA human leukocyte antigen

References

1. Jordan SC, et al. *Transplantation*. 2021;105(8):1808–1917.
2. Kjellman C, et al. *Am J Transplant*. 2021;21(12):3907–3918.
3. Jordan SC, et al. *New Engl J Med*. 2017;377(5):442–453.
4. Idefirix GB Summary of Product Characteristics. December 2025.

JOB CODE: HANS-PR.GLO.26.003-001 | March 2026

HANSA
BIOPHARMA



40TH EUROPEAN IMMUNOGENETICS & HISTOCOMPATIBILITY CONFERENCE

*Bridging Genetics and Immunology
in Translational Medicine*

25-28 May 2027

Essen, Germany

Messe Essen Congress Center



**WE LOOK FORWARD TO WELCOMING
YOU IN ESSEN NEXT YEAR**

